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Cervical carcinoma is one of the leading causes of cancer-related death in women. The 
prevalence of this disease is particularly high in South Africa, occurring on average, in 60 out 
of every 100 000 women. Previous studies have demonstrated over-expression of 
cyclooxygenase-2 (COX-2) enzyme and enhanced synthesis of prostanoids, such as 
prostaglandin E2 (PGE2), in cervical carcinomas. PGE2 mediates its effects by interacting with 
one of four receptors termed EPI-4. Expression and signalling of EP receptors, including 
EP4, are elevated in cervical carcinomas. It has been proposed that in addition to endogenous 
PGE2, EP receptors in cervical carcinomas can be activated by seminal plasma prostaglandins. 
Prostaglandin concentration in seminal plasma is 10,000 times higher than that found at a site 
of inflammation, and PG~ is the predominant type of prostaglandin detected in semen. This 
thesis investigates the potential activation of the EP4 receptor by seminal plasma 
prostaglandins or PG~ in wild type (WT) and EP4 receptor over-expressing (EP4S) cervical 
adenocarcinoma (HeLa) cells. Treatment of EP4S cells with seminal plasma or PGE2 results 
in a rapid augmented accumulation of cAMP (p<0.001) and phosphorylation of ERK1/2 
(p<0.001) compared with WT cells. The phosphorylation of ERK1/2 is inhibited by co-
treatment of cells with seminal plasma and MEK inhibitor (pD98059), EP4-selective receptor 
antagonist (ONO-AE2-227) or an inhibitor of epidermal growth factor (EGF) receptor 
tyrosine kinase (AGI478). Treatment of EP4S cells with PGE2 or seminal plasma also 
resulted in elevated expression of COX-2 (p<O.OOI), vascular endothelial growth factor 
(VEGF; p<0.00l) and basic fibroblast growth factor (bFGF; p<0.05). Expression of COX-2 
and VEGF is inhibited by co-treatment of cells with seminal plasma or PGE2 and the MEK 
inhibitor, the EP4-selective receptor antagonist or the EGF receptor tyrosine kinase inhibitor. 
In conclusion, our data demonstrate that seminal plasma prostaglandins can activate signalling 
and expression of inflammatory and angiogenic genes via the EP4 receptor, in an EGFR- and 
ERK-dependent manner. These data suggest that the progression of cervical carcinoma in 
sexually active women may be exacerbated following exposure to seminal plasma and 
activation of EP-receptor signal transduction pathways. Therefore, COX-enzyme inhibitors on 
their own may not be sufficient to inhibit prostaglandin action in sexually active women. A 
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ABSTRACT 
Cervical Carcinoma is one of the leading causes of cancer-related death in women. The 
prevalence of this disease is particularly high in South Africa, occurring on average, in 60 
out of every 100 000 women. Previous studies have demonstrated over-expression of 
cyclooxygenase-2 enzyme and enhanced synthesis of prostanoids, such as prostaglandin 
E2, in cervical carcinomas. Prostaglandin E2 mediates its effects by interacting with one 
of four receptors termed EPI-4. Expression and signalling of EP receptors, including 
EP4, are elevated in cervical carcinomas. 
The initial aim of this study was to localise the site of expression of EP4 receptors in 
cervical squamous cell- and adenocarcinomas. Immunohistochemical analysis performed 
on paraffm wax-embedded cervical tissue sections localised the site of EP4 receptor 
expression to the neoplastic epithelial cells of all squamous cell carcinomas and 
adenocarcinomas studied. Minimal EP4 receptor immunoreactivity was detected in 
normal cervix. The site of localisation of the EP4 receptor within the epithelial 
compartment suggested that prostaglandin E2 may act in an autocrine/paracrine manner to 
modulate epithelial cell function and promote tumourigenesis. 
In addition to endogenous prostaglandin E2, EP receptors in cervical carcinomas can be 
activated by seminal plasma prostaglandins. Prostaglandin concentration in seminal 
plasma is 10,000 times higher than that found at a site of inflammation, and prostaglandin 
E2 is the predominant type of prostaglandin detected in semen. In order to investigate the 
potential activation of the EP4 receptor by prostaglandin E2 or seminal plasma 
prostaglandins, we developed an EP4-overexpressing adenocarcinoma cell model system 
using HeLa (cervical carcinoma) cells. 
Using this model system the signal transduction pathways activated by prostaglandin E2-
or seminal plasma-EP4 receptor interaction in HeLa wild type and EP4 receptor over-
expressing (EP4S) He La cells were investigated. Treatment of EP4S cells with seminal 
plasma or prostaglandin E2 resulted in a rapid accumulation of cAMP (p<0.001) and 
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phosphorylation of ERK1I2 (p<O.OOI) in EP4S compared with wild-type cells. This 
elevated phosphorylation of ERK1I2 is inhibited by co-treatment of cells with chemical 
inhibitors of MEK (PD98059), epidermal growth factor receptor tyrosine kinase 
(AGI478) or EP4-selective receptor antagonist (ONO-AE2-227). We next investigated 
the target genes activated by seminal plasma or prostaglandin E2-EP4 ligand-receptor 
interaction. Treatment of EP4S cells with seminal plasma or prostaglandin E2 also 
resulted in elevated expression of the twnourigenic gene, cyclooxygenase-2 (p<O.OOI), 
and two genes associated with angiogenesis, vascular endothelial growth factor (p<O.OOI) 
and basic fibroblast growth factor (p<O.05). Expression of these genes was inhibited by 
co-treatment of cells with seminal plasma or prostaglandin E2 and the MEK inhibitor, the 
epidermal growth factor receptor tyrosine kinase inhibitor or the EP4-selective receptor 
antagonist. 
Our data presented in this thesis demonstrate that seminal plasma prostaglandins or 
prostaglandin E2 can activate mitogenic signalling and promote the expression of 
inflammatory and angiogenic genes via the EP4 receptor, by a mechanism involving 
transactivation of the epidermal growth factor receptor and ERK1I2. These data suggest 
that in sexually active women, cervical carcinoma may be exacerbated following 
exposure to seminal plasma and activation of EP-receptor signal transduction pathways. 
As a result, cycooxygenase enzyme inhibitors on their own may not be sufficient to 
inhibit prostaglandin action in sexually active women. These data raise the possibility 
that EP4 receptor antagonists used in combination with cyclooxygenase enzyme 
inhibitors may be a potential therapy for these women, 
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CHAPTER 1 - INTRODUCTION 
Introduction 
The development of carcinoma is a multi-factoral process resulting from aberrations in 
cell regulatory pathways governing homeostasis and cell proliferation. There have been 
more than 100 different reported cancers occurring in cells and organs throughout the 
hwnan body. Although the initial triggers of neoplastic cell transformation may vary, 
different cancers have been shown to have common characteristics. These include a 
limitless reproductive potential, insensitivity to anti-growth signals, self-sufficiency in 
growth signals, as well as sustained tissue invasion and metastasis coupled with 
angiogenesis. Numerous studies have implicated a role for COX-enzymes and COX-
enzyme products in the regulation of tumourigenesis in a wide variety of cancers (Chang 
et al. 2000; Jabbour 2001; Kulkarni et al. 2001; Sales et al. 2001; Denkert et al. 2002; 
Hawk et al. 2002; Sales et al. 2002; Song et al. 2002; Gupta et al. 2003). The effect of 
these COX-enzyme products, or prostaglandins (PG) are mediated by specific receptors, 
which result in the activation of various signalling pathways ultimately culminating in the 
transcription of target genes which may enhance tumourigenesis or angiogenesis. 
The focus of this work is on the possible regulation of tumourigenesis through the PG 
EP4 receptor. This introduction will give a brief overview of the epidemiology, histology, 
risk factors, and staging of cervical carcinomas, and the roles of COX-enzymes, PG and 
PG receptors (specifically the EP4 receptor) in mediating tumourigenic effects. 
1.1. Cervical Carcinoma 
Cancer of the uterine cervix is one of the leading causes of cancer-related death in 
women worldwide, with nearly 500 000 women developing the disease each year 
(Williams et aI. 1998; Molina et al. 2003; Waggoner 2003). There has been a substantial 
decrease in incidence and mortality in developed countries, which is though to be as a 
result of more effective screening. However, in the less developed regions of the world 
including South-East Asia, South and Central America, and Sub-Saharan Africa, as 
detailed in Table 1, cervical cancer continues to be a major problem for female 
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reproductive health (Munoz et al. 1992; Aareleid et al. 1993; Moore et al. 2004) 
(Table 1). 
Registry Recording Cases Rate per 100 000 
period women 
Ten highest rates 
Zimbabwe, Harare 1990-92 295 67.21 
(African women) 
Brazil, Belem 1989-91 931 64.78 
Peru, Trujillo 1988-90 288 53.48 
Uganda, Kyadondo 1991-93 248 40.76 
India, Madras 1988-92 2540 38.91 
Brazil, Golanla 1990-93 506 37.13 
Columbia, Call 1987-91 1061 34.41 
New Zealand 1988-92 193 32.21 
(Maori women) 
Argentina, Concordia 1990-94 108 32.05 
Ecuador, QUito 1988-92 697 31.66 
Ten lowest rates 
Spain, Navarra 1987-91 82 4.68 
USA, Hawaii 1988-92 10 4.55 
(Chinese women) 
China, llanjln 1988-92 454 4.39 
Israel 1988-92 187 4.07 
(Jewish women born in USA 
or Europe) 
USA, Los Angeles 1988-92 20 4.05 
(Japanese women) 
Rnland 1987-92 893 3.62 
China, Shanghai 1988-92 860 3.26 
Israel 1988-92 40 2.99 
(Non-Jewish women) 
Italy, Macerata 1991-92 12 2.77 
China, Qidong 1988-92 97 2.64 
Table 1: Registries with the highest and lowest incidence rates of cervical cancer. 
(Waggoner et al. 2003) 
The prevalence of cervical cancer disease is particularly high in South Africa, occurring 
on average, in 60 out of every 100 000 women (Bailie et al. 1996; Sitas et al. 1997) 
(Sales et al. 2001). In certain groups of South African women screened at the primary 
health care clinic in Soweto, Johannesburg, the detection rate of invasive cervical cancers 
is 1.8 per 1000 women (Leiman 1976). The peak incidence of this disease in women is 
between 50 and 54 years of age, with more than 80 % presenting with cervical dysplasia 
at 40 years of age or older (Bailie 1995; Wright et al. 2004; Wright et al. 2004). 
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Although ttrvical carcinOflUl is g .. m.rally associated with middle·aJed women. several 
5!udi .. s have shown an jnnea~ in the in .. idence of boll! squamous ttll Cln'lIloma and 
adenocarcinoma m YOllnfCT women (Bulk .. , al. 2004: Smith", al. 2004: SmtkolJ .. , al. 
~). 
While a dedme in incidentt and monality from cervical cancer has been documented in 
first world C<H.Imries such as thoe Unikd Slates. Canada, and Scandinavia (Moodley tl ,II. 
200)). Ihis trend is nOl apparent for most rn,v .. loping c{)UnlTies due to lack of. or 
ineffidenr scteeninl proarnms (Williams 1" 01. 1998). This results in women being 
diagnosed wirh rhe di:>ease when it has progressed subslantiaJly. often with LymJIh node 
melastasis. when wrgel)' or clinicallrealmenl is not possible. Canur of the uterine cervi ~ 
is thus stiLi regarded as lin imponllnt dinical problem in many developing coumries. 
especially SOIllh Africa. 
1.2. Histology of the ..... rvi~ 
Tile cervix is the cooe_shaped ned: of Ihe uterus thlt prQIrudes into Ihe vagina (Figure 1.1 
A). II is about one inch lonl and is fibromuscular in origin. It surrounds the endocervical 
canal (the os). whicll permits the menstrual period and the fetus to pass from the uterus 
into the ,·agina. and sperm \0 pass from rile "Igina into the uterus. 
fAL.~Of'IAH TUBE 
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Figure LI.B, RI'pn:sen ll!!ive cruss Stell"" of Uteone em';:, fHacmOlQ,S)"hn- and roSIn· 
:iI4!1l\!d; magnification .J()Q~), 
The epi thelial lining of the 10"'cr genital t!'llCt in women consists of twO disiioci cdl 
l)peS. namely sqlUtmous and oolumn .. u tpithelial cells (Fichorl)vlI el III 1999). The 
epithelial liniog of the ~agllla and C\ocervl~ consists of mlll l;ple la}trs of Slralificd 
squamous epuketl!l cells (Fiaure 1. 1. B); this is a non-Slcri lc environment lhal tolerales 
an abundaoce uf vaginal micl'OIWgallisms as well as dhcr.;c seminal antigens. 011 Ihe 
Oilier luIoo. the- elldocenical canal is liard by a single layer of columnar-type epithelia l 
cells and forms D Llsunll) Slenle pass.1!,!t imo tile upper gl."niml Imel (Fichorova <'I al. 
1999). The junction between the sqliBlllOUS ",pi tllelium of the cervi~ and the columnar 
cpl\lIelium originatlll& from tile endoc('nical glands is referred to as the squamocolumnar 
junction. During adolescence and pregMnc.y. the squamous epilhelium replaces tile 
columnar ePltllellum by metastasis 10 furm a new squan1ocolumnar j unction. Tile area 
bel"een the ncw and old squamocolumnar junction is refurta 10 as tile transformation 
ZODe. Se>cral studies ha\c pmp(l~d tllm cnrcinogcns Ilct at the tra nsformation zone to 
cause (',",ical neoplasia ( Kristensen el (II. 1989: Martm. Hirsch 1'1 ul. 1999). 
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1.3. Histology of pre-invasive lesions 
About 90 % of cervical carcinomas arise from flattened or "squamous" cells covering the 
cervix. Most of the remaining 10 % arise from the glandular, mucus-secreting cells of the 
cervical canal leading to the uterus (Waggoner 2003). However the incidence of 
adenocarcinoma is rising in relation to that of squamous cell carcinoma (Young et al. 
2002). In most cases, adenocarcinoma-in-situ is probably the precursor lesion, but it is 
detected much less efficiently by Pap smear screening than are pre-invasive squamous 
lesions. Clear-cell carcinoma is a rare adenocarcinoma subtype, which accounts for fewer 
than 5 % of adenocarcinomas (Young et al. 2002). Previously, many cases developing in 
young women were associated with in utero exposure to diethylstilbestrol (Li et al. 2003; 
Waggoner 2003). Since use of diethylstilbestrol in pregnancy has been prohibited, the 
nwnber of cases associated with this drug has diminished (Li et al. 2003). In the absence 
of diethylstilbestrol exposure, clear-cell carcinoma most commonly occurs in 
postmenopausal women. The remaining cases are made up of various subtypes, such as 
adenosquamous cancers and small-cell (neuroendocrine) carcinomas (Young et al. 2002). 
The development of cervical cancer is gradual and begins as a pre-cancerous condition 
called dysplasia. Dysplasia, depending on its severity, can resolve without treatment, 
particularly in young women. However, it often progresses to actual cancer termed 
"carcinoma in situ" (CIS) if it has not spread, or "microinvasive" if it has spread only a 
few millimetres into the surrounding tissue and not into the lymph channels or blood 
vessels. It may take a few years for dysplasia to turn into CIS or microinvasive cancer, 
but once this process occurs the cancer can quickly spread deeper into surrounding tissue 
or other organs, such as the bladder, intestines, liver, or lungs (Juneja et al. 2003). 
5 
1.4. Pathology of pre-invasive lesions (Cervical Intraepithelial Neoplasia) 
Much controversy still surrounds the histopathologic classification of cervical cancer 
precursors. The World Health Organisation (WHO) classification system uses the 
terminology 'dysplasia' and 'carcinoma in situ' to refer to precursor lesions. In the 
1960's, Richart introduced the terms cervical intraepithelial neoplasia (ClN) (Richart et 
al. 1993). The nomenclature ClN grades I to III are used to describe pre-invasive 
epithelial lesions or various categories of dysplasia and carcinoma in situ (Wright et al. 
2003). ClN grade I is equivalent to mild dysplasia in which undifferentiated cells occupy 
approximately the lower one third of the epithelium. ClN grade II is equivalent to 
moderate dysplasia where undifferentiated cells replaces two thirds of the thickness of 
normal epithelium. ClN III denotes severe dysplasia or carcinoma in situ. Severe 
dysplasia describes a condition in which undifferentiated cells replace all but one or two 
of the most superficial cell layers of the cervical epithelium (Wright et al. 2003). All 
degrees of dysplasia are pre-invasive, meaning that the basement membrane (stromal 
epithelial junction remains intact). 
A newer classification, the Bethesda Classification, has been introduced which designates 
squamous intra-epithelial lesions (SIL) as either low-grade or high-grade. Low-grade SIL 
involves mild dysplasia or ClN I, with features of HPV infection. High-grade SIL 
corresponds to moderate to severe dysplasia, or ClN II and ClN III. In the last stages of 
neoplasia, before definite invasive carcinoma develops, ClN III is indistinguishable from 
carcinoma in situ. The clinical and biologic utility of the Bethesda Classification has lead 
to widespread acceptance by both pathological laboratories and clinicians, however there 
is no widespread consensus as to which terminology should be used. 
1.5. Staging and Prognosis of Cervical Cancer 
Once a tissue diagnosis of invasive carcinoma has been established, the degree of 
invasiveness is determined according to the stage of disease set out by The International 
Federation of Gynecology and Obstetrics (FIGO) as outlined in Table 2. 
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Modifications to the FIGO staging system were made in 1994 to clarify the description of 
microinvasive cervical cancer (stage !AI and IA2) and to subdivide stage IB into IBI 
(tumour < 4 cm) and IB2 (tumour> 4 cm) tumours. For smaller lesions (stage !A and 
IB 1), stage is assigned after measurement of the depth of tumour invasion (on cone 
biopsy), pelvic examination to assess tumour size clinically, or both. For more advanced 
tumours, pelvic examination under anaesthesia is occasionally necessary to allow 




















Carcinoma-in-situ, intraepithellal carcinoma 
Invasive carcinoma strictly confined to cervix 
Invasive carcinoma identified microscopically 
(all gross lesions, even with superficial invasion, 
should be assigned to stage IB) 
Measured invasion of stroma 3 mm or less in 
depth and no wider than 7 mm 
Measured invasion of stroma more than 3 mm 
but no greater than 5 mm in depth and no wider 
than 7 mm 
Preclinical lesions greater than stage IA or 
clinical lesions confined to cervix 
Clinical lesions of 4 cm or less in size 
Clinical lesions more than 4 cm In size 
Carcinoma extending beyond cervix but not to 
pelvic sidewall; carcinoma involves vagina but 
not Its lower third 
Involvement of upper two-thirds of vagina, no 
parametrial involvement 
Obvious parametrial involvement 
carcinoma extending into pelvic wall; on rectal 
examination, there Is no cancer-free space between 
tumour and pelvic sidewall. The tumour Involves 
lower third of the vagina. All patients with 
hydronephrosis or non-functioning kidney are 
included unless known to be the result of other 
causes 
Involvement of lower third of the vagina; no 
extension to pelvic sidewall 
Extension to pelvic sidewall and/or hydronephrosis 
or non-functioning kidney 
Carcinoma extends beyond the true pelviS or clinically 
involves mucus of bladder or rectum. Bullous 
oedema does not allow a case to be designated as 
stage IV. 
Spread of growth to adjacent organs 
Spread to distant organs 
Table 2: FIGO staging for cervical cancers. 
(Waggoner SE, 2003) 
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Clinical stage is a reliable prognostic indicator for patients with cervical carcinoma. Five-
year survival approaches 100 % for patients with twnours of stage IA and averages 70 -
85 % for those with stage ml and smaller lIA lesions (Waggoner 2003). Treatment 
strategies for stage m and early stage lIA invasive carcinoma include: 
1) a primary surgical approach with radical hysterectomy and pelvic 
lymphadenectomy or 
2) primary radiation therapy with external beam radiation and either high-dose-rate 
or low-dose-rate brachytherapy (Wright et al. 2003). 
Survival for more locally advanced twnours (stages m2 to N) varies and is influenced 
significantly by the volume of disease, the patient's age, and co-morbidities. Overall, 5-
year disease-free survival is 50 -70 % for stages m2 and 1m, 30 - 50 % for stage III, and 
5 - 15 % for stage N. Once cervical cancer has extended beyond the cervix, cure with 
radical surgery alone is unlikely. Treatment strategies for stage 1m and greater involve 
external-beam and brachytherapy radiation and concurrent cisplatin-based chemotherapy 
(Waggoner 2003). Metastasis to pelvic, and especially para-aortic, lymph nodes are 
associated with poorer survival. Although they comprise less than 5 % of cervical 
carcinomas, adenosquamous twnours and small-cell carcinomas with neuroendocrine 
features have a particularly poor prognosis (Waggoner 2003). 
Surveillance after primary therapy for invasive carcinoma of the cervix is recommended. 
Approximately 35 % of patients will have persistent or recurrent disease (Waggoner 
2003). The main goal of surveillance is early detection of recurrent disease so that 
patients may be offered potentially curative salvage therapy. The potential benefit of 
salvage therapy depends on the stage of disease, type of treatment, and location of the 
recurrence (i.e. local, regional, or distant). In general, radical radiation therapy is used for 
recurrent cervical cancer after primary hysterectomy, while salvage surgery is required 
for patients who relapse after primary radiation therapy. 
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1.6. Risk Factors for Cervical Cancer 
1.6.1 Human Papilloma Virus (HPV) 
Human papilloma virus (HPV) is considered to be the most important risk factor 
contributing to the development of cervical intraepithelial neoplasia and cervical cancer 
(Juneja et al. 2003; Riley et al. 2003; An et al. 2004; Silins et al. 2004). More than 90% 
of squamous cell carcinomas contain HPV virus DNA (Waggoner 2003). HPVs are 
mucosal-trophic viruses infecting basal squamous epithelial cells, with the protective 
phase of the viral life cycle elaborated in the upper squamous epithelial cell layers (Riley 
et al. 2003). Most HPV infections are transient (Hinchliffe et al. 1995), but in the 
minority of patients, persistent viral disease localises in basal squamous cervical 
epithelial cells of the cervix, and underlies neoplastic progression and emergence of 
invasive malignancies. 
Although many HPV types have been associated with anogenital neoplasia, types 16, 18, 
31,35,39,45,51,52,56, and 58 cause most invasive cancers (Juneja et al. 2003; Rileyet 
al. 2003; Waggoner 2003). HPV 16 and 18 have two transcriptional units, E6 and E7, 
which encode proteins essential for viral replication (An et al. 2004; Szkaradkiewicz et 
al. 2004). These oncoproteins bind to various tumour-suppressor genes to disrupt the cell-
cycle progression (Riley et al. 2003). Fortunately, not all women who have had HPV 
infections, or genital warts develop cervical carcinoma. There are other factors believed 
to playa role in increasing the risk of developing cervical cancer. 
1.6.2. Sexual behaviour 
Other risk factors believed to contribute towards cervical carcinoma include sexual 
activity starting at an early age «16 years), multiple sexual partners and/or partners who 
have multiple partners, as the risk of contracting sexually transmitted diseases would be 
much greater in these individuals (Taylor et al. 1959; Martin 1967; Brown et al. 1984). 
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Domenico Rigoni-Stern in the middle of 19th century, who was an Italian chief physician 
of Verona Hospital and an instructor at University of Padua, first raised the issue of 
cervical cancer and marriage. He had observed for the first time that more uterine 
cervical cancer is found in married than unmarried women, based on mortality reports. 
The relationship of cervical cancer with sexual behaviour is supported by the fact that 
disease is rare in nuns (Taylor et al. 1959; Martin 1967; Brown et al. 1984). 
Studies performed by Martin in 1967, based the epidemiology of cervical neoplasm on 
three fundamentals, which are (i) near absence of neoplasms among nuns (ii) near 
absence of neoplasms among other species (other than humans), and (iii) extremely low 
incidence of disease among virgins. The main factors explored were early age at 
marriage, marital dissolution and remarriage. In all studies, cervical carcinoma cases 
occur more frequently following early coitus, marital dissolution and remarriage than in 
controls. This highlighted sexual behaviour as an important contributing factor in the 
process of cervical tumourigenesis. 
1.6.3. Other risk factors associated with cervical cancer development 
Patients receiving immunosuppressive agents and those who are HIV -positive are also at 
an increased risk of developing cervical cancer, as any pre-neoplastic cells would be 
rendered more susceptible to viral infection (Waggoner 2003). Infections with genital 
herpes or chronic Chlamydia infections (Anttila et al. 2001), both sexually transmitted 
diseases, may also increase risk rendering the cells more susceptible to neoplastic 
transformation. 
Cigarette smoking (and perhaps even exposure to environmental tobacco smoke) is an 
independent risk factor for significant cervical dysplasia and invasive cervical 
(Winkelstein 1990; Szarewski et al. 1996). Tobacco-specific carcinogens and polycyclic 
aromatic hydrocarbons have been identified in the cervical mucus or epithelium of 
smokers. These compounds can bind to and damage cellular DNA and might act, together 
with HPV, to facilitate malignant transformation. 
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Recent studies have also implicated a role for steroid contraceptive hormones in the 
pathogenesis of invasive cervical cancer (Moodley et al. 2003). Steroid hormones are 
thought to increase the expression of the E6 and E7 HPV 16 oncogenes, which in turn 
bind to and degrade pro-apoptotic factors, leading to apoptotic failure and carcinogenesis 
(Baldus et al. 2004). However, to date, the molecular mechanisms through which these 
agents function is unclear. 
1.7. Diagnosis of cervical carcinoma 
The symptoms of early cervical carcinoma include watery vaginal discharge, intermittent 
spotting, and postcoital bleeding and because these signs may apply to a broad range of 
pathologies, the symptoms often go unrecognised by the patient. Since the introduction of 
the Pap smear by Papanicolaou and Traut in 1943 to detect precursors of cervical cancer 
in women, cytological screening has been one of the most successful public health 
measures introduced for the prevention of cancer. 
The Pap smear test samples approximately 500, 000 - 600, 000 superficial surface cells 
from the epithelium of the cervix (exfoliative cytology). Smear preparations are made 
from these samples and screened for the presence of precursor malignant (dysplasic) cells 
by using morphologic criteria (Williams et al. 1998). A pap smear can pick up dysplasia 
and early forms of cervical cancer that have not yet spread. Most women diagnosed today 
with cervical cancer have either not had regular Pap smear tests or they have not followed 
up after having an abnormal smear (Misra et al. 2004). However, it must be understood 
that the purpose of Pap smear is just to screen for intraepithelial lesions before they 
progress to invasive disease, and this is subjected to limitations (Hussein et al. 1992). It 
has reduced the incidence of cervical cancer, but it is not expected to detect all the 
precursor lesions and it is not appropriate to detect large invasive neoplasias. 
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Due to the accessibility of the cervix, accurate diagnosis often can be made with 
cytologic screening (Pap smear) or visualisation of a lesion on the cervix (Misra et al. 
2004). A biopsy sample must be taken from any suspicious lesion, because many pap 
smears are non-diagnostic or falsely negative in the presence of invasive cancer. These 
may be either a colposcopically directed biopsy, or biopsy of a gross or palpable lesion. 
In cases of suspected microinvasion and early stage cervical carcinoma, cone biopsy of 
the cervix is indicated to evaluate the possibility of invasion or to define the depth and 
extent of microinvasion. Cold knife cone biopsy provides the most accurate evaluations 
of the margins (Misra et al. 2004). 
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1.8. Arachidonic acid metabolism 
All mammalian cells except erythrocytes synthesize lipid-derived autocoids, known as 
eicosanoids (Murakami et al. 1999). These molecules are extremely potent, able to cause 
profound physiological effects at very dilute concentrations. All eicosanoids function 
locally at the site of synthesis, through receptor-mediated G-protein linked signalling 
pathways. 
Eicosanoid biosynthesis, outlined in Figure 1.2, is controlled by the rate-limited release 
of the C20 fatty acid, arachidonic acid, from plasma membrane phospholipids by a 
receptor-activated cytosolic phospholipase A2 (pLA2) (Murakami et al. 1999). 'The major 
source of arachidonic acid is through its release from cellular stores. The immediate 
dietary precursor of arachidonate is linoleic acid. Following its release into intracellular 
stores, arachidonic acid is oxidised by either cytochromes P450 to epoxyarachidonic 
acids, or COX to a hydroperoxide cyclic endoperoxide, prostaglandin G2 (PGG2). PGG2 
then acts as the substrate for a glutathione-dependent hydroperoxidase, to yield a hydroxy 
cyclic endoperoxide (PGH2). PGH2 is then the substrate for terminal prostanoid synthase 
enzymes, leading to the prostaglandins, PGE2, PGD2, PGF2a, prostacyclin (PGI2) and 
thromboxane A2 (TxA2) (Goetzl et al. 1995). 
A widely used class of drugs, the non-steroidal anti-inflammatory drugs (NSAIDs) such 
as ibuprofen, indomethacin, naproxen, phenylbutazone and aspirin, all inhibit both COX-
1 and COX-2, as depicted in Figure 1.2. The mode of action of aspirin involves its 
acetylation of a Ser residue near the active site, preventing arachidonic acid binding. 
Because inhibition of COX-1 activity in the gut is associated with NSAID-induced 
ulcerations, pharmaceutical companies have developed drugs targeted exclusively against 
the inducible COX-2 activity [e.g. Celebrex (celecoxib), Bextra (valdecoxib), Prexige 
(lumiracoxib) and the recently removed Vioxx (rofecoxib)]. Another class, the 
corticosteroidal drugs, act to inhibit phospholipase A2, thereby inhibiting the release of 
arachidonate from membrane phospholipids and the subsequent synthesis of eicosinoids. 
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1.9. Cycloo.'l.}gena«e (COX) Enzy~ 
Tllr~ jsoforms of!1Ie COX enzyme (COX-I. COX-2 and COX-)) ha~e be-en identified 
(Chartdrasc:kharan rl al. 2002: Morna 2(02). The COX- ] eDNA was cloned III 1988 ff()tll 
sheep. mOllS<!'. and human soorces (Kniss 1999; 1>larnen 2002). The human COX·! gene 
has been mapped 10 chrom05Qmc 9q12-q3J.l .nd h 2S kb in .size. II has II uoos. 
prodtIC« a 2.8 - 3.0 kb mRi\A and 68 kOIi proleln (Fri lsclle t'l ul. 200 1). 
The protem lias an N-terminal membrane SIgnal 5C\juc:tlCe. a C-temunal endoplasmil:: 
rellculum retenLLOO !tilla!. and fow potential glycos)'lallon Sltcs Tkn:: is 110 eyidcllCe 
that phosphorylation plays a role in tbo:: regulation of COX actiyity (Tunm 1.'1 al 2002) 
COX-2 is an immediate e;\1ly rnponsc: Io'<:ne of 8 kb "tuth is tOntposro of 10 eJlons aod 
]()(3ted on human chromosome Iq2S.2-q2S.3 (KniSS 1999). The mR:-lA is 4 1 - 4.5 kb 
~!ld em:ooes a protcm of 68 kDa (Ilia el 01. 1992). 
One of the umque dlffl'Tenc:es bo::t"t'CI1 the t,,·o COX CfiZytnCS is the e.\lended C-Imllinus 
tOll of COX·2. broui;hl about oy the UISl.'rtion of 18 aa. Inserted 6 residuC5 from Ibe C-
tcnntnlJ!l Po&I-translallonal proccsslng of the COX-2 tr.lD5Crlpl results In the ellOprcssion 
of protein homodi~rs of 72 ltDa and 74 kDa. comp;irI,\1 "lib Inmslallon of the COX-J 
Inlnscript. "hieh results In protein homodinlml of 72 kDa subunit! (KlIlss 1999; Snllth et 
al. 2000). Bolh COX~nzymes e:<ist as dimmen both structur~lIy and functionally. Botb 
isofomlS Dre N-i>1)'Cosylaled at Asn&l, Asn!" aoo Asn"·. Gl)'Cosytation is necnS3ry at 
Asn'lu and either Am" or Asn'" for expression of the CycJOOllOYSCIllISC and pcroxul:ise 
activities. In addition. the COX-2 <:nZ)lne is w>",=os)lated at Asn<JII 50·", of the lIRIC, 
which explams thc presence of the 72 kIh and 74 ldJa subumts (O'Neill 1.'1 al. 1'>93; Otto 
1.'111/. 1993; Smith ci al. 20(0) . 
Buth COX isoforms arc integral membrallC heme-g1ycoprtKeins. carry Out esscrlllully rhe 
same catalytic reaction and have sinuJar ternary S\nIClUr'l.:S (Smith '"~ al. 2001). I-Io"c'cr, 
the pro-Infbrnmarory role appears 10 be mediated mainly by COX-2, Yo hereas most Ortlle 
'hoU5eke~'PlIlg' functions appear to be regulated by COX-I (Smith '"~ "I 2001). Both 
enz},m:s an: present on the Iwmnal surfaces of the endoplasmic relleulum and innc-r BnU 
outer membranes of the noclcar envelope, although COX-2 appears to be more BSSOCI UU:U 
with the m.o;lear envelope than COX-l (Smith cl "I. 2000). This predominantly nuclear 
localiS.1tion of COX -2 TlIisc! the possibility thai it may be in' ohcd 11\ l:(enc IrDnscnplioll 
or rel:(ulatton at a nuclear le"el. 
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More recently, stw:hes hne suggested that both COX~yme Lsoforms C3.0 be 
upregubted (Narko tl al. [997; Mald\"e 1'1 a/. 2000: Takeda 1'1 oJ 2(03). In 1'lIm models 
ha~ demonstnltOO dut the transc:ription of both COX~ymes can be IndUCed by 
arachidonic acid, prostaglandins, 11l5l;u[ar endothelial gnm lh factor (VEGF). forskolm 
(an activator of 3dcn~'late e)'dase) and dibutyryl eAf,.'1P (a cAMP analogue) {Mald'e 1'1 
(,I 2000; Prescon tl al. 2000; Marnell 2002, Iwasaki tl aI, 2003; Tal.cda tl a/ 2003; 
Chang el 01. 2()04: Wung tl al. 2{)(14). These snlliie5 havc also sho"n that COX-I IIIId 
COX·2 are differently regulated m response: 10 vaooLlS stinlLlli, lind nUlY be coupled 10 
different prostanoid m:eptors. "hleh "''Quld allow (or different pl'05lOooid proliles.. 
The Ihird i50form of COX, oamely COX·3, is a product of COX·, ~oe thai retams 
inlloo I io the mRNA (ChaodnLsekharan el a/. 2(02), In hUl1l3ns. LI IS expressed 11.5 a S.2 
kb transcript m cerebral cortex and heart and sdccu"ely Inhibited by ;./SAI05. However, 
the role orlh,s isoform in both mflammallon and lumoungencsLs L$ unknown. 
1.9. 1. Regulation orcox coz),ncs 
In general. COX-I synthesises prosllIglandlOli that servc IIOb1c purposes m housckccpl!l& 
such 35 prot~'Cting the stomach from ulcers and regulallng n::nal blood flo" (I'rcso;:on il 
01. 20(0). III selected cell s lind tisslles, including endometrilllll. OIOOOCytCS. platelets, 
renal collc:cting tubes nnd seminal vesicles. COX- I has been reponed 10 be consltlUu,cly 
expressed at h,gh levels {Swlb C{ al 2000; SIMh ('I al. 2001 ). Sc~cr.11 Sloo!es hale also 
reported expression of COX· J (0 be incrcased in differentiating cells. II hlch suggcsts th:11 
II may be dc"elopmcnUlJly rCilulatcd (Narlu cl al. 1997). 
There arc $C"crnl plltatlve lranscnptional feilulatory elements (Sp l, AP·2 , Nf·IL·6 and 
GATA) in the promoter regIOn of the COX·1 gene. However. the COX·I gene has 00 
TAT A or CAA T box and is GC·nch, eOllSIStCnl with the feluUfes o( a housckeeplrlS gene 
(Fib'Ul"e L3). COX·1 expression IS comrolled by the Spl tl1lnscription factor (Tamura 1'1 
uJ 2002). The Spl els·regulatory clemen! (CRE) on the COX- I promoter binds (hc {fans· 
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lK"u\ating Spl protcm. Deleuon of the Spl Sill.' is llSSOC iatcd wuh signtficant reducllon In 
basallc,cls of COX· I (Smith 1'1 .. / 2000: Smith 1'1 .. I. 2001: Sub/l3ram3.lah elilt 2002), 
COX·2 is !lIpidly IndUCed following stimulation of cells with growth facton; and 
rroroiaton; of m/lammation. such as the pro-inflammatory e)'lokine lL·1. 11.·1 is 
upregulated It tlte site of innammatlon and plays a major role in inducing COX·2 by 
activating the mmscription f;!Ctor NFtdJ (Kanckul1l 1'1111. 2002; Sarnad ct <II. 20(2). The 
stimuli necessary faT mducing COX·2 expTes~io n di ffer depending on cell t}PC and 
rh)'$iologtcal acllvity. In the kidney. COX·2 IS uprcgulatcd in response to increasmg 5.1111 
concenl/ailon, whereas in granulosa cells COX·2 is IndUCed m response to follicle .. 
51111111131111g homlDlIC und IUICil1llmg hannonI.'. SlgnaltransdlJClion palhways linked 10 me 
tl'"Jnscriptional activation of COX·2 may differ depending 00 the shmulus (Gasparini n 
til. 20(3). 111= pathways lI1 ay be shared or convcrgCOt IlJId include the NF .. S and 
''>'lAPK pathways (KanckunI 1'1 til 2002; GlISpmm .. , .. I 20(3). COX·2 gcm.' 
transcription is induced through NF .. B by an extl1lCellul;lf·signal·related kmue (ERK), 
p38, and Jun N·lcmlinal kinase (J!'.K), through 'IF· IL6 \." p38, WId Ihrough CRE Via 
ERK1 and JNK p:nhways. PKC Sttms to mediate COX·2 tnlnscnptlon through 311 thn:c 
promoter sites. COX·2 IS lI:1rlSC\1ptionaUy downregubted by APe and regu lated by c· 
Myb, and nuclear acrumulallOn of [katcmn. through the lI'nt·5I/PIalhng path" ay. 111 
human colon and liver carcillogenesis, ",hereas k·("(U induces COX·2 mR..'A slabllisl\l.lOO 
(Gasparini l'f Ill. 2003). 
The molecular rcgu1atlOn of COX·2 gc:nc: expression is tightly controlled on 
tnmscriptional and post· transcnptional Ic\·cls. lIo,,"e ... er, dysn:gulation at cllher !C\'cI of 
COX·2 gene regulation prormtcs consutulI\'e COX·2 ol·erexpression. which ploys I key 
role .n tUmowigenCSIS. Fi\"C' major regulatory clcmcnl5 nan!cing the 5' .. region of thc 
COX·2 gene: have been idrntified as rigorous regulators of COX·2 tronSCnPIlOn, These 
regulatory cI~l1Cl\\S an:: o\'erhJpping E·box and ATF'CRE sequences, NFI[L·6 CAAT 
enhancer binding Siles and NhB binding Sites (Figun: 1.3.). The NF .. B Signalling 
path" ay nt:ly be IICltl'ated by various efTe<:tors. including hypox la. endothclln. I L· I P and 
tumOuf necroSIS f:ICtar alpha (TNFo) In \"arious celt type$. 
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I\IUlallo ns In the NF .. S cil'-regulatOl)' region causes allenualed activalion d COX-2 in 
response to TKFa stimulation as well as reduced binding of NF .. S -like prOleins. 
suggesling Iha l NF .. S regulales COX-2 express ion in response to cenain activators 
(Turini tlal. 20(2). The ATFICRE sile is nct ivatcd by hetc ro- and homodimers of the c-
fos. c-j un Dnd ATF families lind the cAM P regu lalory bind ing protein (CRES) {Hawk t l 
(11. 20(2), MUlatioll$ in the AT FICRE sequence reduces serum-. PDGF-. and Src-
stimulaled transcri ption of COX-2 ill mice. This $uggesl$ a role for cAMP in regulating 
COX-2 expression. In add ition. the COX-2 promoter al so contains a peroxisome 
prol ireralor.;. activnled response element (PPRE) COI1seMUS site IlUggesilll& thai 
pc ro~ i son\(\ proliferalOrs may IllOd ulale transcription of COX-2 (Inoue d /II . 2(0:): I-Ian d 
al 2003: Murakami el al. 2/))4). 
I I I In I COX-1 gene 
AP2 MVb GATA I Spl \ ." 
AP2 ~F~L6 
_1l1ll-ID 
I I " II----lrI ~COX-2'~." 
AP2~F.fL6 CREJE.oo~ TATA ." NhB 
fig ure I 3 ReguJalOQ' clements in the pro!PO(('r re : jon of the burnan COX- I and COX·2 
acnes (Murakami and Kudo. 7ip11. These promoU'r regions iAlllcate thai COX- I and 
COX-2 are housekeepin, and immediaUl early genes. resJIC(lively. 
" 
Several studies investigating the regulalOry mrehanisms of COX-2 expressIon has 
demonstrated the post-transcriptional regulation to playa rolc (Dixon 2(04). Rapid 
COX-2 mRNA decay and translational inhibi tion is mediated through a consel"\oo AU-
nch dcmell1 (ARE) presenl within the 3' -untranslated region (J·UTR). The COX-2 ARE 
exerts its control through association with ARE RNA-binding proteins. These trans-
:>cting regulatory factors influence the fate of COX·2 mRNA hy cOl1trolling mRNA 
degradation, stabilization. or translatioll. Recent evidence demonstrales the functional 
significance rapid mRNA decay and translational inhibition pby in controlling COX·2 
gene expression and Ihal. if dysrcgulatod. allow for overexpression of COX·2 and other 
associated angiogenic tactors delected in neoplasia (Dixon 2004). 
1.10. The role of cydooxygenase (COX) enzymes in cancer 
The mecl1anisms involving PG biosynthesis were initially outlined m 1967 by Hamberg 
and Samue1sson. The tmn prostaglandin ernloperoxide (PGH) s>l1thase or 
c~looxygeuase (COX) was coined to describe the enzyme responsible for calalysing the 
conversion of fally adds to prostaglandins (Chandrasekharan <'I al. 2004: Zha 0:1 al. 
2(04). Several prostaglandins have subsequently been isolated (Marnell 0:1 al. 1999: 
Marnen <:1 "I. 1999). This lead 10 the punfication of COX-I In 1976 as a key enzyme in 
the prostaglandin bioS}1lthetir JXllhway (Mametl el al. 1999; I-l3mcn el III 1999). 
Subsequmtl y the mode of action of nOll-steroid.:! 1 anti-inflanunatory drugs (NSA IDs) was 
attributed to inhibition of a single COX-enz)1Tle (Davis 0:1 "I. 20(4). The disco\cry of a 
second. inducible fonn of COX enzyme. known as COX-2, dramatically altered the role 
of NSAIO in health and disease (Kniss 1999; Dav)s el a/. 2(04). Recmtly, a thIrd 
isofoml of the COX-enzyme (t~nned COX·J) has !;leen disco\cred. It is hypothesised that 
COX·2 functions in resolution of """Ie inOamm"lmy re<pfmse~ and lh"t mX·l .. 
""Iurned on'" later in inflammation and rn;lY be invoh'ed in the biosynthesis o f mdogcnous 
:mtl·inflammatory mediators (Davis el al. 20(4). 
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Inittal observations by Rolland rI ul. (1980) ind icated IMII'G prodllcllon .... a5 elevated In 
human breast cancers (Rolland ('/ ul. 1980). ' l11is h)'llQlhcsis WIS based on the fim.lmg.5 
that PG production in human breast carcmomas cOl'TClntcd with noopl l\S.tit cell dcnsily 
and active tUmoUT itwasion. flirthl.'T epidemiological studies revealed that long-trnn 
cootinual administration of the NSAiD aspirin reduced the risk of colorectal disease by 
40 - 50 % . This demonstrnted a negattve COTTCla1l00 between NSAiD usc md 
development of colorectal cancer (Tsujii ('/ ul 1998; Tsujii rt ul ( 998). COX inhib,tOfS 
also exhibit dramatic anti-ncoplasllc actIVity in a nuni>cr of tumour nlildel s)'SIems. 
These include colon cancer cells impllllltcd mto nude mice. tumour production m APe 
mutant mice, and carcinogen-mduced tumours in rats (Oshima ('I ul. 1996; Sheng I!I ul. 
1997; Kawamori ell/I. 1(98). In one sllCh study. Seed I!I ul, (1997). demonstrated that 
topical administration of non-sclooi\'c COX inhlbllOf' (dlclofcnac) reduced the growth of 
colon-26 cancer cells, which express COX and produce !'GEl, '" hen implanted into nude 
mice (Seed ('/ <II. (997). ht this Sillily. the authors made an IOtponant obscr"Dlion lhatlhc 
IIIlti_tumouT efft:<;ts of diclofenac .... ere due 10 an antl·angiogeDic effect. This raised the 
possibili ty that elevated COX. cspe<:ially COX-2. plays a role 10 the growth of colon 
cancer cells due to ils ability 10 act !IS a tWllOur promoter viB stimulation or 
tumourigCllesis and angiob'Cnesis (Kakiuchi t:1 al. 20(2). Such a mechmism might also 
explain the 90 % Inh,b,tIOn or the growth of COX-2-posllivt: IICA-7 tumours in ,;,'0 
following COX-2 InhibItor trealrnent (Sheng el al 1997). 
Sludio:s po:rform:d by Foll..man (1m) confirmed the hypothesis that IUmour growth is 
dependent on IIIlgJosenc5is (Folkman 1990: Folkman 19901. Any sigJUfieant merease lD 
tumour mass mU5\ boo: l .. «eded by an lO~ase in tbe 13SCular supply 10 dell,'cr nutrients 
and oxygen to the tumour. Thc abiht), of B tumow to Induce angJoge/'ICsi$ represents an 
essential step for tumour growth beyond 2 J mm in si:.ce_ Data produced by TsuJil'" ul. 
(1998) emplo}'ed an experimental model in .... h,ch endothelial and cancer cells wcre co-
cultured n 'sujii ('I DI. 1998). They fQUlld that COX-2 C)\'ercxpress lOg cells produce high 
Ic\'els of Illlliogemc factors. " 'him stimulate cndothchaltuoc foml:lllon 10 the CG-<:ulture 
model. A $Clecti\<e COX-2 inhlbitor("'S-J98) mhiblled both the expresslOII ofanSlOgm~ 
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factors and oodothclial tube formation by the COX-2 overexprcssing cells lT5UJli ef 01. 
1998: Caughey cr al. lOCH). 
Sincc then many studies have implicated a role for COX enzymC$ m the developmoot of 
lUmourigencsis and angiogencsis in a "ide variety of cancers. including ovarian, 
endometrial , CCT\licol. gallbladder, colon. and many other fomlS of cancer (Ryu 10'1 (1/. 
2000: Jabbour et al. 2001 ; Kulkarni 10'1 al. 2001 ; Asano 10'1 al. 2002; Kundu 10'1 al. 2002; 
Ristimakl CI al. 2002; Sales KJ. 2002: Sales 01 al. 2002: Gupta or al. 2003: Sales CI al. 
2003: Gately 01 al. 2004: Zha 1'1 til 20(4). 
1.11 . Prostaglandins (PGs) 
Prostaglandms were fi rsl discovered and isolated from human semen in the 1930's by Ulf 
von Euler of Sweden. ProSianoids are ulISatul1llcd carbox)'lic acids, consisting of a 20-
carbon skeleton Ihal also contains a fil"c-mcmher ring. They are biochemically 
S)l1lhesiscd COX products derived from C20 uns:ttumted fally acids such as arachidonic 
acid. Prostanoids can be divided into two groups, namely prostaglandins (PGs) and 
thrombo.,anc:s (TXs), lUld include PG01, PGE1• PGF/», PGh and TXAI (Nurumiya 
2003). Each proslanoid IS formed by scquenlial catalysis of COX and specific synthase, 
and is released outside of the cells immediately after s)TIthesis. Although il has been 
shown that Pes can cross the mcmbranc by simple diffUSion, the estimaTed ftow raTe is 
too low to maintain biological function. Therefore, prostanoids are lrun~poned out of the 
cell by means of 3 carrier-mediaTed process through a prostaglllndin transponer (PG1) 
belonging to the organic anion transponcr polypepTide family (Nomura el al. 2~). It 
has bc<.11 proposed that PGT mediaTes both the efflux of newly symhcsiscd rGs to effcct 
their biological actions as 3ulocrineiparocrinc lipid mediators (i.c. Ihey sign31 at or 
immediately adjacenl to their sile of synlhesis) (Funk 2001) throl1gh their cell surtilee 
receptors, lind in nux of Pes from Ihe extracellular milieu for thei r inaol; "3Iion or 3ction 
Ihrough specific nuclear receplors (Ballu 1.'1 11/. 2003). 
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The role prostanoids play in tbe body bas been examined by the usc of NSAIDs and by 
analy?ing actions of prostanoids added exogenously Thesc studies suggest \h:U 
prostanoids Ilork in a variely of processes such as fever generation, mflammatory 
swell ing and pain, and bleeding and hemostasis. 1liromboJ( ane has becn found to 
stimulalC constriction and clolling of blood I'csscls (Caughcy el III 2()(H), Convcrsely, 
!>Gb is produced to hal'c the opposite effecl on the waHs of blood vessels, where dol. 
should not be fomling {Gately el 01 20(4). 
C~'I1ai n prostanoids halC also been associated with the induction of labor and OIher 
reproductive processes. I'GEl has been shown 10 cause uterine eontraeuons and has been 
used 10 induce labor (Kniss 1999). Prostanoids arc also involved in scICfal other organs, 
such as the gastrointestinal tract (mhibil acid syntheSIS and incr;:ase secrelion of 
protec tive mucus) (Hoshino el ai, 2003), illl:rcase blood flow lO kidneys (Breyer 01111/, 
2001). and leukolriens promote constriction of bronchi associated wilh asthma. A few 
proswnoids ha , 'e also been impl icated in the immune response. for example 111 studlcs 
using EP4-dcficlcnt micc, stimulation of the EN receptor by PGE~ in dendritic cells 
facilitated thdr migration and maturation. however stimulation in T-eclls potently 
suppresses their acti\'ation and proliferation {Narumiya 2(03), This lalter action is 
eVIdent in PGEr medl3ted suppression ofT cell proliferation in the gut of mice subjected 
to dex tran sodium sulfate-induced colitis. a mcx:Iel of innammatory bowel disease 
(Narumiya 2003). These studies have revealed mat prostanoids work at various silc~ or 
levels of immlUlc responses and eJ(~'I1 many. often opposing actions, 
1.12. Prostaglandin rL'Ccptol"S 
The biological actions of PGs arc med iatlxi by ~pccific heptahelical G protcin-<.:ouplcd 
receptors (GPCRs) (Breyer el 01. 20()]) (Figure l A). There arc at least 9 known 
prostanoid rcrcptor foml5 in mouse and man, as well as several addillonal splice variants 
with divergent carboxy tennim. Four of the receptor suhlypcs bmd !>GEl (El'1, EI'2, EI'3 
and EN), two bind rGOl (01'1 and 01>2), and the rcccp(OrS that bind I'GF1a , l'Gl;. and 
TXAl (FP. IP, and TP, rcspt.'Ctivcly) cach denve from a single gclH." (Funk 2001), The 
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prostaglandin I'C("tplors bc' lonllto three clusters (on the basiS of homology and signalling 
attributes rather than by ligand binding prIJperties) WIthin u dlstinCI subfamIly or lhe 
GPCRs. The IOlle e:>.eepliOIl is DP2. which is a nlClIlbcr of Ihe chcllIoaUTlIClllnt receptor 
subgrouping The ··,ela.l /lnl" rc<:cplors IP. DP!, EP2. and EP4 fomt Olle clustcr. 
SIgnalling through Gu,-medialed increases ." intracellular C)'clic adCnosl1'\C 
monophosphme (tA MI'); the "cOlllrnclilc" receplors EP I. FP. lind TP form II second 
group Ihat signals Ihrough Gu~ medillled increases in intracellular caldlllll (Funk 20(1) 
The EPJ reccptor has seve.rI\l splice vari'"I1$ that IlIlIy couple to eIther Ga, or Gu, 
resulting in eithe r an increalOe or decrease in I1l1 rllcellular cAMP; or Gu". result'"!! in an 
accumulation of inositol lTi phosph~te (I P ,) and an i nCrell'IC In imractlJular Cal. dependl ng 
on the splice vari alll and type of cell (I'\arumlya el al. 1993. Suguno(O el al. 1993; 
Narumiya erat. 2001). 
• • • • • • • 1" IP,IC'" 
. + 
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1" .... cAMP 
, 1" I' ;CI" • 
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.. l' IP ,tea" 
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1' IP,IC ' ''' 
fj gyn~ I ,4, Pros!anOids and IlIcit jDlcrlClioo ... i!h sp:cjfic p!'OStl!oojd reC(nto!'S. 
(Jabbour and Sale~ 2()(}.t) 
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Within the prostanoid family, the receptors share a sequence homology of 20 - 30010, and 
overall, there are 65-amino-acid residues conserved among the prostanoid receptors 
(Breyer et al. 2001). The majority of these conserved residues lie within the 
transmembrane regions, although a significant stretch of conserved amino acids exist in 
the second extracellular loop region. Functionally, there is evidence that both 
transmembrane and extracellular regions of the prostanoid receptor are involved in ligand 
binding (Breyer et al. 2001). In general, it has been assumed that signal transduction 
cascades are initiated after ligand-receptor binding at the plasma membrane. However, 
Bhattacharya et al., (1998, 1999) have ascertained a nuclear localisation for EP receptors, 
indicating that PGE2 could directly regulate the transcription of target genes after the 
release of calcium from nuclear calcium pools or by activation of calcium channels 
(Bhattacharya et al. 1998; Bhattacharya et al. 1999). In addition, it is possible the PG~ 
influences transcription of target genes by interacting with nuclear PP ARs. Although no 
role for PGE2, PGF2a and PP AR in regulation of gene transcription has been described, 
prostanoids such as PGI2 and PGh have been reported as ligands for PP ARa. and PP ARcS, 
which alter transcription of target genes involved in lipid metabolism and homeostasis 
(Forman et al. 1997; Sales et al. 2003). This diversity of receptors with opposing 
functions may confer a homeostatic control of an autocoid, which is released in high 
concentrations close to its site of synthesis (Ashby 1998; Sales et al. 2003). 
1.12.1. The role ofprostanoid receptors 
The complex biological actions of the prostanoids may be at least partly due to the 
existence of multiple subtypes and isoforms ofprostanoid receptors. Molecular cloning of 
the individual receptor subtypes and subsequent elucidation of their biochemical 
properties and expression patterns have been a pivotal step in understanding prostanoid 
physiology. The importance of the activity of each prostanoid has also been assessed by 
the analyses of phenotypes of knockout mice for each receptor subtype, under various 












Decreased allergic responses In ovalbumin-Induced bronchial asthma 
Decreased aberrant foci ronnatlon to azoxymethane 
Impaired ovulation and fertilization 
Salt-sensitive hypertension 
Vasodepressor or Impaired vasodepressor response to Intravenous PGE2 
Loss of bronchodllatlon with PGE2 
Impaired osteoclastogenesls In vitro 
Impaired febrile response to pyrogens 
Impaired duodenal bicarbonate secretion and mucosal Integrity 
Enhanced vasodepressor response to Intravenous Infusion of PGE2 
Disappearance of indomethadn-sensltlve urine diluting function 
Patent ductus arteriosus 
Impaired vasodepressor response to Intravenous Infusion of PGE2 
Decreased Inflammation-dependent bone resorption 
Loss of parturition 
Thrombotic tendency 
Decreased Inflammatory swelling 
Decreased acetic acid writhing 
Bleeding tendency and reSistance to thromboembolism 
Table 3. Major phenotypes ofprostanoid rece,vtor knockout mice. 
(Kobayashi et al. 2002) 
1.12.1.1. Receptors mediating central nervous system actions 
Fever 
Fever is a representative component of acute phase response to immunological challenge 
and is elicited by cellular components of infectious organisms, such as LPS, as well as by 
non-infectious inflammatory insults (Kobayashi 2002). Both infectious and non-
infectious insults stimulate the production of cytokines that work as endogenous 
pyrogens. These cytokines, including IL-l, IL-6, TNF-a., IFN-a., and IFN-y transmit a 
signal to the preoptic area, which then stimulates the neural pathways that raise body 
temperature (Kobayashi 2002). Fever can be suppressed by NSAIDs such as aspirin and 
indomethacin, indicating that PGs are important in fever generation. 
Ushikubi et al. (1998) used knockout mice models for each of the EP receptors to 
investigate their febrile responses to PGE2, IL-ll3 and LPS. These studies showed that 
EP3 receptor-deficient mice failed to show febrile responses to all of these stimuli, 
implying an important role for this receptor in fever regulation (Ushikubi et al. 1998). 
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Sleep 
PG~ is a potent endogenous sleep promoting substance in rats and other mammals, 
including humans (Hayaishi 2000). To clarify the involvement of the DPI receptor in 
PGD2-induced sleep, Mizoguchi et al. (2001) infused PG~ into the lateral ventricle of 
wild-type and DPI-deficient mice and determined the number of non-rapid eye 
movements (NREM) and rapid eye movement (REM) sleep. Results from this study 
indicated that PGD2 predominantly increased NREM sleep in wild-type mice and that DP 
receptors are crucially involved in PGD2-induced NREM sleep (Mizoguchi et al. 2001). 
1.12.1.2. Receptors mediating inflammation and pain 
Local reddening, heat generation, swelling and pain are classic signs of acute 
inflammation. Each of these symptoms, except pain, is caused by increased blood flow 
and vascular permeability with resultant edema (Kobayashi 2002). Previous studies 
suggested that PGs are primarily involved in vasodilation in the inflammatory process 
and synergise with other mediators, such as histamine and bradykinin to cause an 
increase in vascular permeability and edema. These studies have also showed that PGE2 
and PGh are potent prostanoids in causing these effects and that both these PGs are 
present in high concentrations at sites of inflammation (Davies et al. 1984). Murata et al. 
(1997) used IP-deficient mice to test the role of PGh in inflammatory swelling. They 
employed a carageenan-induced paw swelling as a model. In this model, paw swelling 
increasedin a time-dependent manner following injection and was decreased by about 
50% by treatment with indomethacin. IP-deficient mice developed swelling only to a 
level comparable to that observed in indomethacin-treated wild-type mice. These data 
demonstrate that PGI2 and IP receptor work as the principal PG system mediating 
vascular changes in this model of inflammation (Murata et al. 1997). 
The role of prostaglandins in inflammatory pain is also well accepted. This is partly due 
to the antinociceptive effects of aspirin-like drugs, and also because of documentation in 
various model systems that PGs added exogenously are able to induce hyperalgesia, an 
increased sensitivity to painful stimulus, or allodynia, a pain response to a usually non-
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painful stimulus (Kobayashi 2002). These studies using exogenous PGs show that PGE2 
and PGI2 exert stronger effects than the other types of PGs, indicating the involvement of 
EP or IP receptors in inducing inflammatory pain (Bley KR et al., 1998). Ueno et al. 
(2001) pretreated EPI-I-, EP2-1-, EP3-1-, EP4-/-, IP-/- receptor knockout and wild-type 
mice with LPS and then examined their hyperalgesic responses. Results demonstrated 
that the nociception of the writhing response in non-treated mice is mediated mainly by 
the IP receptor and the perception of enhanced pain in LPS-pretreated mice can be 
mediated by both the IP and EP3 receptors (Deno et al. 2001). 
In addition to hyperalgesic actions, PGs in the spinal cord are also reported to be involved 
in elicitation of allodynia. To characterise the PGE receptor subtype(s) involved in PGE2-
induced mechanical allodynia, Minami et al. (2001) examined whether PGE2 could 
induce allodynia in EP1- and EP3-deficient mice. Intrathecal administration of PGE2 
induced allodynia in wild-type and EP3-deficient mice, but not in EPI-deficient mice 
(Minami et al. 2001). These results clearly demonstrate that the EPI receptor is involved 
in PGE2-induced allodynia. 
1.12.1.3. Receptors mediating allergy and immunity 
Allergic asthma is caused by the aberrant expansion of Th cells in the lung that produce 
Th2-cytokines, and is characterised by the infiltration of eosinophils and bronchial 
hyperreactivity (Kobayashi 2002). This disease is often triggered by mast cells activated 
by an immuglobulin (Ig) E-mediated allergic challenge. Activated mast cells release 
various chemical mediators. PG02 is the major prostanoid produced by these cells in 
response to antigen challenge (Murray et al. 1986). However, the pathological 
significance of PG02 in allergic asthma remains unclear. Matsuoka et al. (2000) used 
OP-deficient mice to focus on the role of PG02 in asthma. These studies demonstrate that 
PG02 produced in response to allergic challenge acts at OP receptors in the lung to 
recruit lymphocytes to the site of challenge (Matsuoka et al. 2001). Thus, PG02 functions 
as a mast cell-derived mediator to trigger asthmatic responses. PGE2 has also been 
reported to attenuate some acute inflammatory responses initiated by mast cell 
degranulation. Raud et al. (1988) demonstrated that indomethacin markedly potentiates 
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antigen-induced plasma protein extravasation, leukocyte accumulation and histamine 
release in sensitised hamsters. PGEz completely reversed the indomethacin-induced 
potentiation of plasma extravasation and also effectively reversed the number of 
emigrating leukocytes after indomethacin treatment (Raud et al. 1988). Histamine release 
was reduced by almost 60 % in the presence of PGEz. The identity of the EP receptor 
mediating this action remains to be clarified. 
PGs have also been shown to regulate the production or release of pro-inflammatory 
cytokines. Recently, Shinomiya et al. (2001) collected peritoneal macrophages from 
wild-type, IP-I-, EP2-1- and EP4-1- mice and examined the effects of PGEz or the PGIz 
analogue carbacyclin on the production of TNFa and IL-I0 by these macrophages 
stimulated with zymosan (Shinomiya et al. 2001). The addition ofPGEz or carbacyclin to 
wild-type macrophages reduced the TNFa production to one-half, whereas IL-I0 
production increased several fold (Shinomiya et al. 2001). Macrophages collected from 
IP-deficient mice showed a down-regulation of TNFa production and up-regulation of 
IL-I0 production only in response to EP2 and EP4 agonists or PGEz, but not to 
carbacyclin. Conversely, EP2-1- and EP4-1- macrophages lacked the response to EP2 and 
EP4 agonists, but not to PGEz or carbacyclin (Shinomiya et al. 2001). These results 
demonstrate that PGEz and PGIz regulate production of pro-inflammatory (TNFa) and 
anti-inflammatory (IL-l 0) cytokines redundantly through EP2, EP4 and IP receptors. 
1.12.1.4. Receptors mediating vascular homeostasis 
Thrombosis and hemostasis 
Most PGs elicit contractile and/or relaxant activities on vascular smooth muscles. In 
particular, PGh and TXAz produced abundantly by vascular endothelial cells and 
platelets, respectively, are a potent vasodilator and vasoconstrictor, respectively. Murata 
et al. (1997) created mice deficient in IP receptor and found that while IP-deficient mice 
lack the hypotensive response to the synthetic IP agonist cicaprost, their basal blood 
pressure and heart rate were not different from those of control animals. This result 
indicates that the PGh and IP system does not work constitutively in regulating the 
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systemic circulation but more likely works on demand in response to local stimuli 
(Murata et al. 1997). PGI2 and TXA2 also act on platelets to inhibit or induce, 
respectively, platelet activation and aggregation. Because of their opposite actions on 
blood vessels and platelets, it has been proposed that a balance between the PGb and 
TXA2 systems is important for maintaining vascular homeostasis (Le. to prevent 
thrombosis and vasospasm while performing efficient homeostasis) (Murata et al. 1997). 
PGE2 also elicits contractile and/or relaxant responses when tested on vascular smooth 
muscles in vitro. Kennedy et al. (1999) administered PGE2 and PGE analogs 
intravenously into wild-type and EP2-deficient mice and examined the response in vivo. 
They observed that infusion of PGE2 or an EP2 agonist, butaprost, induces a transient 
hypotension in wild-type mice, whereas injection of the mixed EP1I3 agonist, 
sulprostone, resulted in an increase in mean arterial blood pressure. The hypotensive 
response to butaprost was not observed, and the hypertensive effects of sulprostone 
persisted in EP2-deficient mice, and, surprisingly, PGE2 evoked considerable 
hypertension. Kennedy et al. (1999) suggested that the absence of the EP2 receptor 
abolishes the ability of the mouse vasculature to vasodilate in response to PGE2 and 
unmasks the contractile response mediated via the vasoconstrictor EP receptor(s). 
Interestingly, when fed a high-salt diet, the EP2-deficient mice develop significant 
hypertension with a concomitant increase in urinary excretion of PGE2 (Kennedy et al. 
1999). These results indicate that PGE2 is produced in the body in response to a high-salt 
diet and works to decrease blood pressure via the relaxant EP2 receptor and that 
dysfunction of this pathway may be involved in the development of salt-sensitive 
hypertension (Kennedy CR et al., 1999). Studies performed by Audoly et al. (1999) 
demonstrated striking differences in the hemodynamic actions of PGE2 using knockout 
mice for each of the EP receptors (Audoly et al. 1999). In females, EP2 and EP4 were 
found to mediate the major portion of the vasodepressor response, whereas in males most 
of the vasodepressor effect was mediated by EPI. The EP3 receptor in males actively 
opposes the vasodepressor actions of PGE2. This demonstrated that the hemodynamic 
actions of PGE2 are mediated through complex interactions of several EP receptor 
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subtypes, and the role of individual EP receptors may differ dramatically in males from 
that in females (Audoly et al. 1999). 
Vascular remodelling: closing of ductus arteriosis 
At birth, mammals including humans undergo a dramatic change in their circulation with 
the commencement of respiration, i.e. from the fetal circulation system that shunts blood 
flow from the main pulmonary artery directly to the aorta via the ductus arteriosus, to the 
pulmonary circulation system of the neonate (Kobayashi 2002). This adaptive change is 
caused by the closure of the ductus arteriosus. The patency of the ductus during the fetal 
period is maintained principally by the dilator effects of POs, and its closure is induced 
by withdrawal of the dilator prostaglandins as well as active contraction exerted by an 
increased oxygen tension (Smith et al. 1998). This concept is supported by the fact that 
administration of aspirin-like drugs or a vasodilator PO, such as POE!, suppresses or 
maintains, respectively, the patency of the ductus in neonates with patent ductus arteiosus 
(Smith et al. 1998). A study using various synthetic PO analogs suggested that both IP 
and EP4 receptors are present in the ductus and are involved in the dilation of this vessel 
(Smith et al. 1994). Disruption of the mouse IP gene did not appear to cause any 
abnormality of the ductus (Smith et al. 1994). On the other hand, most EP4-deficient 
mice die within 3 days after birth, due to marked pulmonary congestion and heart failure. 
Administration of indomethacin into maternal mice during late pregnancy elicited 
premature closure of the ductus in wild-type fetuses, but not in the ductus of EP4-
deficient fetuses, indicating that the dilatory effect of POE2 on this vessel is mediated by 
the EP4 receptor (Smith et al. 1994). 
These results suggest a critical role for the EP4 receptor in the ductus and can be 
interpreted to mean that in the absence of the EP4 receptor a compensatory mechanism 
maintains ductus patency not only in the fetal period but also after birth. 
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1.12.1.5. Receptors mediating reproduction 
Ovulation and fertilization 
Recent studies on COX-2-deficient mice showed multiple reproductive failures in early 
pregnancy, such as in ovulation, fertilization, implantation, and decidualization, 
suggesting that PGs play essential roles in these processes (Hizaki et al. 1999; Kennedy 
et al. 1999; Tilley et al. 1999; Kobayashi 2002). Because IP-, EPI-, EP3-, EP4- and TP-
deficient females are fertile, these receptors may be dispensable in female reproduction 
(Kobayashi 2002). Recently, three groups reported reproductive failure in early 
pregnancy in EP2-deficient female mice (Hizaki et al. 1999; Kennedy et al. 1999; Tilley 
et al. 1999). Kennedyet al. (1999) and Tilley et al. (1999) reported that EP2-deficient 
female mice consistently deliver fewer pups than their wild-type cOWlterparts irrespective 
of the genotypes of mating males. They detected slightly impaired ovulation and a 
dramatic reduction in fertilization in EP2-deficient mice and concluded that the 
reproductive failure during early pregnancy in COX-2-deficient mice is due to 
dysfunction of the EP2 receptor. 
As described above, it has been suggested that COX-2 and its products contribute to 
implantation. The EP2 receptor may playa role in this process, since its mRNA is highly 
induced in luminal epithelial cells during the pre-implantation period via a steroid-
dependent pathway (Katsuyama et al. 1998). However, the uteri of EP2-deficient 
females appear normal in their ability to support implantation of wild-type embryos. One 
possibility is that EP4 expression in the luminal epithelium can compensate for the EP2 
receptor in implantation (Kobayashi 2002). Recently, Lim H et al. (1999) reported that 
the impaired ability for implantation in COX-2-deficient mice is reversed by both PGI2 
analogs and an agonist for PPARo. They proposed that COX-2-derived PGI2 may 
participate in implantation through PP ARo (Lim et al. 1999). 
Leuteolysis and parturition 
PGF2a is accepted as an inducer of leu teo lysis in domestic animals such as the sheep and 
cow, and has been implicated in parturition via its action as a strong uterotonic substance 
(Kobayashi 2002). However, FP-deficient mice do not show any abnormalities in early 
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pregnancy, and there were no changes in the estrous cycle. Sugimoto et al. (1997) found 
that, despite no alteration in the estrous cycle, FP-deficient female mice do not undergo 
parturition, apparently due to lack of labor. They further found that FP-deficient mice do 
not undergo parturition even when given exogenous oxytocin and that they show no 
prepartum decline in progesterone (Sugimoto et al. 1998). These experiments show that 
the luteolytic action of PGF2a is required in mice to diminish progesterone levels and thus 
permit the initiation of labor. Administration of exogenous PGF2a to these mice can 
furthermore rescue parturition and result in nonnal birth. It has been shown in many 
species that a large amount of PGs are produced in intrauterine tissues during labor, but 
the exact roles of these PGs remain to be fully elucidated. 
1.12.1.6. Receptors mediating gastrointestinal functions 
The PG are widely distributed in the digestive system and are involved in a nwnber of 
physiological processes including motility, blood flow, water and electrolyte absorption, 
and mucus secretion (Kobayashi 2002). In addition, treatment with aspirin-like drugs 
reduce the risk of colorectal neoplasia, and the involvement of PGE2 in the proliferative 
activity of the colonic epitheliwn has been suggested (Kobayashi 2002). In spite of the 
accwnulating evidence for the involvement of PGs in these physiological and 
pathophysiological processes, little is known about the receptor types involved in each of 
the processes occurring in the gastrointestinal tract. Takeuchi et al. (1999) showed that 
EP3, but not EPl, is involved in acid-induced duodenal bicarbonate secretion, which is 
physiologically important in mucosal defence against acid injury (Takeuchi et al. 1999). 
Studies performed by Boku et al. (2001) reported that endogenous PGh, but not PGE2, 
had a role in adaptive cytoprotection of gastric mucosa (Boku et al. 2001). The rationale 
for COX-isoforms and their products having roles in the development of colon cancer are 
based on both human epidemiological data and experiments on rodents (Rao et al. 1995; 
Kobayashi 2002). Epidemiological studies have shown that aspirin reduces colon cancer 
mortality in humans (Thun et al. 1991; Thun et al. 1993). Further support of a role for 
COX-2 in intestinal neoplasia has been presented by Oshima et al. (1996), who showed 
that genetic disruption of COX-2 reduces the nwnber and size of the intestinal polyps 
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dramatically in Ape-knockout mice. Sonoshita et al. (2001) demonstrated that 
homozygous deletion of the EP2 receptor in Ape knockout mice caused significant 
decreases in the number and size of the intestinal polyps, effects similar to those induced 
by COX-2 gene disruption (Sonoshita et al. 2001). Studies performed by Watanabe et aI., 
(1999) used EP1 and EP3 knockout mice in a model of colon carcinogenesis. Treatment 
of EP3-deficient mice with the colon carcinogen, azoxymethane caused aberrant crypt 
foci, putative pre-neoplastic lesions of the colon with an incidence similar to that of wild-
type mice (Watanabe et al. 2000). In contrast, foci formation was decreased in EP1-
deficient mice to .....(j0 % of the level of wild-type mice. Furthermore, partial reduction of 
foci formation was observed following the administration of an EP1-specific antagonist 
(ONO-8711) in the diet of azoxymethane-treated mice (Watanabe et al. 2000). A similar 
treatment also reduced the number of polyps in Min mice (Watanabe et al. 1999). These 
results suggest that PGEz may contribute to colon carcinogenesis to some extent through 
its action on the EP1 receptor. 
1.12.1.7. Receptors mediating bone metabolism 
Bones undergo continuous resorption and renewal, a process termed bone remodelling. 
Bone resorption is carried out by o steocl asts, and bone formation, by osteoblasts 
(Kobayashi 2002). These events are controlled by systemic humoral factors such as 
parathyroid hormone, estradiol, and Vitamin D as well as by local cytokines such as IL-
1[3, IL-6 and insulin-like growth factor (Kobayashi 2002). PGs, particularly PGEs, can 
also affect bone remodelling, in both bone formation and resorption. The bone resorptive 
activity of PGE is associated with an increase in the number of osteoclasts. Studies 
performed by Sakuma et al. (2000) and Miyaura et al. (2000) reported impaired 
osteoclast formation in cells cultured from EP4-deficient mice. PGEz was added to 
cultures of parietal bone from mice deficient in each of the EP receptors, as well as wi1d-
type mice, and the bone resorptive activity was examined. Bone resorption was much 
decreased in bones from EP4-deficient mice. These studies confirm the role of the EP4 
receptor in PGEz-mediated bone resorption (Miyaura et al. 2000; Sakuma et al. 2000). 
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1.12.1.8. The role ofEP receptors in cancer development 
Some EP receptors are also reported to be involved in twnourigenesis (Table 4). 
Although the efficacy of selective blockade of prostanoid receptor signalling in 
angiogenesis has not been investigated fully, an anti-PGE2 antibody is reported to have an 
anti-twnour effect (Zweifel et al. 2002) and other results indicate that EP receptor 
subtypes promote twnour-associated angiogenesis (Seno et al. 2002; Yang et al. 2003). 
As discussed previously, PGE2 has been shown to promote the growth of colorectal 
carcinomas, in part through activation of EP1 and EP4 receptors. Studies performed by 
Watanabe et al. (1999) and Mutoh et al. (2002), treated several lines of knockout mice 
with a colon carcinogen, azoxymethane, and found that aberrant crypt foci were 
significantly suppressed in both EP1- and EP4-deficient mice. This is particularly 
important as aberrant crypt formation represents an initial step in colon twnourigenesis 
and illustrates an important role for both the EP1 and EP4 receptors in this process. 
Further studies performed by Pozzi et al. (2004), used mouse colon adenocarcinoma 
(CT26) cells to investigate the role of PGE2 in cell proliferation. CT26 cells express both 
COX-1 and COX-2 and metabolize arachidonic acid to PG~. Treatment with 
indomethacin, or COX-selective inhibitors, prevented PGE2 biosynthesis and CT26 cell 
proliferation. The anti-proliferative effects of COX inhibition were rescued specifically 
by treatment with PGE2 or the EP4 receptor-selective agonist via PI3K1ERK activation, 
thus providing a functional link between PGE2-induced cell proliferation and EP4-
mediated signalling (Pozzi et al. 2004). 
An important factor in twnour development is angiogenesis, and twnour-associated 
angiogenesis is mediated by the migration and proliferation of host endothelial cells. 
Substantial increases in twnour mass must be preceded by an increase in blood supply to 
provide the nutrients and oxygen required for twnour growth and it has been suggested 
that the mechanisms that promote angiogenesis are activated in the early stages oftwnour 
development (Majima et al. 2003). Studies performed by Yang et al. (2003) using 
isolated synovial cells demonstrated in vitro that EP2 receptor signalling is related to 
VEGF concentration. The sponge models in prostanoid receptor knockout mice have 
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clarified the prostanoid receptor signalling responsible for angiogenesis in vivo (Amano 
et al. 2003). Proliferative granulation tissues fonned around the sponge implants exhibit 
extensive angiogenesis in a COX-2 dependent manner, which mimics the stromal 
angiogenic response around tumours. Topical injections of wild-type mice with specific 
EP agonists revealed that only the EP3 receptor agonist markedly increased the extent of 
angiogenesis (Amano et al. 2003). Data published by Spinella et al. (2004) implicate a 
role for PGE2-EP4 receptor interaction in the expression and secretion of VEGF in 
ovarian carcinoma cells. Their data suggest that targeting the PGE2- and EP4-related 
signalling cascade in ovarian carcinoma could effectively impair the transcription of 
target genes associated with angiogenesis and invasiveness (Spinella et al. 2004). 
PG~ EP1 EP1 raceptor antagonist decreases the incidence of Watanabe Ket ai" 2000 
aberrant crypt foci In azoxymethane-treated mice 
EP1 raceptor -1- mice are resistant to azoxymethane- Watanabe K, 1999 
Induced aberrant aypt foci 
PG~ EP2 In EP2 ra<:eptor -I. mice, the number GI1j:)c _"0 Sonoshlta Met a/. , 2001; Seno Het a/. , 2002 
Intesttnal polyps and the Intensity of angiogenesis 
and VEGF expression are decreased 
EP2 raceptor -1- mlceexhlbit cancer-assoclated Yang Let al ., 2003 
Immunodefldency and defective dendritlo-cell 
differentiation 
EP2 raceptor -I. mice exhibit reduced tumour growth Yang L et ai" 2003 
but nonnal tumour-assocJated angiogenesis and 
VEGF Induction 
EP3 EP3 -1- mice have reduced tumour-associated Amano Het ai" 2003 
angiogenesis and tumour growth because Induction 
of VEGF Is reduced 
EP4 EP4 receptor mediates cell proliferation and motility Sheng Het ai" 2001 
of coIorectaI carcinoma cells 
EP4 raceptor -1- mice are resistant to azoxymethane- Mutoh Met ai" 2002 
induced aberrant crypt foci 
Table 4: PGE1 signalling and cancer development. 
(Majima et al. 2003) 
1,13. Prostaglandin E2 (PGE2) and its receptors 
As discussed previously, PGE2 is a major product of cyclooxygenase-initiated 
arachidonic acid metabiolism. PGE2 may have multiple and at times apparently opposing 
functional effects on a given target tissue. For example, the vasodilator effects of PGE2 
have long been recognised in both arterial and venous beds (Lawrence et al. 1992; 
Coleman et al. 1994; Lydford et aI. 1996; Davis et al. 2004). 
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PGE2 has also been shown to be a potent constrictor in other smooth muscle beds, 
including trachea, gastric ftmdus, and ileum (Breyer et al. 2001). Renal PGE2 synthesis is 
critical for the maintenance of normal renal ftmction (Schweda et al. 2004). PGE2 not 
only dilates the glomerular microcirculation and vasa recta, supplying the renal medulla, 
it also modulates salt and water transport in the distal tubule (Breyer et al. 2001). PGE2 
has also associated with the induction of labor (causing uterine contractions) and other 
reproductive processes, such as menstruation (Rees et al. 1984). 
PGE2 elicits its autocrinelparacrine effects on target cells through interaction with 
transmembrane GPCRs as mentioned in Section 1.12. To date four main sub-types of 
PGE2 receptors have been identified based on responses to agonists and antagonists and 
are pharmacologically divided into EP1, EP2, EP3 and EP4, which utilise alternative and 
in some cases opposing intracellular signalling pathways (Tsuboi et al. 2002). 
1.13.1. EP1 receptors 
The EP1 receptor was originally described as a smooth muscle constrictor. The cloned 
human EP1 receptor cDNA encodes a 402-amino acid polypeptide. EP1 receptor mRNA 
is expressed most highly in the kidney, followed by gastric muscularis mucosae and then 
adrenal tissue. PGE2 interaction with the EP1 receptor increases intracellular calcium via 
Gq, leading to signals via IP3 generation and increased Ca
2
+. 
Okuda-Ashitaka E et al., 1996, described distinct signalling for an EP1 receptor mRNA 
variant (Okuda-Ashitaka et al. 1996). Although this variant binds ligand in a manner 
similar to that of the rat EP1 (rEP1) receptor, it does not elicit detectable signal 
transduction. When the rEP1-variant was stably co-transfected with the longer rEP1 
receptor in CHO cells, the Ca2+ mobilisation mediated by the EP1 receptor was 
significantly suppressed, suggesting that the shorter variant antagonised rEP1 receptor 
signalling. Furthermore, when the rEP1-variant receptor was expressed in CHO cells, 
cAMP formation by activation of endogenous EP4 receptor was blocked. These authors 
suggest that the rEP1-variant receptor may affect the efficiency of signal coupling of 
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PGE receptors and attenuate the action ofPGE2 on tissues (Okuda-Ashitaka et al. 1996). 
Although the mechanism of action of this altemative variant of the EPI receptor is 
unclear, recent evidence suggests that GPCRs may form dimers (Jordan et al. 1999). If 
this EPI variant associated with other EP receptors, it might form non-productive dimers 
and act as a dominant-negative regulator of signal transduction (Breyer 2001; Wise et al. 
2002). 
1.13.2. EP2 receptors 
EP2 receptor cDNA, originally reported in Genbank as EP4 receptor in 1995 (Bastien et 
al. 1994), encodes a 358-amino acid polypeptide that signals through an increase in 
intracellular cAMP. The tissue distribution of EP2 receptor has been only partially 
characterised, using northern blot analysis of mRNA distribution, which revealed a 
mRNA species of -3.1 kb, which is most abundantly expressed in uterus, lung, and 
spleen (Smock et al. 1999; Desai et al. 2000). In general, EP2 mRNA is expressed at 
much lower levels in tissue than EP4 mRNA (Desai et al. 2000). 
The EP2 receptor was originally characterised by its ability to cause smooth muscle 
relaxation in cat trachea (Gardiner 1986). Moreover, relaxation of the trachea could be 
stimulated with the EP2 specific agonist, known as butaprost. The use of butaprost has 
allowed functional distinguishing between the EP2 and EP4 receptors. 
Although they have similar affinities for PGE2, and function similarly to activate cAMP, 
the EP2 and EP4 receptors have distinct structural characteristics, and only share 
approximately 38 % identity in their transmembrane domains. This is not appreciably 
different from the aa identity they share with the EPI (37 %) and EP3 (34 %) receptors. 
EP2 is a 358-amino acid protein with a relatively short intracellular loop and C-terminal 
domains (Regan et al. 1994). On the other hand, the EP4 receptor consists of 488 aa, and 
has a long third intracellular loop and a long cytoplasmic tail (Slipetz et al. 2001). The 
EP2 receptor does not undergo agonist-induced, short-term desensitisation, whereas EP4 
desensitises rapidly (Bastepe 1997; Bastepe et al. 1999; Slipetz et al. 2001). Hence, 
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although boundaries between the roles of the EP2 and EP4 receptors remain to be 
clarified, agonist-induced short-term desensitisation is a significant regulatory element in 
EP4-mediated signalling, but not in EP2-mediated signalling. This suggests that EP2 may 
be involved in mediating sustained actions of PGE2, whereas EP4 mediates rapidly 
waning events (Desai et al. 2000). 
Although initial studies of the EP2 and EP4 receptors indicated that these receptors did 
not appear to activate IP3 or inhibit cAMP formation, it now appears that they are capable 
of activating other secondary messenger pathways, which in the case of the EP4 receptors 
may be cAMP independent. Studies performed by Fujino H et al. (2002) demonstrated 
that by using a T-cell factorllymphoid enhancer factor (Tcf/Lef) responsive luciferase 
reporter gene, PGE2 could stimulate promoter activity in HEK cells stably expressing 
these receptors (Fujino et al. 2002). This stimulation of reporter gene activity was 
associated with an agonist dependent phosphorylation of glycogen synthase kinase-3 
(GSK-3), which is known to inhibit activity of this enzyme. Inhibition of GSK-3 
decreases the phosphorylation of cytosolic l3-catenin to the nucleus where it can alter 
gene expression via interactions with the Tcf/Leffamily of transcription factors (Cadigan 
et al. 1997). Interestingly, this stimulation of Tcf/Lef reporter gene activity by the EP2 
and EP4 receptors occurs through different mechanisms. EP2 receptor-mediated 
activation of Tcf transcriptional activity is primarily through a cAMP/protein kinase A 
(PKA) dependent mechanism; whereas EP4 receptor mediated activation occurs 
primarily through a phosphatidylinositol 3-kinase (PI3K) dependent pathway (Fujino et 
al. 2002; Fujino et al. 2003). 
1.13.3. EP3 receptors 
The EP3 receptor generally acts as a constrictor of smooth muscle. Nuclease protection 
and Northern blot assays have demonstrated high levels of EP3 receptor expression in 
several tissues, including kidney, uterus, adrenal, and stomach. This receptor is unique in 
that it has several splice variants defined by unique C-terminal cytoplasmic tails (Breyer 
et al. 2001; Bockaert et al. 2003). These splice variants encode proteins of a predicted 
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molecular mass between 40 and 45 kDa. Proposed functional differences between the 
splice variants of EP3 include alternate signal transduction pathway usage, receptor 
phosphorylation and desensitisation, and intracellular trafficking (Breyer 2001). Several 
of the phenotypes may be interrelated, for example, the intracellular localisation may 
determine the signal transduction pathway activated. Although these variants generally 
inhibit cAMP generation via pertussis toxin-sensitive OJ-coupled mechanism, additional 
signalling mechanisms including Os and Ca2+ release appear to be differentially activated 
by C-terminal tails (Breyer et al. 2001). Recent studies suggest that the EP3 receptor 
signals through the small O-protein Rho (Aoki et al. 1999; Hatae et al. 2002). Studies 
performed by Yano et al., 2002, have also implicated the EP3 receptor in activation of the 
Ras signal pathway (Yano et al. 2002). The EP3 receptor also activates protein kinase C 
(PKC) and cAMP-independent CRE-mediated gene transcription in HEK293-transfected 
cells (Audoly et al. 1999). 
Despite the extensive characterisation of EP3 receptor splice variants in cell culture 
systems, physiologic significance of these different C-terminal splice variants remains 
uncertain. 
1.13.4. EP4 receptors 
As mentioned previously, EP4 receptor signals through increased cAMP. The human EP4 
receptor cDNA encodes a 488-amino-acid polypeptide with a predicted molecular mass 
of -53 kDa. In addition to the human EP4 receptor, EP4 receptors for the mouse, rat, 
rabbit, and cow have been cloned (Honda et al. 1993; Bastien et al. 1994; Nishigaki et al. 
1995; Breyer et al. 1996; Breyer et al. 1996; Boie et al. 1997; Arosh et al. 2003). EP4 
receptor mRNA is widely distributed in many human tissues, including thymus, ileum, 
lung, spleen, adrenal, and kidney. POE2 is a potent mediator of the immune system, and 
activation of EP4 receptor has been shown to stimulate isotype switching to 19B and 
inhibit B-cell activation (Fedyk et al. 1996). Recent evidence also suggests that the potent 
anabolic effects of POE2 in mouse and rat bone marrow are mediated via the EP4 
receptor (Ono et al. 1998; Weinreb et al. 1999). In support of this hypothesis, a potent 
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and selective EP4 antagonist suppressed PGE2-mediated increases in trabecular bone 
volume in young rats (Machwate et a1. 2001). 
Important vasodilator effects of EP4 receptor activation have been described in venous 
and arterial beds (Coleman 1994). As mentioned previously, an important role for the 
EP4 receptor in regulating the peri-natal closure of the pulmonary ductus arteriosis has 
also been suggested by the recent studies of mice with targeted disruption of the EP4 
receptor gene (Nguyen et a1. 1997; Segi et al. 1998). Thus, EP4 receptor ligands may 
prove useful in promoting closure or maintaining patency of the ductus arteriosus in 
newborns with congenital heart disease (Kajino et a1. 2004). Other roles for the EP4 
receptor in controlling blood pressure have been suggested, including the ability to 
stimulate the release of aldosterone from zona glomerulosa cells (Csukas et a1. 1998). 
These reports illustrate the emerging importance of EP4 and the potential for therapeutic 
intervention with EP4 agonists in many human diseases. 
Table 4 (Section 1.12) illustrates a role for the EP4 receptor in carcinogenesis. The use 
of gene knockout mice studies has contributed significantly to our understanding of the 
potential physiological and pathophysiological role of prostanoid receptors. Some of 
these gene knockout studies are now being complemented by pharmacological studies 
using selective agonists and antagonists that have been developed to these receptors 
(Narumiya et a1. 2001). Gene knockout studies have also been used to study the potential 
involvement of the EP4 receptor in colon cancer. Homozygous deletion of the EP4 
receptor decreased the formation of aberrant crypt foci (putative preneoplastic lesions) in 
animals that had been treated with azoxymethane, a known colon carcinogen (Mutoh et 
a1. 2002). Further evidence of the potential involvement of the EP4 receptor in colon 
cancer was obtained in pharmacological studies in which an EP4-selective antagonist 
decreased the number of aberrant crypt foci in azoxymethane-treated mice (Mutoh et a1. 
2002). This EP4 selective antagonist also decreased intestinal polyp formation in Min 
mice (Mutoh et al. 2002). The Min mouse model for human familial adenomatous 
polyposis, whereby a mutation in a tumour suppressor gene results in a nearly 100 % 
incidence in colon cancer. 
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Recent studies by Fujino H and Regan JW, (2003) have also proposed a mechanism that 
could explain how the EP4 receptor could induce the expression of COX-2 and PGE2 
synthase, which are both known to be upregulated in cancer and inflammation (Fujino et 
al. 2003). PGE2 stimulation of the EP4 receptor can activate a PI3KfERK signalling 
pathway resulting in the induction of functional EGR-l expression. This involvement of 
PI3K with EP4 receptor signalling has been further strengthened by a recent study 
showing that PGE2 stimulation of HEK cells stably expressing EP4 receptors leads to the 
phosphorylation of extracellular signal-regulated kinases (ERKs) by a PI3K dependent 
mechanism (Fujino et al. 2003; Fujino et al. 2003). Furthermore, this activation of 
PI3KfERK signalling by the EP4 receptor induced the functional expression of early 
growth response factor (EGR-l) and it was not observed in HEK cells stably transfected 
with the EP2 receptor. This induction ofEGR-l is potentially significant since a number 
of genes, including PGE2 synthase, cyclin Dl and TNFa are known to be regulated by 
EGR-l (Fujino et al. 2003; Fujino et al. 2003). These interactions of the EP4 receptor 
with various signalling pathways could also help explain the recent gene knockout studies 
that demonstrate a role for EP4 receptor in cancer and inflammation. Likewise, EP4 
receptor stimulation can activate a PI3K dependent pathway resulting in Tel 
transcriptional activation (Fujino et al. 2002) and COX-2 expression has been shown to 
be upregulated by nuclear j3-catenin accumulation and Tef-mediated transcriptional 
activation (Araki et al. 2003). j3-Catenin is a transcriptional activator and has been 
implicated in embryonic development and cancer (Moon et al. 2002). GSK-3 
phosphorylates j3-catenin leading to cytosolic sequestration and degradation; 
phosphorylation of GSK-3 inhibits its activity and allows j3-catenin to translocate to the 
nucleus. 
Thus, stimulation of the EP4 receptor has the potential to induce expression of both 
PGES and COX-2, thereby setting up a positive feedback loop in which the increased 
synthesis ofPGE2 would further stimulate the receptor (Regan 2003). 
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1.14. Other prostaglandins and their receptors 
PGD] 
PGD2 is the major prostanoid released from mast cells after challenge with 19B, and it has 
also been shown to affect the sleep-wake cycle and body temperature (Lewis et al. 1982; 
Lewis et al. 1982; Urade et al. 1999). Peripherally, PGD2 has been shown to mediate 
vasodilation and vasoconstriction, as well as inhibition of platelet aggregation (Leff et al. 
1992). PGD2 exerts its effects by binding and activating two distinct GPCRs - the DP 
receptor (DP1) and the recently discovered CRTH2 receptor (DP2) (Hata et al. 2004). 
The DPI receptor shows significant sequence homology with the other members of the 
prostanoid GPCRs, such as the IP and EP2 receptors (Hata et al. 2004). DPI receptor 
mRNA is expressed at low levels in bronchial epithelium and has been proposed to 
mediate production of chemokines and cytokines that recruit inflammatory lymphocytes 
and eosinophils, leading to airway inflammation and hyperreactivity seen in asthma. 
Activation of the DP1 receptor leads to mobilisation of intracellular calcium, but not 
production of inositol phosphate (Boie et aI. 1995). DPI receptor knockout mice display 
decreased allergic responses towards ovalbumin-induced bronchial asthma suggesting 
that PGD2 may act as a mediator of allergic asthma (Narumiya et al. 2001). 
The CR1H2 (DP2) receptor shows little similarity with the DPI receptor, despite the fact 
that it possesses similar affinity for PGD2; instead it is more closely related to other 
chemoattractant receptors (Hata et al. 2004). This receptor binds an overlapping but 
distinct set of ligands compared with the DPI receptor. This raises the possibility that 
certain metabolites of PGD2 may exert effects through CRTH2 but not the DPI receptor. 
Similar to many chemoattractant receptors, CRTH2 receptor activation leads to increases 
in intracellular calcium in a variety of cell types. CRTH2 receptor is expressed on Th2 
lymphocytes, eosinophils, and basophils. CRTH2 receptor activation has been reported to 
lead to pertussis toxin-insensitive activation of PI3-kinase, PLC, and MAP kinases in 
eosinophils. These pathways mediate eosinophil shape change, actin polymerisation, and 
CDII up-regulation (Hata et al. 2004). 
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Therefore, PGD2 acting through both DP1 and CRTH2 receptors likely contributes to the 
eosinophilic infiltration that is a hallmark of allergic asthma. Characterization of mice 
deficient in the CRTH2 receptor will begin to clarify the exact role that each receptor 
plays in mediating the effects of PGD2 in allergic inflammation. 
PGF2a 
PGF2a is produced during the menstrual cycle by secretory endometrium and plays a 
crucial role in mamma1ian reproduction. PGF2a also plays a role in renal function (Breyer 
et al. 2001), cardiac hypertrophy, and regulation of intraocular pressure (Rata et al. 
2004). PGF2a exerts its action via FP receptors, which are expressed most abundantly in 
the corpus luteum. It is critical for normal birth, and homozygous disruption of the 
murine FP receptor gene results in failure of parturition, apparently due to failure of the 
normal preterm decline in progesterone levels (Sugimoto et al. 1994). PGF2a-FP 
interaction results in tyrosine phosphorylation and subsequent increase in Ca2+, PLC 
activation and DNA synthesis (Narumiya et al. 2001). Recent studies have ascertained a 
role for PGF2a-FP receptor interaction in endometrial cancer (Sales et al. 2004). 
PGI2 
Prostacyclin (PGh) is a primary prostaglandin produced by endothelial cells and plays an 
important role in vascular homeostasis as a result of its potent vasodilatory and 
antithrombotic effects (Caughey et al. 2001). PGh exerts its physiological functions via 
IP receptors. IP receptors are widely distributed throughout the dorsal root ganglia 
suggesting it is also a mediator of acute inflammation and inflammatory pain 
transmission (Sales et al. 2004). In the kidney, IP receptors are localised to the 
glomerulus suggesting a role in glomerular filtration (Breyer et al. 2001; Breyer et al. 
2001). The IP receptor usually couples to a Gs-type protein leading to an increase in 
cAMP, although differential coupling to multiple signalling pathways may be modulated 
by C-termina1 modification (Sales et al. 2004). IP knockout mice display sensitivity 




Thromboxane A2 (TXA2) has been most extensively characterized for its role in 
modulating hemodynamics and cardiovascular function (Caughey et al. 2001). It is a 
potent mediator of platelet shape change and aggregation. TXA2 or thromboxane exerts 
its functions via TP receptors, which are expressed abundantly in the vasculature as well 
as the heart, lung and kidney (Breyer et al. 2001). TXA2 receptors signal via Gq G-protein 
activating Ca2+ IDAG signalling pathways (Breyer et al. 2001). TP null mutations in mice 
are associated with bleeding tendency and resistance to thromboembolism (Narumiya et 
al.2001). 
1.15. Seminal plasma composition and prostaglandins 
PGE2 and 19-hydroxyprostaglandin E (19-hydroxy PGE) present in mM concentrations 
within semen (Figure 1.5.) (Taylor et al. 1974; Templeton et al. 1978) are thought to be 
the principal effectors of the immunosuppresssion. These levels of prostaglandins are 5 
orders of magnitude (10 000 times) greater than those found locally at a site of 
inflammation (Figure 1.5.). They are potent stimulators of cAMP, thus inhibiting 
lymphocyte proliferation and natural killer cell activity, and are likely to modify cytokine 
release from antigen-presenting cells (Kelly 1995). Human seminal plasma has powerful 
immunosuppressive properties containing high concentrations of the soluble p55 tumour 
necrosis factor-a (TNF-a) receptor (Uabakk et al. 1993), receptors for the Fc portion of 
'Y-globulin, transforming growth factorj3 (TGFj3) (Nocera et al. 1993), spermine (Evans et 
al. 1995), complement inhibitors (Kelly 1995), interleukin-6 (IL-6) and vascular 
endothelial growth factor (VEGF) (Gutsche et al. 2003). 
Studies performed by Gutsche S et al. (2003) demonstrated that seminal plasma 
stimulates expression of pro-inflammatory cytokines in endometrial epithelial cells in 
vitro (Gutsche et al. 2003). Robertson et al. (2002) suggested that seminal plasma might 
elicit the production of pro-inflammatory cytokines by endometrial epithelial cells in the 
outer endocervical canal or cervical ectropion, thereby leading to the formation of a post-
coital inflammatory response (Robertson et al. 2002). The cervical inflammatory cells 
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may Ihen aller Ihe local lJ1eriue immu!lc n:SPOfl~. which in Turn indirectly affects 
bJaSi()cysT fUIICTion (Robenson et al. 2002). 
figure 1.5. Levels of proSl3~landins in seminal plasma. 
(K eUy RW) 
45 
Aims and Objectives of the Thesis 
As discussed in Section 1.1, cervical carcinoma is an important clinical problem in South 
African women. Gynaecologic malignancies of this nature have an enormous socio-
economic impact on health care, resources and morale of a country. Research into the 
molecular mechanisms governing cervical cancer and its precursors could lead to 
improved therapies for women suffering from this condition. 
Several researchers have implied an important role for prostaglandins and their receptors 
in the development of tumourigenesis. However, in the case of cervical tumourigenesis, 
pre-neoplastic cervical epithelial cells will potentially be under the direct influence from 
PGE available in seminal plasma. As discussed previously, levels of PGs in seminal 
plasma are 10 000 times higher than those found at a site of inflammation. Cervical 
tumourigenesis may thus be regulated in an autocrinelparacrine manner by PGE present 
in seminal plasma via PGE-EP receptor interaction. 
Previous studies have confirmed that seminal plasma and PG~ induce expression of 
COX-2 and cAMP linked PGE receptors (namely EP2 and EP4) in the HeLa cervical 
epithelial cell line (Sales et al. 2001). These findings are coincident with enhanced 
intracellular signalling of the EP2IEP4 receptors in response to stimulation with seminal 
plasma or exogenous PGE (Sales et al. 2002; Sales et al. 2002). 
Taken together, these data suggest that endogenously and exogenously (via seminal 
plasma) induced COXIPGE biosynthetic pathways may play a critical role in the 
regulation of cervical tumourigenesis and highlight the risk of seminal plasma in 
enhancing cervical tumourigenesis in sexually active women with dysplasias. 
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The specific aims of research were to: 
i) Detennine the localisation of the site of expression of EP4 receptor in cervical 
carcinomas and normal cervix. This was conducted using immunohistochemical 
analysis on cervical tissue sections as outlined in Chapter 3. 
ii) Investigate the molecular signal transduction pathways mediating the role of 
elevated EP4 receptor in cervical carcinoma cells. This was achieved using a 
stably transfected EP4-overexpressing HeLa cell line, which was established as 
described in Chapter 4. 
iii) Investigate the interaction between seminal plasma and cervical neoplastic 
epithelial cells. This was conducted by investigating possible signal transduction 
pathways, genes and receptors regulated by PGE2-EP4 receptor activation as 
outlined in Chapter 5 and 6. 
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CHAPTER 2 - GENERAL MATERIALS AND METHODS 
2.1. Chemicals and Suppliers 
All chemicals used were molecular biology grade, and were obtained from Sigma 
Chemical Company (Dorset, UK or Cape Town, South Africa) and IBI (Cambridge, UK) 
unless otherwise stated. Enzymes were purchased from Boehringer Mannheim 
(Buckinghamshire, UK) or Promega (Southhampton, UK or Cape Town, South Africa). 
Phenol/Chloroform, pre-buffered with Tris pH 8.0, was purchased from Camlab 
(Cambridge, UK) and all photographic film was purchased from Eastman Kodak 
(Rochester, NY, USA) and supplied by Sigma Chemical Company. 
Dulbecco's modified Eagle's medium (DMEM) nutrient mixture F-12 was purchased 
from Life Technologies (Gibco, Life Technologies, Paisly, UK), penicillin-streptomycin 
was purchased from PAA (PAA Laboratories Ltd., Middlesex, UK). 
Samples and synthetic standards for the PGE2 ELISA assays were purchased from 
Applied Therapeutics (Applied Therapeutics, Paisly, UK). ECF and ECLpius 
chemiluminescence systems were purchased from Amersham (Amersham, Little 
Chalfont, Bucks, UK). cAMP kits were purchased from Biomol (Biomol Affiniti, Exeter, 
UK). VEGF ELISA assay kits were purchased from Oncogene (Oncogene, Beeston, 
Nottingham, UK). 
Seeblue™ pre-stained molecular weight marker was purchased from Novex (Novex, 
UK). Whatman no. 3 paper was purchased from Whatman (Whatman, UK) and 
polyvinylidene difluoride membrane (PVDF) membrane was purchased from Millipore 
(Mi1lipore, Watford, UK). G418 and indomethacin were purchased from Sigma (Sigma 
Chemical Co., Dorset, UK). NS-398 was purchased from Calbiochem (Calbiochem, 
Beeston, Nottingham, UK). The MEK inhibitor (PD98059) (18.7mM stock in 
dimethylsulfoxide, DMSO) and an inhibitor of EGF receptor tyrosine kinase (AG 1478) 
(10mM stock in DMSO) were purchased from Calbiochem (Nottingham, UK). 
EP4 antagonist (ONO-AE2-227) was chemically synthesised by Charnwood Molecular 
Ltd., Leics, UK (See Appendix II). 
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The following antibodies used for Western blotting were purcbased from Santa Cruz 
Biotechnology, inc. (Autogenbioclear, Wiltshire, UK): COX-2 goat polyclonal (sc-1745); 
B-actin goat polyclonal (sc-1616); VEGF rabbit polyclonal (sc-152); c-Myc (9EI0) (sc-
40); Total 42/44 MAPK antibody (ERK) (sc-93). EP4 receptor rabbit antibody (101775) 
was purchased from Cayman Chemical Company (Caymen Chemical, Cheshire, UK). 
Phospho-p42/44 MAPK antibody (9101); phospho-AKT antibody (9271); Total AKT 
antibody (9272); phosphorylated JNK antibody (9251); Total JNK antibody (9252); 
Phospho-p38MAPK antibody (9211) and p38MAPK antibody (9212) were purchased 
from Cell Signalling Technology (Cell Signalling Technology, New England Biolabs 
(UK) Ltd., Herts, UK). Anti-goat-alkaline phospbatase, anti-rabbit-alkaline phospbatase, 
were purchased from Sigma (Sigma Chemical Co., Dorset, UK). 
2.2. Tissue Collection and processing 
Cervical specimens were obtained at the time of surgery or biopsy from patients that were 
attending the Gynaecologic Oncology Clinic at Groote Schuur Hospital, Cape Town and 
that bad previously been diagnosed with invasive carcinoma of the cervix. Punch biopsies 
were taken from the lesion by an experienced gynaecologist with a special interest in 
oncology. Histologically normal cervical samples were obtained from patients 
undergoing Wertheims hysterectomy for non-malignant conditions. Informed consent 
was obtained from all patients before tissue collection. This study was approved by the 
University of Cape Town Research Ethics Committee. 
Tissue sections for innnunohistochemical analysis were obtained from biopsy material, 
which bad been fixed in fonnalin. The tissue was placed in disposable embedding moulds 
(polysciences) followed by paraffm wax-embedding. Glass slides to be used for 
innnunohistochemistry were washed in a 0.25 % solution of 3-aminopropyl 
triethoxysilane (TESP A, Sigma) in acetone, followed by a wash in acetone and finally a 
rinse in filtered double-distilled water and dried. Paraffin wax-embedded tissue was 
sectioned to a thinkness of 5 J.1M using a hand-operated "820" Spencer Microtome 
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(American Optical Corporation) and a D-profile knife. Sections were floated on water, 
transferred to coated slides and dried overnight before use. 
2.3. Seminal plasma collection 
Semen was collected from healthy male volunteers. The collected ejaculates were pooled 
and incubated at room temperature for 30 minutes prior to overlaying on a 100-50 % 
percoll gradient. Seminal plasma was isolated from the pooled ejaculate by percoll 
density gradient centrifugation at 500 g for 20 minutes. The seminal plasma was then 
pooled and stored at -70°C. The seminal plasma was used on the cells at various 
concentrations of 1:50 up to 1:5000. At these dilutions, seminal fluid has been reported to 
exert no effect on HeLa cell viability (Jeremias et al. 1999). 
2.4. Maintenance of HeLa cell lines 
The HeLa-S3 wild-type cells were purchased from Bio Whittaker (Bio Whittaker, 
Berkshire, UK). Stable EP4-overexpressing HeLa (EP4S) cells and stable antisense 
(EP4AS) cells were routinely cultured under sterile conditions in culture flasks with a 
surface area of 170 cm2 (Corning Science Products, UK). Cells were grown at 37°C and 5 
% C02 (v/v) in 50 mIs of complete DMEM (Dulbecco's Modified Eagle's medium 
nutrient F-12 (Gibco) with glutamax and pyroxidine), supplemented with 10 % Foetal 
Calf Serum (Clontech), and 1 % antibiotics (stock 500 IU/mI penicillin and 500 IlgimI 
streptomycin). Cells grew as a monolayer on the bottom of the flask. Cells were observed 
using an inverted light microscope (Olympus CK40), to determine the level of confluence 
and were passaged at about 80 % confluency. The growth medium was removed by 
vacuum suction (Dymax 30, Charles Austen Pumps, UK), and cells were washed twice 
with PBS, thereafter 1 mI of trypsin-EDTA (0.1 % trypsin and 0.04 % EDTA in PBS) 
was added to each flask. The trypsin was allowed to flow over the monolayer surface, 
and the flask was then left at 37°C for 3 minutes. Flasks were then tapped to loosen cells. 
Trypsin was inhibited by the addition of 9 mI of complete DMEM into the flasks. Cells 
were re-suspended by pipette action and 1 mI cell suspension was transferred into a new 
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170 cm2 flask. Cells were then transferred into the incubator and incubated at 37°C in 
humidified 5 % C02 (v/v). The EP4S and EP4AS cells were maintained under the same 
conditions with the addition of200 JLglml ofG418. 
2.5. Plasmid Preparation and Transfections into HeLa cells 
2.5.1. Plasmids 
The cDNA (l.5kb) for hwnan prostanoid receptor EP4 was ligated into the EcoRV site of 
the mammalian expression vector pcDNA3 (Invitrogen) (see Appendix I). These 
pcDNA3 vectors containing the EP4 cDNA in both the sense and antisense directions 
were kindly supplied by Dr. Mark Abramovitz in the Department of Biochemistry and 
Molecular Biology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada. 
Other plasmids used in this study are listed as follows: pcDNA3 containing dominant 
negative cDNA EGFR insert (see Appendix I); pcDNA3 containing dominant negative 
cDNA MEK insert (see Appendix I); pcDNA3 containing dominant negative cDNA RAP 
insert (see Appendix I) were kindly supplied by Prof. Zvi Noor, Department of 
Biochemistry, Tel Aviv University, Israel. 
2.5.2. Transformation of competent cells with plasmid DNA 
Plasmids were transformed into competent TOPI0 cells using TOPI0 One Shot kit 
(Invitrogen, UK). Two JLI of 0.5 M 6-mercaptoethanol was added to a vial of competent 
cells together with 2 JLI of TOPO cloning reaction and 100 JLg of DNA and mixed prior to 
incubation on ice for 30 minutes. Cells were then heat shocked at 42°C for 30 seconds 
and transferred to ice for 2 minutes. To this mixture, 250 JLI SOC medium (supplied with 
the kit) was added and the tube incubated under vigorous shaking at 37°C for 30 minutes. 
Thereafter, 50 JLI and 100 JLI aliquots were streaked out and grown on LB agar plates 
containing 10 mglml ampicillin at 37°C overnight. Single colonies were picked, and 
inoculated into 10 ml of LB broth containing 10 mglml ampicillin and grown at 37°C 
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under constant agitation overnight. Plasmid DNA was recovered using Qiagen endofree 
plasmid isolation kit (Qiagen, GmbH, Crawley, UK). 
2.5.3. Large Scale Plasmid DNA Recovery - Maxiprep 
Large-scale plasmid recovery was carried out using the Endofree™ plasmid Maxi kit 
(Qiagen), an alkaline lysis plasmid recovery system, according to manufacturers 
instructions. Briefly, 100 ml of an overnight bacterial culture was pelleted by 
centrifugation at 4°C for 15 minutes at 6000 g. The pelleted cells were resuspended in 10 
m1s of buffer PI (50 mM Tris-HCI pH 8.0, 10 mM EDTA and 100 )J.glml RNAse A). The 
cells were then incubated for 5 minutes at room temperature with 10 ml of buffer P2 (200 
mM NaOH and 1 % SDS), which facilitates cell lysis. The cell lysate was neutralised by 
the addition of 10 ml of 3 M potassium acetate pH 5.5, transferred to a QIAfilter, 
incubated for 10 minutes and then filtered. Thereafter, 2.5 ml of buffer ER (Qiagen) was 
added and the filtered cell lysate was incubated for 30 minutes on ice. Subsequently, the 
cell lysate was applied to the QIAGEN-tip and then washed twice with 30 ml of buffer 
QC (1 mM NaCI, 50 mM MOPS pH 7.0 and 15 % isopropanol). The plasmid DNA was 
then eluted with 15 ml of buffer QN (1.6 mM NaCI, 50 mM MOPS pH 7.0 and 15 % 
isopropanol) and precipitated with 10.5 ml of isopropanol. The sample was then 
centrifuged at 4°C for 30 minutes at 15 000 g. The supernatant was removed, the DNA 
pellet was washed with 15 ml of 70 % ethanol and then centrifuged at 4°C for 15 minutes 
at 15 000 g. Thereafter, the pellet was air dried and resuspended in 1.5 ml of TE buffer 
(10 mM Tris-HCI pH 8.0 and 1 mM EDTA). The concentration and quality of the DNA 
was determined using spectrophotometry at 260 nm and 280 run. The concentration of the 
DNA was calculated from the 260 nm value obtained, given that an optical density of 1.0 
is equal to 50 )J.glml for double-stranded DNA and 33 )J.glml for single-stranded DNA. 
DNA quality was determined by dividing the 260 nm reading by the 280 nm reading; a 
ratio of 1.6 to 1.9 was taken to be of sufficient quality containing minimal protein 
contamination. Purified DNA was stored at -20°C. 
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2.6. cAMP assays 
EP4 receptor signalling was assessed by measuring cAMP accumulation following 
stimulation of cells with either PGE2 (300 nm) or seminal plasma (various dilutions of 1 :250 
up to 1:5000). Cells (2x105) were seeded in 6 well dishes and allowed to attach overnight. 
The next day, cells were washed twice with PBS followed by incubation with serum-free 
DMEM for a minimum of 16 hours to allow synchronization. Cells were then stimulated for 
the time periods indicated in the figure legends. Following treatments, the medium was 
removed and the cells washed in ice-cold PBS before being lysed in 0.1 M HC!. cAMP 
concentration was quantified by ELISA using a cAMP kit (Biomol Affiniti, Exeter, UK) as 
per the manufacturer's protocol and normalized to the protein concentration of the lysate. 
Protein concentrations were determined using protein assay kits (Bio-Rad) as described in 
Section 2.8.2. The ELISA was performed using a 96 well micro titre plate provided in the 
assay kit. The wells of the plate are pre-coated with goat anti-rabbit IgG. cAMP standards 
(100 J.11 of each), ranging from 200 pmollml up to 0.78 pmollml, were added to the plate to 
produce a standard curve. A 100 ji1 volume of sample was then added to the plate in 
duplicate. Alkaline phosphatase-cAMP conjugate (50 pI) and 50,.11 ofpolyc1onal rabbit anti-
cAMP antibody (both provided with the kit) were added to each well of the plate. 
The plate was then incubated at room temperature for 2 hours on a plate shaker at ~500 rpm. 
Thereafter, the wells were aspirated and washed three times with the wash buffer provided 
(TBST; 50 mM Tris-HCl, 150 mM NaCI, 0.5% Tween®20, pH 7.4; containing sodium 
azide). The assay was developed by the addition of 200 J.1l1well of p-nitrophenyl phosphate 
(provided with the kit). The colour reaction was allowed to develop for 20 minutes and was 
stopped by the addition of 200 J.1l/well of stop solution provided (trisodium phosphate in 
water). Colour reaction was measured at 405 nm by spectrophotometry. The concentration of 
cAMP per sample was calculated by extrapolation from the standard curve using the Assay 




2.7.1. Total RNA extraction 
Total RNA was isolated from HeLa cells, which had been routinely maintained as 
described in Section 2.2. RNA was isolated using a commercially available guanidinium 
thiocyanate-based extraction reagent Tri-reagent (Sigma-Aldrich, Dorset, UK) according 
to the manufacturer's protocol. Volumes were adjusted appropriately, allowing 
approximately 1 ml Tri-reagent per lxl06 cells. Cells were lysed for 1 minute in Tri-
Reagent until completely dissociated and then supplemented with 0.1 volume of 1-
bromo-3-chloropropane (BCP) per volume of Tri-reagent used. After vigorous shaking 
for 20 seconds, the mixture was allowed to stand at room temperature for 5 minutes 
before centrifuging at 14 000 g for 20 minutes at 4°C. Thereafter the upper aqueous layer, 
containing the RNA was transferred to a fresh RNAse-free eppendorf tube and the RNA 
was precipitated with 1 volume of isopropanol (Sigma-Aldrich). The RNA was pelleted 
by centrifugation at 14 000 g for 20 minutes at 4°C. Following removal of the 
supernatant, the RNA pellet was washed in 75 % ethanol and then dissolved in RNAse-
free water at 65°C for 5 minutes. RNA was quantified using spectrophotometrically. 
2.7.2. Determination of RNA concentration 
The concentration and quality of RNA was determined by spectrophotometry at 260 nm 
and 280 nm. The concentration of the RNA was calculated from the 260 nm value 
obtained, given that an optical density of 1.0 is equal to 40 /Jgtml for RNA. RNA quality 
was determined by dividing the 260 nm reading by the 280 nm reading; a ratio of 1.6 to 
1.9 was taken to be of sufficient quality containing minimal protein contamination. 
Purified RNA was stored at -70°C. 
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2.7.3. Reverse-Transcription (RT) Reaction 
Total RNA was extracted from HeLa cells using Tri-reagent (Sigma-Aldrich) following 
the manufacturer's instructions as described in Section 2.7.1. For reverse transcription 
reactions, 200 J.lg of RNA was reverse transcribed using a TaqMan GeneAMP RNA PCR 
kit (Perkin Elmer, PE Biosystems, Warrington, UK). After incubation for 10 minutes at 
room temperature, polymerase chain reaction (PCR) was performed for 1 cycle (1 hour at 
42°C, 5 minutes at 99°C and 5 min at 5°C) and contained 5 mM MgCh, PCR buffer, 1 
mM of each deoxynucleoside triphosphate, 1 U/J.lI RNAse inhibitor, 2.5 U/J.lI MuL V 
reverse transcriptase, random hexamers (1.25 J.lM), oligo-dT (1.25 J.lM) each (all from PE 
Biosystems) and RNAse-free water to a fmal reaction volume of 10 J.ll. The resultant 
cDNA was stored at -20°C 
2.7.4. Real-time quantitative polymerase chain reaction (RT -PCR) 
Real-time quantitative RT-PCR was performed to assess the relative expression of COX-
2, VEGF, FGF and prostaglandin receptor subtypes EPl, EP2, EP3 and EP4 in HeLa 
wild-type and EP4 over-expressing sense cells (EP4S). RNA samples were extracted 
from treated WT and EP4S HeLa cells using Tri-reagent as described in Section 2.7.1 and 
were reverse transcribed as described in Section 2.7.3. A reaction mix was made 
containing Taqman buffer (5.5 mM MgCh, 200 J.lM dATP, 200 J.lM dCTP, 200 J.lM 
dGTP, 400 J.lM dUTP), ribosomal 18s fOlWard and reverse primers and probe (all at 50 
nM), fOlWard and reverse primers for all target genes were used at 250 nM (See Table 5: 
Sequences of Primers and Probes), AmpErase UNG (0.01 U/J.lI) and AmpliTaq Gold 
DNA Polymerase (0.025 U/I.tl; all from PE Biosystems, Warrington, UK). A volume of 
48 J.ll of reaction mix was aliquoted into separate tubes for each cDNA sample and 2 
J.lllreplicate of cDNA was added. After mixing 23 J.lI of sample were added to the wells 
on a PCR plate. Each sample was added in duplicate. A no template control (containing 
water) was included. Wells were sealed with optical caps and the PCR reaction run on an 
ABI Prism 7700 Quantitative PCR machine. Primers were designed using the PRIMER 
express program (PE Biosystems). 
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Gene • SequerlCle of primers and probes 
COX-2 FOI'WaId 5'-CCTTCCTCCTGTGCX;TG.6.TG-3' 
Reverse 5'-ACAATCTCATITGAATCAGGAAGCT-3' 
Probe (FAM labelled, 6-carboxyfIuorescein) 5-TGCCa?ACTCCCTTGGGTGTCA-3' 
VEGF FOI'WaId 5'-TAGCTGCGCTG.6.TAG.6.CAT -3' 
Reverse 5'-TACCTCCACCATGCCAAGT-3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5-ACTTCGTG.6.TG.6.TTCTGCC-3' 
FGF FOI'WaId 5'-CCGA.CGGCCGCGTG6.C-3' 
Reverse 5'-G.6.CACAACTCCTCTCTCIT-3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5-AGAAGA~CACA-3' 
EP1 FOI'WaId 5'-AG,l\TGGTGGGCCAGCrTGT-3' 
Reverse 5'-OCC/lCCAACAGCATTG-3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5'-CA.GCAl3ATGCAOOACACCACCATG-3' 
EP2 FOI'WaId 5-GACCGCITACCTGCAGCTGTACr3' 
Reverse 5'-TGAAGTTGCAGGCGAGCA-3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5'-CCACCCTGCTGCTGCTTCTCATTGTCT-3' 
EP3 FOI'WaId 5'-GACGGCCATTCAGCTTATGG-3' 
Reverse 5'-TTGAAG.6.TCATTTICAACATCATTATO\-3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5'-CTGTCGGTCTGCTGGTCTCCGCTCr3' 
EP4 FOI'WaId 5'-ACGCCGCCTACTCCTACATG-3' 
Reverse 5'-AG,l\GGAC:J::J3rC?J3CJ3AGAAT -3' 
Probe (FAM labelled, 6-carboxyfluorescein) 5 -ACGCGGGCTTCAGCTCCTTCCT-3' 
Ribosoma118s Faward 5'-03GCrACCACATCX:;AAl::J3N::'r·3' 
Reverse 5'-GCTGGt\ATTACCGCGGC'T-3' 
Probe (VIO!J).labelled PE Bios"f,stems) 5'·TGCTGGCACCAGACITGCCCTCr3' 
Table 5: Sequence of Primers and Probes 
Data were analysed and processed using Sequence Detector v1.6.3 (PE Biosystems). 
Expression of each gene was normalised to RNA loading for each sample using the 18s 
ribosomal RNA as an internal standard. Fold induction was calculated as fold increase in 
mRNA expression of cells treated with PGE2 (300 nM) or seminal plasma (1 :500) above 
vehicle-treated cells at the same time point. 
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2.8. Protein 
2.8.1. Protein extraction 
HeLa cells were grown until the desired confluency was reached in 5 cm dishes. Cells 
were lysed by addition of 250 J11 protein lysis buffer (1 % Triton X~100, 150 mM NaCI, 
10 mM TrisIHCI pH7.4, 1 mM EDTA, 0.1 % SDS containing 2 mM PMSF). Proteins 
were extracted by allowing the dishes to sit on ice for 10 minutes and the cells were then 
scraped off using a plate scraper. Thereafter insoluble material was pelleted by 
centrifugation at 14 000 g for 15 minutes at 4°C. The clarified lysate was then transferred 
to a new eppendorftube for protein quantification and SDS~PAGE. 
2.8.2. Protein quantification 
Proteins were quantified according to the BIO~RAD DC Protein microassay (Biorad, UK) 
as per manufacturer's instructions. Samples were diluted in distilled water to a ratio of 
1:30. A concentration range of bovine serum albumin (BSA, supplied with the assay) 
ranging from 0 J1g/ml to 200 J1g/ml was made up in distilled water to achieve an ODS9S 
response from 0.1 to 1.0 OD units. For the assay, 25 J11 standards or samples were added 
to each well (in duplicate) of a 96 well plate. To this, 25 J11 Reagent A, followed by 100 
J11 Reagent B was added and the plate incubated at room temperature for 10 minutes. 
Thereafter, the colour reaction was assayed at an absorbance of 690 run using a 
Multiscan® MCCl340 plate reader. A standard curve was produced using the Assay Zap 
computer software program (Biosoft) and used to detemrine the average protein 
concentration of each sample. 
2.8.3. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS~PAGE) 
SDS-PAGE was performed using pre~cast 4 % - 20 % Tris-Glycine gels (NOVEX, 
Invitrogen). Gels were set up in the gel running tank with running buffer (25 mM Tris-
HCI, 0.2 M glycine, 0.1 % SDS). A total of 40 J1g protein was resuspended in a total 
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volume of 25 J.11 sample loading buffer (125 mM Tris-HCI pH 6.8, 4 % SDS, 20 % 
glycerol, 5 % 2-mercaptoethanol and 0.05 % bromophenol blue), boiled for 5 minutes at 
95°C and loaded into separate wells of the gel. 10 J.11 of Seeblue™ (Novex) pre-stained 
molecular weight markers were loaded into a separate well. Gels were run at 4 rnA 
constant current for about 90 minutes prior to immunoblotting. 
2.8.4. Western Blotting 
Following electrophoresis, the gel was transferred to a protein-free tray and equilibrated 
with transfer buffer (25 mM TrisIHCl, 0.192 M glycine, 20 % methanol) for 5 minutes. 
Whatman no. 3 paper (Whatman, UK) and polyvinylidene difluoride membrane (PVDF) 
membrane (Millipore, Watford, UK were cut to the dimensions of the gel and 
equilibrated in transfer buffer. The PVDF membrane was pre-soaked in methanol for 1 
minute followed by a rinse in distilled water prior to equilibration with transfer buffer. 
The blot was assembled by overlaying three pieces of pre-soaked Whatrnan paper with 
the PVDF membrane followed by the gel and three layers of Whatrnan paper to form a 
sandwich. Air bubbles were then removed by rolling a clean glass pipette over each 
surface. Protein was transferred to the membrane for 1 hour 45 minutes at 14 V constant 
voltage using a semi-dry blotter (BIO-RAD, UK) assembled as per the manufacturer's 
instructions. Pre-stained molecular weight markers run in parallel on SDS-PAGE were 
used to determine whether transfer was successful. Following transfer, membranes were 
blocked for 1 hour at 25°C using 4 % BSA made up in TBS-Tween (50 mM Tris-HCI, 
150 mM NaCI and 0.05 % v/v Tween-20). Thereafter, membranes were incubated with 
the relevant primary antibody at 4°C for 18 hours. After washing 3 times with TBS-
Tween, membranes were subsequently incubated for 1 hour respectively with the relevant 
secondary antibody. Proteins were either revealed on photographic film by 
chemiluminescence (ECLplus kit) following the manufacturers instructions and 
quantified by scanning densitometry or by the ECF chemiluminescence system following 
the manufacturers instructions. Proteins developed by the ECF system were revealed and 
quantified by PhosphorImager analysis using the STORM 860 system (Molecular 
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Dynamics, UK). The molecular weights of the proteins were determined relative to the 
mobility of the pre-stained markers on SDS-PAGE. 
2.9. Immunohistochemistry (IRC) of cervical sections and cells 
2.9.1. IRC of cervical sections 
Levels of EP4 expression in cervical sections was carried out using archival cervical 
blocks obtained from the Department of Anatomical Pathology, University of Cape 
Town, South Africa. Tissue samples were prepared and mounted onto coated slides. 
Sections were dewaxed in xylene for 15 minutes, rehydrated in graded ethanol (100 %, 
96 % and 70 % respectively), washed in water followed by Tris buffered saline (TBS; 50 
mM Tris-HCl, 150 mM NaCI pH 7.4). Thereafter the tissue sections were blocked for 
endogenous endoperoxidase for 30 minutes in 1 % hydrogen peroxide (H202) in 
methanol to reduce endogenous peroxidase activity as a peroxidase detection method was 
used for immunodetection. The slides were then washed in TBS for 5 minutes. Antigen 
retrieval was performed by pressure cooking for 2 minutes in 0.01 M sodium citrate 
buffer (PH 6.0). Sections were blocked for 30 minutes at 25°C by incubation with 5 % 
normal rabbit serum diluted in TBS. The tissue sections were then incubated with 
polyclonal EP4 specific antibody (Cayman Chemical Company Ltd.) at a dilution of 
1:250. The slides were covered with Gelbond film (Flowgen, Rockland, ME, USA), 
hydrophobic side down and incubated in a humidified chamber at 4°C for 18 hours. The 
following day, the tissue sections were washed three times for 5 minutes each with TBS 
to remove excess primary antibody. Tissue sections were then subjected to secondary 
antibody and Horseradish Peroxidase detection. The tissue sections were incubated 25°C 
for 40 minutes with swine anti-rabbit secondary IgG antibody (Dako) at a dilution of 
1:500. Excess secondary antibody was washed from slides by three washes of 5 minutes 
with TBS. Thereafter the tissue sections were incubated with streptavidin-peroxidase 
complex (Dako) for 20 minutes at 25°C and then washed thoroughly three times for 5 
minutes each with TBS. The horseradish peroxidase complex was prepared according to 
suppliers protocol (Dako) in 0.05 M TrisIHCI pH 7.6 at least 20 minutes before use. 
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Bound antibody was visualised by incubating the tissue sections with a solution of 225 
J.1M 3.3'-diaminobenzidine in 0.05 M TrisIHCl pH 7.6 containing 0.01 % H202. After the 
colour reaction had developed, the reaction was stopped by washing the slides in distilled 
water. The tissue sections were then counterstained with haemotoxylin and eosin, rinsed 
in acid-alcohol and blued in Scotts tap water. Finally sections were dehydrated, cleared in 
xylene and coverslipped with pertex (Cellpath, Hemel Hampstead, UK). 
2.9.2. Immunofluorescent microscopy of cells 
The site of EP4 receptor expression was localized in wild-type and EP4S HeLa cells by 
immunofluorescence microscopy. Approximately 10 000 wild-type and sense cells were 
seeded in chamber slides, allowed to attach and grow overnight, before being fixed in 100 
% ice-cold methanol. Following fixing, cells were washed in TBS (50 mM Tris-HCI, 150 
mM NaCI, pH 7.4) and blocked using 5 % normal swine serum diluted in TBS. 
Subsequently the cells were incubated with polyclonal rabbit anti-EP4 receptor antibody 
at a dilution of 1:50 at 4°C for 18 hours. Control cells were incubated with rabbit 
immunoglobulin (IgG). Thereafter the cells were incubated with secondary swine anti-
rabbit tetramethyl rhodamine isothyocyanate (TRITC; Dako Corp, High Wycombe, UK) 
at 25°C for 20 minutes and counterstained with To-Pro at a dilution of 1 :2000 for 2 
minutes. Cells were then mounted m Permafluor (lmmunotech-Coulter, 
Buckinghamshire, UK) and coverslipped. Fluorescent images were visualised and 
photographed using a Carl Zeiss (Jena, Germany) laser scanning microscope LM510. The 
Alexafluor 546 and 488 was captured using the helium/neon 1 laser (excitation beam, 543 
nm) and an emission band pass ffiter 560-615 nm. 
2.10. Vascular Endothelial Growth Factor Enzyme-linked Immunosorbent Assay 
(VEGF ELISA) 
Secreted VEGF was measured using an ELISA kit. Cells were seeded out in 6 well plates 
at 2xl0s cells per well and allowed to adhere overnight. Cells were first synchronized by 
serum withdrawal for at least 16 hours in serum-free medium. Thereafter, cells were pre-
60 
treated with vehicle, specific inhibitors or the EP4 antagonist (ONO-AE2-227) for 1 hour 
prior to stimulation with 300 run PGE2 or 1:500 dilution of seminal plasma (for the time 
periods specified in the figure legends). Culture mediwn was removed and VEGF protein 
was measured using a Human VEGF ELISA kit (Oncogene) as per manufacturers 
instruction. Serial dilutions ofVEGF standards (15.6 p&,ml up to 1000 p&,ml) were made 
up in Calibrator diluent RD5K (supplied with kit). Samples were diluted 1:10 with 
Calibrator diluent RD5K to ensure that VEGF detection levels fall within those on the 
standard curve. A 96-well plate coated in monoclonal antibody specific for the VEGF 
protein (supplied with the kit) was loaded with samples and standards. The plate was then 
incubated at room temperature for 2 hours, this allows any VEGF present in the samples 
to bind to the capture antibody. Following this incubation, the plate was washed 
thoroughly 3 times with wash buffer (supplied with kit) to remove any unbound material. 
Polyclonal, horseradish peroxidase (HRP)-conjugated anti-VEGF antibody (200 Ill) is 
added to each of the wells. Following an incubation of 2 hours at room temperature, the 
plate is washed again three times using the wash buffer provided in the kit. A 
chromogenic substrate (200 Ill) is added to the wells and the plate incubated for 20 
minutes at room temperature. The horseradish peroxidase catalyses the conversion of the 
chromogenic substrate tetra-methylbenzidine from a colourless solution to a blue 
substrate. Stop solution (50 Ill) (2 N sulphuric acid) (supplied with the kit) is added to 
each well, causing the colour to turn yellow. The intensity of each well is proportional to 
the amount of hwnan VEGF protein in the test samples. The coloured reaction product is 
measured on a spectrophotometer at 450/540 run. Quantification is achieved by the 
construction of a standard curve using known concentrations of human VEGF protein. By 
comparing the absorbance obtained from a sample containing an unknown amount of 
human VEGF protein with that obtained from the standards, the concentration of hwnan 
VEGF protein in the test samples can be determined. Data are expressed as fold change in 
comparison to basal where the amount ofVEGF secreted in treated cells is divided by the 
amount secreted in cells treated with the vehicle. 
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2.11. Prostaglandin E2 (PGE2) Assay 
The PGE2 levels in seminal plasma samples were measured using PGE2 assays. The ELISA 
was performed using 96 well plates (Amine-binding plates; Cosar; High Wycombe, UK) 
coated with donkey anti-rabbit antibody. Plates were then coated with rabbit 
immunoglobulin G (1 mglml diluted in PBS with 1 % carbonate buffer, pH 9.6) at 200 
J.1l1well for 16 hours at 4°C. The solution was aspirated and blocking solution (50 mM 
glycine, 10 mglml bovine serum albumin) added at 25 J.1l1well for 2 hours at 23°C. The 
plates were then washed and donkey anti-rabbit serum (Scottish Antibody Production Unit, 
Carluke, UK) added to a final volume of 150 J.1l1well, before washing, air-drying and storage 
with dessicant at 4°C. The link was prepared by ether extraction and reverse phase 
chromatography using 20 mg of synthetic PGE2, 320 J.11 dry dimethylformamide, 3 J.11 
butylchloroformate and 0.05 mM biocytin. Samples and synthetic standards were diluted in 
ELISA buffer (150 mM NaCI, 100 mM Tris-HCI, 0.05 % Tween-20, 50 mM phenol red, 1 
mM 2-methylisothiazolone, 1 mM bromonitrodioxane, 2 mM EDTA, 2 mglml bovine serum 
albumin to a final pH 7.2), and 100 J.11 of each added in duplicate to the plate. The link was 
diluted 1:1.5xl06 in ELISA buffer and 50 J.11 added to each well. Antisera, diluted 1:50000 
in ELISA buffer, was added to a final volume of 50 J.11 to all wells except those used for 
measuring non-specific binding. Plates were incubated at 4°C for 16 hours, washed and 100 
J.1l1well of 0.2 unitlml streptavidin-peroxidase (Boehringer Mannheim) was added Plates 
were then incubated for 20 minutes at 23°C on an orbital shaker, washed and substrate (0.3 
giL urea-hydrogen peroxide, 0.1 giL tetramethyl benzine in 100 mM sodium acetate, pH 6.0) 
added to a fmal volume of 200 J.1l1well for 10 minutes before quenching with 50 J.1l1well 1M 
sulphuric acid. Colour reaction was measured at 450 nm by spectrophotometry. The rabbit 
antiserum that was raised against PGE2-complexed keyhole limpet hemocyanin has been 
previously characterised (Kelly et al. 1989). 
2.12. Statistical Analysis 
The data in this study were analysed by ANOV A and Fishers PLSD tests using Statview 
5.0 (Abacus Concepts Inc., Berkeley, CA, USA). The data is presented as Mean ± SEM. 
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• CHAPTER 3 - EXPRESSION AND LOCALISATION OF EP4 
RECEPTOR IN CERVICAL TISSUE SECTIONS. 
3.1. Introduction 
Prostaglandin E2 (PGE2) is a major cyclooxygenase (COX) product in a nwnber of 
physiological settings. In the gastrointestinal tract, COX-I-derived PGE2 plays a 
protective role in maintaining the integrity of the gastric mucosa (Hoshino et al. 2003). 
PGE2 production in the kidney is crucial for normal renal function (Breyer et al. 1996; 
Breyer et al. 1996), and it has also been shown to playa role in the maintenance of blood 
pressure (Audolyet al. 1999). Prostaglandins (PGs) have also been recognised for many 
years as potent mediators of female reproductive tract physiology, including ovulation, 
implantation, cervical ripening, cervical dilation, menstruation, luteolysis, myometrial 
contractility, placental vascular tone and parturition (Kniss 1999; Matswnoto et al. 2001; 
Sales et al. 2003). In addition, COX-enzymes and PGs, such as PGE2, are elevated in 
various carcinomas, including cervical carcinoma (Prescott et al. 2000; Sales K.J. 2001; 
Sales et al. 2001; Marnett et al. 2002; Mann et al. 2004). Cervical cancer is an important 
problem in sub-Saharan Africa and has a major impact on morbidity and health care costs 
(Leiman 1976; Bailie et al. 1996). There is much evidence indicating Human Papilloma 
Virus (HPV) to be an initiator of cervical neoplastic transformation, however nwnerous 
studies have suggested that development and progression of cervical carcinomas may be 
regulated by COX-enzyme products, including PGE2 (Kulkarni et al. 2001; Sales et al. 
2001; Riley et al. 2003; Szkaradkiewicz et al. 2004). In addition, nwnerous studies have 
shown elevated COX-enzymes in cervical carcinoma (Ryu et al. 2000; Kulkarni et al. 
2001; Sales etal. 2001; Han et al. 2003). 
The diverse effects of PGE2 may be accounted for in part by the existence of four G-
protein coupled receptors (GPCRs) termed EP1, EP2, EP3, and EP4 receptors (Breyer et 
al. 1996; Boie et al. 1997). Interaction of PGE2 with the EP1 receptor mobilizes 
intracellular calciwn and inositol triphosphate (IP]) via Gaq (Samad et al. 2002). EP2 
and EP4 are both coupled to Gas, and signal via stimulation of adenylyl cyclase resulting 
in an increase in cAMP (Samad et al. 2002). There are several splice variants of the EP3 
receptor, which are coupled to different signalling pathways that result in either a positive 
or negative cAMP response to PGE2 administration or an increase in intracellular calciwn 
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mobilization and accumulation of IP3, depending on the splice variant and cell type 
(Hatae et al. 2002). 
Functional roles for prostaglandin EP receptors have been determined by studies in 
knockout mice systems, deficient for each of the receptors as described in Section 
1.4.12.8. (Table 4) (Audoly et al. 1999). These data have ascertained an important role 
for the EP2 and FP receptors in normal reproductive function. Recent data, however, 
have shown an association between aberrant expression and signalling of prostanoid 
receptors (EP2IEP4 and FP receptors) and pathologies of the reproductive tract, including 
endometrial adenocarcinoma and cervical carcinoma (Sales et al. 2004; Sales et al. 
2004), suggesting that the EP2/EP4 receptor may playa role in cervical tumourigenesis. 
In support of this latter observation, Sheng et al. (2001) and Sonoshita et al. (2001) have 
demonstrated a role for EP2IEP4 receptors in enhancing colon tumourigenesis. In these 
model systems, PGE2, via the EP2 receptor has been shown to accelerate intestinal polyp 
formation (Sonoshita et al. 2001) as well as enhance proliferation and tumourigenic 
effects via the EP4 receptor (Sheng et al. 2001). Similarly, Fujino et al., 2003 have 
ascertained a role for EP4 receptor in mediating mitogenic signalling, which may lead to 
activation of target molecules implicated in cancer (Fujino et al. 2003). Taken together, 
these fmdings and that of elevated EP2/4 receptors in cervical carcinoma strongly suggest 
a role for PGE2 signalling via EP4 receptor in modulating tumourigenesis, however, the 




Previous studies have demonstrated elevated expression and signalling of EP4 receptor in 
cervical carcinoma, indicating a potential autocrine/paracrine regulation of neoplastic 
cervical cell function by PG~ via the EP4 receptor (Sales et al. 2001). The aim of this 
section was to determine the localisation of the site of EP4 receptor expression in cervical 
carcinomas. 
3.3. Materials and Methods 
Informed consent was obtained from patients prior to tissue collection. Five squamous 
cell carcinoma, 4 adenocarcinoma and 5 normal cervical tissues were collected and 
processed as described in Section 2.2. The localisation of the site of expression of EP4 
receptor in the cervical tissue was investigated by immunohistochemistry using EP4-
specific antibodies as described in Section 2.9. Briefly, cervical sections were dewaxed 
and sub sequentially rehydrated as described and incubated with specific primary and 
secondary antibodies prior to detection with DAB. Ethical approval for this study was 
granted by University of Cape Town Research Ethics Committee. 
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3.4. Results 
Levels of immunoreactive EP4 receptor were upregulated in all cervical carcinoma 
samples investigated compared with the expression in normal cervix. 
The site of EP4 receptor expression was localised by immunohistochemistry to the 
neoplastic ally transformed squamous epithelium in squamous cell carcinoma (n=5; 
arrowhead, Figure 3.1. A), and to neoplastic ally transformed columnar epithelium lining 
the endocervical canal and the glandular epithelium of the endocervical glands in 
adenocarcinomas (n=4; arrowhead, Figure 3.1. B). One representative squamous 
carcinoma and one adenocarcinoma are shown respectively. Normal cervical tissue 
sections showed no elevated EP4 immunoreactivity above basal levels (n=5; Figure 3.1. 
C). Sections probed with IgG in place of primary antibody (EP4 negative control; Figure 







Figure 3.1. Locahs.alloll 0( Ibe site of EN receptor e.Wressloll ill epithelial ce ll s of 
squnmous ce ll CIIrcinoma (A). adcllOCan::inoma (8 ) and normal cervix (C). Seclioo of 
tissue Incubated with IgG (ncgalJ~c conlrol) arc s.no..n ror adenocarc iDOma (D), Scale 
bar is 100 14m. 
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3.5. Discussion 
This study confinns the expression of EP4 receptor in cervical squamous cell carcinomas 
and adenocarcinomas. EP4 receptor expression was localised to the neoplastically 
transformed epithelial cells in all carcinomas investigated, compared with normal cervix. 
This pattern of expression of EP4 is similar to that observed for COX-2 and PGE2 in 
cervical squamous cell carcinoma and adenocarcinoma cases reported previously by 
Sales et al., 2001. The role that PGE2 plays in cancer development and progression is not 
fully elucidated, though numerous mechanisms have been outlined in various model 
systems. Enhanced synthesis of PGE2 resulting from upregulated COX-2 can induce 
malignant change in epithelial cells through immunosuppression (Wang et aI. 2004), 
inhibiting apoptosis (Song et al. 2002), increasing metastatic potential of cells (Chang et 
al. 2000; Kundu et al. 2002), and promoting angiogenesis (Tsujii et al. 1998; Jones et al. 
1999; Dormond et al. 2001; Chang et al. 2004). 
These data show that the site of EP4 expression is in close proximity to the site of PGE2 
biosynthesis, suggesting an autocrine/paracrine control of neoplastic cell function by 
PGE2 via the EP4 receptors. Such an interaction has been proposed for several other 
model systems (Regan 2003; Pozzi et al. 2004; Spinella et al. 2004; Timoshenko et al. 
2004). Studies performed by Pozzi et al., 2004, using mouse colon adenocarcinoma 
(CT26) cells to investigate the role of PGE2 in cell proliferation showed that CT26 cells 
express both COX-l and COX-2 and metabolize arachidonic acid to PGE2. Treatment of 
these cells with indomethacin, or COX-selective inhibitors, prevented PGE2 biosynthesis 
and CT26 cell proliferation. These anti-proliferative effects of COX inhibition were 
abolished specifically by treatment with PGE2 or the EP4 receptor-selective agonist 
(ONO-AE2-227) via PI3-kinaseIERK activation, thus providing a functional link between 
PGE2-induced cell proliferation and EP4-mediated ERK signalling (pozzi et al. 2004). 
The role of EP4 receptor in tumourigenesis has been further strengthened following data 
published by Spinella et al., 2004. These data associated EP4 receptors in the induction 
of VEGF expression and cell invasiveness via PGE2-dependent machinery, which 
resulted in increased angiogenesis and invasive phenotype in ovarian carcinoma cells 
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(Spinella et al. 2004). Other data published by Timoshenko et al., 2004, reported that 
endogenous PGE2, resulting from COX-2 expression in a metastatic murine breast cancer 
cell line C3L5 upregulates IFN-y and LPS-induced nitric oxide synthase expression and 
nitric oxide production. This action of PGE2 was mediated through the EP4 receptor in a 
cAMP-dependent manner (Timoshenko et al. 2004). 
The reduction of PGE2 biosynthesis by the action ofNSAIDs on COX-enzymes, has been 
shown to down-regulate the survival, metastatic, and angiogenic potentials of cancerous 
tissue (Grosch et al. 2001; Turini et al. 2002; Zweifel et al. 2002; Zha et al. 2004). Thus, 
treatment of cervical carcinoma with NSAIDs will suppress endogenous expression of 
COX-2 and synthesis of PGE2, which may be acting in an autocrine/paracrine manner via 
various EP receptors, including the EP4 receptor. It is important to emphasize however, 
that in addition to endogenously synthesied PGE2, neoplastic ally transformed cervical 
epithelial cells in sexually active women will potentially be under the direct stimulation 
of prostaglandins (PGs) from seminal plasma. PG levels in seminal plasma are 10 000 
times higher than that found at a site of inflammation, and PGE is the predominant type 
of prostaglandin detected (Kelly 1995). Thus, in sexually active women with pre-
neoplastic lesions, up-regulation of expression of genes that may modulate mitogenesis 
and invasiveness of neoplastically transformed cervical epithelial cells, may be regulated 
in part by endogenous expression of PGE, as well as PGE available in seminal plasma. 
Enhanced PGE-EP4 interaction as a consequence of elevated EP4 receptor expression in 
cervical carcinomas, may lead to enhanced or sustained cervical tumourigenesis. Hence 
the application ofNSAIDs on their own may not be sufficient to treat cervical carcinoma, 
a more effective treatment may lie in the use of prostanoid receptor antagonists, such as 
those targeting the EP4 receptor, coupled with NSAIDs. 
Following the observation of elevated EP4 receptor in neoplastic epithelial cells of the 
cervix (outlined in this chapter), I proceeded to investigate the effects of seminal plasma 
prostaglandins on cervical epithelial cells using a HeLa cell line stably overexpressing the 
EP4 receptor (outlined in Chapter 4). 
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CHAPTER 4 - CONSTRUCTION OF A IlELA EP4 RECEPTOR 
OVEREXPRESSING CELL MODEL SYSTEM 
4.1. Introduction 
In the previous chapter, the site of expression of the EP4 receptor was localised to the 
neoplastic epithelial cells in all cervical carcinomas. These cells have previously been 
reported to be the site of synthesis of PGE2 in cervical carcinoma. 
PGE2 is a major product of COX-initiated arachidonic acid metabolism. The mode of 
action of PGE2 is brought about by coupling to multiple PGE2 receptors (EPl, EP2, EP3, 
and EP4 receptors), which are often co-expressed together in the same cell type, 
indicating that PGE2 may have multiple and at times opposing functional effects on a 
given target tissue (Breyer 2001). Roles for each of the EP receptors have been 
ascertained (as described in Chapter 1) (Breyer et al. 1996; Boie et al. 1997; Audolyet 
al. 1999; Hatae et al. 2002; Kawamori et al. 2003), and several studies in in vitro model 
systems and animal models have implicated an important role for EP4 receptor in 
tumourigenesis (Sales et al. 2001; Sales et al. 2002; Fujino et al. 2003; Regan 2003; 
Pozzi et al. 2004; Spinella et al. 2004; Timoshenko et al. 2004). The EP4 receptor is a 
seven transmembrane-segment GPCR, which signals through an increase in cAMP 
accumulation. The human EP4 receptor cDNA encodes a 488 amino acid polypeptide 
with a predicted molecular mass of -53 kDa (Breyer 2001). In addition to the human 
receptor, EP4 receptors for the mouse, rat, rabbit, and cow have been cloned (Honda et 
al. 1993; Nishigaki et al. 1995; Breyer et al. 1996; Boie et al. 1997). EP4 receptor 
mRNA expression is detected in a variety of tissues including, thymus, ileum, lung, 
spleen, adrenal, uterus, and kidney tissue (Regan et al. 1994; Katsuyama et al. 1998; 
Desai et al. 2000). The EP4 receptor protein has a long cytoplasmic tail (156 amino acid 
residues). This C-terminal sequence contains 38 serine and threonine residues that might 
serve as multiple phosphorylation sites (Breyer et al. 2001). Several studies have 
implicated this region in agonist-induced desensitisation (Desai et al. 2001) and EP4 
receptors were found to undergo rapid internalisation in response to PGE2 stimulation 
(Desai et al. 2000). Among the elements that are uniquely present in the carboxyl 
terminus of the EP4 receptor are sites for potential phosphorylation by cAMP-dependent 
protein kinase (PKA) and G-protein coupled receptor kinases (Breyer 2001). Following 
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PGE-EP4 receptor interaction, various signalling pathways, including MAPK or 
PI3kinase may be activated (Breyer 2001). 
Recent studies have demonstrated a role for the EP4 receptor in mediating events 
associated with tumourigenesis. One such study, reported by Spinella et al., 2004, has 
ascertained a role for the EP4 receptor in the promotion of angiogenesis and invasion. In 
this study, activation of the EP4 receptor in ovarian carcinoma cell enhanced VEGF 
expression and promoted cell invasiveness by endothelin-l. Similarly, in a separate study 
Timoshenko et al., 2004 demonstrated the involvement of the EP4 receptor in enhancing 
nitric oxide production mediated by PGE2 in breast cancer cells. Recent work reported by 
Pozzi et al., 2004 has shown that PGE2-EP4 receptor interaction can enhance cell growth 
in colon carcinomas. Moreover, data from our laboratory have demonstrated significantly 
increased expression of EP4 receptor mRNA in reproductive tract carcinomas, including 
cervical carcinoma tissues, compared with nonna! cervix (Sales et al. 2001). Taken 
together, these data suggest that cervical tumourigenesis could be regulated in an 
autocrine/paracrine manner by PGE2 via activation of the EP4 receptor and initiation of 
intracellular signal transduction cascades. 
In order to elucidate the molecular signal transduction pathways activated following 
PGE-EP4 receptor interaction and the role ofEP4 receptor in cervical epithelial cells, we 
constructed a stable cell line over-expressing the EP4 receptor in HeLa (cervical 
adenocarcinoma cells). Since 9 prostanoid receptors have been reported to date, any 
attempt to dissect out the signalling of a given receptor is made difficult due to the 
multiplicity of different signalling pathways and the complex network of crosstalk 
between them. The EP4 model system thus provides a unique opportunity to dissect out 
the signalling of a single receptor, namely the EP4 receptor, and elucidate its potential 
role in cervical tumourigenesis. 
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4.2. Aim 
The initial aims of this study were to establish a HeLa cervical adenocarcinoma cell 
model system overexpressing the EP4 receptor. This model system would subsequently 
be used as a tool to investigate: 
1. Intracellular signal transduction pathways mediating the role of the EP4 receptor 
in cervical adenocarcinoma cells (discussed in Chapter 5). 
2. The potential role of EP4 receptor signalling in mediating events associated with 
cervical tumourigenesis by investigating the target genes activated by PGE2 or 
seminal plasma in our HeLa EP4 model system (discussed in Chapter 6). 
4.3. Materials and Methods 
The HeLa cell line was chosen for this study, because of its cervical carcinoma origin, 
immortality and homogeneity. The HeLa cell model system provides a useful tool in 
studying the in vitro biological properties of cervical carcinoma. HeLa cells were the frrst 
aneuploid epithelial-like cell line to be derived from human tissue and maintained 
continuously in serial cell culture. HeLa was derived from cervical adenocarcinoma 
origin, from the carcinoma of a 31 year old female by GO Gey, WD Coffman and MT 
Kubicek in February 1951 (Gey 1958). Since its origin, the HeLa cell line has been one 
of the most extensively studied cell lines. HeLa cells were maintained as described in 
Section 2.4. 
4.3.1. Transfection ofEP4 containing plasmids into HeLa-S3 cells 
HeLa-S3 cells were purchased for the purpose of creating stable EP4-overexpressing 
HeLa cell line (EP4S) and a stable antisense cell line (EP4AS). Approximately 5000 cells 
were seeded in a fmal volume of 1 ml per well in each well of a 12 well plate in complete 
medium. Cells were allowed to attach and grow overnight. Either the pcDNA3 vector 
containing EP4 cDNA (2 Ilg) in the sense direction, or pcDNA3 vector containing EP4 
cDNA (2 Ilg) in the anti-sense direction was transfected into each well using Superfect 
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reagent (Qiagen, GmbH, Crawley, UK) diluted in Opti-MEM (Gibco, Invitrogen, Paisley, 
UK). Transfected and control cells were incubated for 4 hours at 37°C in 5 % hwnidified 
CO2 (v/v). Thereafter, the medium was replaced with fresh complete medium. Cells were 
allowed to grow for 72 hours. Transfected cells were then seeded together with wild-type 
cells using a ration of transfected:wild-type of 1: 1 O. Clones were then selected against 
200 J.lglml G418. Once control wild-type cells had died, at least 80 G418 resistant clones 
of both EP4S and EP4AS were picked. Clones were allowed to grow under continuous 
selection with G418, and then screened for the level of expression of EP4 receptor by 
Western Blot analysis (Section 4.3.2) and Real-time quantitative RT-PCR (Section 4.3.3). 
Clones were routinely maintained in 200 J.lglml G418. 
4.3.2. Western blot analysis of clones 
Western blot analysis was conducted as detailed in Section 2.8. Briefly, HeLa cells were 
grown until the desired confluency was reached in 5 cm dishes. Cells were lysed by 
addition of 250 J.lI protein lysis buffer (1 % Triton X-I00, 150 mM NaCI, 10 mM 
TrislHCI pH7.4, 1 mM EDTA, 0.1 % SDS containing 2 mM PMSF). Proteins were 
extracted by allowing the dishes to sit on ice for 10 minutes and the cells were then 
scraped off using a plate scraper. Thereafter, insoluble material was pelleted by 
centrifugation at 14000 g for 15 minutes at 4°C. The clarified lysate was then transferred 
to a new eppendorf tube for protein quantification and SDS-PAGE. Proteins were 
quantified according to the BIO-RAD DC Protein micro assay as described in Section 
2.8.2. SDS-PAGE was performed using pre-cast 4 % - 20 % Tris-Glycine gels. A total of 
40 J.lg protein was resuspended in a total volume of 25 J.lI sample loading buffer (125 mM 
Tris-HCI pH 6.8, 4 % SDS, 20 % glycerol, 5 % 2-mercaptoethanol and 0.05 % 
bromophenol blue), boiled for 5 minutes at 95°C and loaded into separate wells of the 
gel. 10 J.lI ofpre-stained molecular weight markers were loaded into a separate well. Gels 
were run at 4 rnA constant current for about 90 minutes prior to immunoblotting. 
Following electrophoresis, protein was transferred to the PVDF membrane for 1 hour 45 
minutes at 14 V using a BIO-RAD semi-dry blotter. Following transfer, membranes were 
blocked for 1 hour at 25°C using 4 % BSA made up in TBS-Tween. Thereafter, 
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membranes were incubated with the EP4-specific primary antibody at 4°C for 18 hours. 
After washing 3 times with TBS-Tween, membranes were subsequently incubated for 1 
hour respectively with the relevant secondary antibody. Proteins were revealed on 
photographic film by chemiluminescence (ECLplus kit) and quantified by scanning 
densitometry. The molecular weights of the EP4 receptor proteins were determined 
relative to the mobility of the pre-stained markers on SDS-P AGE. Data was presented as 
Mean ± SEM from 3 independent experiments. 
4.3.3. Quantitative real-time RT -PCR analysis of clones 
Real-time quantitative RT-PCR was performed to assess the relative expression of 
prostaglandin receptor subtype EP4 in HeLa wild-type and EP4 over-expressing sense 
cells (EP4S). RNA samples were extracted from WT and EP4S HeLa cells using Tri-
reagent as described in Section 2.7.1 and were reverse transcribed as described in Section 
2.7.3. Quantitative real-time PCR was then performed on samples using a reaction mix 
containing Taqrnan buffer (5.5 mM MgCh, 200 J.1M dATP, 200 J.1M dCTP, 200 J.1M 
dGTP, 400 J.1M dVTP), ribosomal 18s forward and reverse primers and probe (all at 50 
nM), forward and reverse primers specific for the EP4 gene were used at 250 nM (See 
Table 5: Sequences of Primers and Probes), AmpErase UNG (0.01 VIJ.1I) and AmpliTaq 
Gold DNA Polymerase (0.025 VIJ.1I). The PCR reaction was run on an ABI Prism 7700 
Quantitative PCR machine. Expression of the EP4 gene was normalised to RNA loading 
for each sample using the 18s ribosomal RNA as an internal standard. Fold increase was 
determined by dividing the relative expression of EP4 receptor mRNA in EP4S cells by 
the relative expression of EP4 receptor in HeLa wild-type cells and presented as Mean ± 
SEM from 3 independent experiments. 
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4.3.4. cAMP assay analysis of clones 
In order to determine the fimctionality of the EP4 receptors, cAMP assays were performed 
on PGE2-treated cells as described in Section 2.6. Cells (2x lOs) were seeded in 6 well dishes 
and allowed to attach overnight. The next day, cells were washed twice with PBS followed 
by incubation with serum-free DMEM for a minimum of 16 hours to allow synchronization. 
Cells were then stimulated with 300 nM PG~ for the time periods of 0,5 and 10 minutes. 
Following stimulations, the medium was removed and the cells washed in ice-cold PBS 
before being lysed in 0.1 M HC!. cAMP concentration was quantified by ELISA using a 
cAMP kit and normalized to the protein concentration of the lysate. Protein concentrations 
were determined using protein assay kits (Bio-Rad) as described in Section 2.8.2. Results are 
presented as Mean ± SEM from 3 independent experiments. 
4.3.5. Immunofluorescence microscopy 
The site of EP4 receptor expression was localized in wild-type and EP4S HeLa cells by 
immunofluorescence microscopy as described in Section 2.9.2. Approximately 10 000 
wild-type and sense cells were seeded in chamber slides, allowed to attach and grow 
overnight, before being fixed in 100 % ice-cold methanol. Following fixing, cells were 
washed in TBS (50 mM Tris-HCI, 150 mM NaCI, pH 7.4) and blocked using 5 % normal 
swine serum diluted in TBS. Subsequently the cells were incubated with polyclonal 
rabbit anti-EP4 receptor antibody at a dilution of 1 :50 at 4°C for 18 hours. Control cells 
were incubated with rabbit immunoglobulin (180). Thereafter the cells were incubated 
with secondary swine anti-rabbit tetramethyl rhodamine isothyocyanate (TRITC) at 25°C 
for 20 minutes and counterstained with To-Pro at a dilution of 1 :2000 for 2 minutes. Cells 
were then mounted in Permafluor and coverslipped. Fluorescent images were visualised 
and photographed using a Carl Zeiss laser scanning microscope LM510. The Alexafluor 
546 and 488 was captured using the helium/neon 1 laser (excitation beam, 543 nm) and 
an emission band pass filter 560-615 nm. 
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4 4 Results 
4.4.1. Western biOi analysis of dones 
Western biOi analysis performed on cellular extfllCl$ from 4S 5en1le Dnd 30 DIltisense 
dones re ... uled 4 sense and 2 antisense clones Wt demonstr:uod the Itighesl and lowcst 
Ie, cis of EN rttcptor eXpRSSlon wlten comp;lre<i wi tlt wild-type eell5. rcspe<:l!\'d y. As 
sho ..... n in figure 4. 1, .n mummore:ocli'e band migraung al appro ~i malcly 52 kDa, 
cOITesponding 10 tltc rc!pti ... c known rnolecular weight of tlte EN receptor protein, ,,'as 
obsm.ed for all clones The lower panel of Figure 4.1. shows fold incrc:ue in levels of 
EP4 re<:eplor expression of "arious clones, as delerntined by seanninll dCllSuonldry, 
compared with wild-Iype ce [[s, Le,'els of EN receptor protein were nonn,llilCd for 
loading againsl p-:lC tin on lite wile blol$ . 
EP4 ..... ---- - -- -
Actin ......... -----~-
81 83 85 813 W1 AS4 AS] AS2 ASI 
Fold ,ncn)_ 4.1:17 2.2 2.9 1 0.$ 2.1 1.6 1.3 
.-iIK..., 4.1 . I ................ b(w. ... , E'~ pool". apr ....... of tk ... C,4S (SI, 53. 55. 51l) clonn, II .... 
... ,id-1ypC (WO. _no! He ... EP4AS (AS!. ASl. A52. ASI) d o .... , A IIp"/kan1 "'.""'$0 in pnllt'lQ 
up ................ """""cd In all EP~5 cloneo .. In ~p;imll<> WT ceU .. EP4AS ckme AS4 ,hD .. 'ed ~ 
do..:~ '. EN ~I "'IftUOOII ... 1n companld I<> " ',kf.I)'PC .:.:11 • . 1.0 ..... pa"el ,110 ... fold ,no ......... 
In EP4 p<oIcoa fnlkw.'_1 P'-~RI>"" a..al)'Jialllld q..."lIIjclI1011. Prote ... a ... ,. ""."..IIst:<! [01 l",dIn, 
"P'mI p.. .. 01l. 
ENS dones willt the greatesllcvel of EN receptor protein exprcuion (SI. S3. S5, S13) 
and EP4AS clone exhibiling the lowest level of ilP;a receptor expression (AS4) were 
selected for fUr1hcr studies. Subsequently. the Ic~el of EN mRNA exp£cssioo of these 
clooes was cont1m.oo by Quantitative real-time RT-PCR. MorC()\'cr. !he functionality of 
the EN receptors was eumined by analysing tlte cAMP response of the clones 10 
treatment with 300 oM PGE1. 
76 
4.4.1. Quantitative real-time RT-PCR analysis of clones 
Quantitative real lime RT-PCR 3nai}'>'is was performed 10 confirm Ihe level of EN 
mRNA expression of the clones $elected by Western BIOI anal}'>'is. As menlioned 
previously. $ense clones 51, 53. 5S and 513 demoostrated significant increases in EN 
receptor protein expression compared with wild-type BeLa cells. Following quantitative 
real-time PCR anai}'>'is. EP45 clones 51 and 55 demonstrate highest levels of EN 
receptor mRNA expression (Figure 4.2), with an increase of 7.4 fold iI1lIl 7.0 fold. 
respe<:tively above wild-type HeLa cells (WT). 
I'IRur~ ~ .l. fold In<= ,n ",,~n orEN ""'<I'IormRNA 'n HeLl EP~S dones (SI , S3. SS. SI3) . 1Id 
HeLl w;ld·1)pe oelll (WO as IkkmIln<rl b~ real·time G.,"uitallve RT ·PCR. Fold ,,",rease wu de1 .. nlln<rl 
by dividina (he: relan"" expreaion in EP4S coils by 1ho rdati¥e ap""",," in HeL. wild .I)'I'" c.Us. 
4.4.3. cAM? analysis of clones 
The EP4 receplor is a Ga.-coupled receptor, which upon activation leads to an 
accumulation of cAMP in the cell (ReglUl 2(03). In nrder tn determine the functionaluy 
of the tnlnsfected EN receptor eDNA expm:sed ill the EP4 clnnes, lhe accwnulation of 
IIllracdlulaT cAMP was measured in WT. EP45 and EP4AS clones following stimuiallon 
for 0, Sand 10 minutes with 300 nM PGEl . 
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The accumulation of imTlICeliulnr cAMP was determined in EP4S clones 51, S5. and 5 13 
to be 17.01; 16.24 and 15.14 pmol cAMP/rug protein. following 5 minutes of PGEl 
stimulation respectively Bnd 18.33; 14.58 and 11.51 pmol cAMP/mg protcin. fo llowing 
10 mHlutes of PGE7 stimulation respectively. The relative accwnulation of cAMP in 
clones SI was elevated at 5 and 10 minutes following PGEl challenge, compared with the 
cAMP accumulation in WT cells (12.49 and 11.53 pmol cAMP/rug pro tein for 5 and 10 
minutes respectively) (Figure 4.J). Howc:\teT, ~n closer evallllltion, the basal levels of 
cAMP occumulation in clones S5 and SI3 ( 15.76 Bnd 14,10 pmol cAMP/rug prolcin) was 
observed 10 bc elcvntlXl compared with clone SI and WT cell s (7.27 1IJId 7.45 pmol 
cAMP/mg protein respeclively). 
51 55 513 wr AS3 AS4 
. 0 Miootes 
a5 Minutes 
al0M'nlles 
~lIU'" '..l. ~A !>1P ~""Is tpmoV",s proIein) In IIc u ENS don .. (SI. S5. 513). lIeLi WlId·type celt. 
(Wl) lII\d ENAS cion .. (AS3. A54) fult"";ng ,tim"t.lion of ~tls WIl" 300 nM PCE, r", lime pcril)d, of 
O. S and 10 m,nul ... 
The accumulation of cAMP was delcnnincd in EP4AS clones AS3 and AS4 10 be 7.58 
and 8.04 pmol cAMP/mg protein, following S minutes of POE1 stimulation respectively 
lind 13.27 IlIld 9.91 pmol cAMP/mg protein. following 10 minutes of PGEl stimulation 
respectively. The relative accumulation of cAMP in clone AS4 was reduced 81 5 and 10 
minutes following POE) challenge. compared with the cAMP IICcumulation in WT cells 
(12.49 and 11.53 plIlol cAMP/rug p['Q(ein for S and 10 minutes respectively) (Figure 4.3). 
Howe\"eT. the basal levels of cAMP LtCcumu!ation in clone AS3 ( 11.86 pmol cAMP/mg 
protein) Willi observed to be eleVllted compared with clone AS4 and WT cells (5.98 and 
7.45 pmo! cAMP/mg prolein respectively) (Figure 4.3.). 
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4.4.4. Selection of ENS and EI'4AS clones 
Western blot analysis (Section 4.4.1). QU3m;tat;ve real-lime RT- peR (5crtion 4.4.2) and 
cAMP assays (Section 4.-1.3) confirmed an elevated EP4 receptor expression in clone Sl. 
Mon.-o\·cr. the rosal cAMP occwlluiation and gTO'" 1h clu.l1,lctL"fislicS of clone S I were not 
sib'nlficantly difTeremto WT cells. Based on th~sc crit...na, done S 1 was thus chosen for 
funhcr stud ies. Western biOI analysis showed similar levels of EP4 receptor protein 
e~prcssion for amisense clone AS4 and WT cells (Figure 4.1). morcovcr amiscnr.<: cione 
4 (AS4) exhibited signilicantly IL'Ss cAMP Dccwl1ulation following 300 nM PGEl 
stimulation compared with \VT' cells and was thus chosen for funhe.- studies. Clonts 51 
ami AS4 clones (t~""I1"\led EN5 and EN AS, rcspeetiwly) ,,'ere e~p3ndcd Hnd 
char:lctenscd by Weslern biOI analysis. QlL1nt;l3t;ve real_lime ItT-I'CR analysis and 
cAMP assay analysis a funher 3 times in order 10 dctcnnine stalistieal signi fitallCe, 
Weslern blot analysis of protein colJ~'I;led Crom Hela wild-lype cells (\IFf). EP4 sense 
clolle I (ENS), and EP4 anlisense clone 4 lEP4AS) demonstraled a 4.10 ± 0.57 fold 
increase in EP4 protein e~press;on ;11 the sense (EI'45) (p': 0.05). and 1.0 '" 0.32 fold in 




• 5 .-.. . !: 4 
e u 3 u < 




- 52kDa - _ 64kDa 
l1&ur~ ~A Immunobloc of Hd.> ,., Id.l)'pl' (IVT). ENS done:md f.P4AS clon~ shOWIng fold '"=_ in 
EP4 =eplO< pt01ein .,p .... ",., of •• 11 •. PM"'"' ,,,,,, IIOfm,hscd fo< ~inll .ponS! 6-0<11" ()al-l" 
,,-,p=kd • M.,., -'- SFM f,om llndepcn<letol ""..-1"""''' ( .... "!I"lficlI1lly dlfferenl fMm ' . p <: 0 OS) 
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I.-I .S. Inullunofluor.scence microscop)' of cells 
EP4 recepror prOiein e~pres.~ion was localised In HcLa wild- type (\\fl). sense done I 
(ENS) nnd Dnlisense don~ 4 (EP4AS) celis by immunofluocescence microscopy (as 
described!D Section 2.8.) to d(termine ",hether all the EN ~ceptor was trafficked to Ibe 
plasma membrane companment. W( performed immunonu~$cence microscopy using 
an EP4-s.pecific antibody as Shown in Figure 4.5. 
hmllunonoUrescenCe microscopy showed elevated EP4 re~ptor Immun~acli"ilY In 
EP4S reUs aud reduced immunoreaClivit} In EP4AS ~lIs compared with \-Ill cells. EN 
Illcepror localised 10 the plasma membrane in all ~Ils. Incubaung cells "'lib rabbit IgG 
abol ished Ihe irnmunoftDC1ivity (Figure 4.5. cooUl'll rellfcsenl&u,c of EN receptor .sense 
cc ll s: C). 
WT EP4S EP4AS c 
.1cur. 4.5 Im"",nofll>.Y'CK~'" mic"""'P) u!in. FJ>.hpecir", ... "t...J"", "" Ild.ll ",id -I) po (wn_ rN~. 
£NAS and lI<1lau .. ~""ror {C)uUs. 
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4.5. Discussion 
In this chapter, a HeLa EP4 receptor overexpressing model system was established in 
human cervical adenocarcinoma cells. EP4 receptor cDNA was introduced in the sense or 
antisense orientations and cells were made stable by antibiotic selection. Various sense 
and antisense clones were selected, expanded and screened by Western blot, Quantitative 
real-time RT-PCR and cAMP assay analysis. Western blot analysis revealed a band, 
which corresponded to the EP4 receptor protein (Figure 4.4.). Following phosphorlmager 
analysis and quantification, data confirmed that levels of EP4 receptor protein expression 
in sense clone 1 were significantly higher, when compared to levels of EP4 receptor 
protein in HeLa WT cells. The increase in EP4 protein expression was consistent with 
findings from quantitative real-time PCR analysis (Figure 4.5), which confirmed 
increased EP4 receptor mRNA in sense clone 1, indicating that an increase in gene 
transcription of the EP4 construct preceded an increase in translation of the EP4 protein. 
As mentioned previously, PGE-EP4 receptor interaction couples to Gas resulting in 
stimulation of adenylyl cyclase and increased cAMP levels (Regan 2003). Therefore, 
functionality of the EP4 receptors was confirmed by cAMP assay analysis (Figure 4.3). 
These data showed increased cAMP in sense clone 1 compared with both antisense clone 
4 or WT cells, confirming functionality of the transfected EP4 receptor. A reduction in 
accumulation of intracellular cAMP was observed in antisense clone 4 when compared to 
WT cells, which confirms lower levels of EP4 signalling in this antisense clone. In 
addition, the fold accumulation of cAMP in sense clone 1 compared favourably with that 
observed in cervical tissue explants treated with PGE2 previously reported by Sales et ai., 
2002. 
It is important to consider that previous studies have demonstrated the presence of both 
EP2 and EP4 receptors in WT HeLa cells, both of which were upregulated in cervical 
carcinoma tissues when compared with normal cervical tissue (Sales et ai. 2001). 
Although both EP2 and EP4 receptors couple to Gas, direct comparison of their relative 
abilities to increase cAMP in HEK293 cells demonstrated much weaker Gas coupling by 
81 
EP4 compared with the EP2 receptor (Fujino et al. 2002). Recent studies have also 
revealed important functional differences that suggest unique roles for each receptor in 
different cell types. For instance, PGE2 stimulation of the EP4 but not EP2 receptor leads 
to PI3-kinase-dependent phosphorylation of ERK. and expression of EGF-1 in COS-7 
cells (Fujino et al. 2003). PI3-kinase has also been reported to playa role in EP4-induced 
activation of the GSK-3/p-catenin signalling pathway in HEK293 cells (Fujino et al. 
2002). p-Catenin is a transcriptional activator and has been implicated in embryonic 
development and cancer (Fujino et al. 2002). Stimulation of the EP2 receptor also leads 
to GSK-3 phosphorylation and subsequent activation of p-catenin, but in a PKA-
dependent, PI3-kinase-independent manner in HEK293 cells (Fujino et al. 2002). Taken 
together, these studies raise the possibility that Gas-mediated increases in cAMP playa 
less important role for EP4 receptor signalling in some cell types compared with the EP2 
receptor, a possibility further supported by observations that the EP4 receptor mediates 
PGE2-stimulated proliferation of colon carcinoma cells in the absence of detectable 
increases in cAMP (pozzi et al. 2004). In the HeLa EP4 overexpressing cervical 
adenocarcinoma cell model system cumulative roles of EP2 and EP4 receptors may be 
contributing to cAMP signalling. This issue was addressed with the use of a specific EP4 
antagonist (ONO-AE2-227), which ensured specificity of signalling and gene responses 
via the EP4 receptor. In addition, it is important to consider that the role of the EP4 
receptor may be different in HeLa cells when compared to the studies performed on 
HEK293 or COS-7 cells. EP4 receptor signalling may be cell-type specific and result in 
differential physiological effects. 
In general, it has been assumed that signal transduction cascades are initiated after ligand-
receptor binding at the plasma membrane (Sales et al. 2003). However, recent data 
implies that prostanoids may act intracellularly. Studies performed by Bhattacharya et al., 
1999, using radio ligand binding studies on isolated nuclear membrane fractions localized 
EP4 receptors in the nuclear envelope of endothelial cells in neonatal porcine brain and 
adult rat liver and in transfected HEK 293 cells that stably overexpress these receptors. 
Data also revealed that nuclear EP receptors are functional as they affect transcription of 
genes such as inducible nitric-oxide synthase and intranuclear calcium transients 
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(Bhattacharya et al. 1999). Therefore, in order to confinn increased EP4 receptor protein 
in the HeLa EP4S cells, immunofluorescence microscopy was performed (Figure 4.5). In 
the HeLa EP4 over-expressing model system, the transfected EP4 receptor levels were 
increased, suggesting that in ligand-receptor binding and intracellular signalling may be 
increased in this cell line. 
The data presented in this chapter confirm the establishment of a HeLa cell line 
overexpressing the EP4 receptor. This is based on elevated RNA and protein expression 
of EP4, as well as elevated cAMP generation in response to PGE2 in the EP4S clone 1 
compared with WT cells. In addition, the levels of cAMP accumulation observed in the 
EP4S clone 1 compared favourably with those reported in cervical tissue explants treated 
with PGE2 (Sales et al. 2001). This clone was used in subsequent studies assess signalling 
pathways and target genes that may be activated by EP4 receptor in cervical epithelial 
cells which may potentiate cervical tumourigenesis. In addition, EP4AS clone was 
established, which demonstrate a comparable EP4 receptor protein expression (as 
determined by Western blotting) but reduced cAMP response to treatment with PGE2. 
During the course of my PhD, an EP4 receptor antagonist (ONO-AE2-227) became 
available. It was deemed that specificity of EP4-mediated signalling on target gene 
transcription in EP4S cells treated with the antagonist is a better control treatment than 
cells transfected with antisense cDNA. All subsequent studies made comparisons of 
responses to seminal plasma or PGE2 in wild-type cells, EP4S (clone 1) cells and EP4S 
(clone 1) cells treated with the EP4 antagonist. 
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CHAPTER 5 - THE INTRACELLULAR SIGNALLING PATHWAYS MEDIATING 
THE ROLE OF EP4 RECEPTOR IN BELA EP4-oVEREXPRESSING CELLS 
5.1. Introduction 
EP4 receptor activation by PGE2, is coupled to Gas, and results in an increase of 
intracellular cAMP. Following PGE2 stimulation, EP4 receptors have been shown to 
undergo rapid agonist-mediated desensitisation and intemalisation (Desai et al. 2000). 
The role of the carboxyl tail in rapid agonist-induced desensitisation and intemalisation 
has been demonstrated for the EP4 receptor using studies of truncated receptor and site-
directed mutagenesis (Desai et al. 2000). Deletion of successive sequences of the human 
EP4 receptor C tenninus identified a stretch of six serine residues in the tail, one or more 
of which might serve as a target for phosphorylation and subsequent desensitisation 
(Bastepe et al. 1999). Receptor phosphorylation by a variety of serine/threonine kinases 
is one of the most rapid events to occur and is critical in affecting receptor function by 
ultimately uncoupling the agonist-occupied form of the receptor from the G-protein, 
thereby limiting receptor function (Slipetz et al. 200 1). Both G-protein coupled receptor 
kinases (GRK) and the second messenger kinases, such as PKA or PKC, are principle 
regulators of GPCR phosphorylation and uncoupling. 
Crosstalk between GPCR and growth factor signalling results a complex myriad of 
pathways being sequentially activated, with mitogen-activated protein kinases (MAPKs) 
playing an integral role (Desai et al. 2001). The MAPK signalling cascades consist of 
several individual signalling pathways: extracellular signal-regulated kinase (ERK)-1I2, 
Jun amino-tenninal kinases (JNKlSAPK) and p38 MAPK (Herlaar et al. 1999; Chang et 
al. 2001; Yeh et al. 2002). The MAPK pathways are key signalling mechanisms that 
regulate many cellular functions such as growth, differentiation and transformation 
(Smith et al. 2000). ERK is mainly activated by mitogenic stimuli such as growth factors 




MAPKs are activated by phosphorylation on Thr and Tyr by dual-specicificity MAP 
kinase kinases (MAPKK), which in tum are activated by SerlThr phosphorylation by 
MAP kinase kinase kinases (MAPKKK) (Tanoue et al. 2003). Upstream of MAPKKKs, 
additional protein kinases may participate, for example members of the Ras and Rho 
families ofGTPases. The small GTPase Ras is one of the key components in the pathway 
which activates the serine/threonine kinase Raf, which in tum phosphorylates and 
activates extracellular signal regulated kinase (ERK) (Kranenburg et al. 2001; Chong et 
al. 2003; O'Neill et al. 2004). Once activated, MAPKs can directly phosphorylate 
proteins containing the minimal phospho accepter motif SerlThr-Pro (Yang et al. 2003). 
Phosphorylation can take place in both the cytoplasm or the nucleus and many of their 
targets are transcription factors or transcriptional coregulators. In addition, MAPKs can 
phosphorylate and activate downstream protein kinases (Yang et al. 2003). Many of these 
regulate gene expression through phosphorylation of histones and transcriptional 
regulatory proteins (Belcheva et al. 2002). Activation of these pathways is often complex 
and may lead to a vast array of signalling molecules being sequentially activated. 
Studies performed by Fujino et al., 2003 have implicated the phosphatidylinositol 3-
kinase (PI3K)/AKT pathway in EP4 receptor activation. PGE2 stimulation of HEK 293 
cells stably transfected with EP4 receptor was shown to phosphorylate extracellular 
signal-regulated kinases (ERKs) by a PI3K dependent mechanism, followed by induction 
of the functional expression of early growth response factor (EGR-l) (Fujino et al. 2003). 
It has been reported that cyclin Dl, a key regulator of cell cycle progression, is under the 
control of EGR-l through a PI3K- and ERK-dependent pathway (Fujino et al. 2003). 
These findings of a PGE2-mediated induction ofEGR-l expression by the EP4 receptor is 
interesting in light of the recent studies with knockout mice that show a potential 
involvement of the EP4 receptor in colon carcinogenesis and rheumatoid arthritis (Mutoh 
et al. 2002; Fujino et al. 2003). EP4 knockout mice showed a reduced formation of 
preneoplastic lesions following treatment with azoxymethane, a known colon carcinogen 
(Mutoh et al. 2002). EP4 knockout mice also showed a significantly decreased incidence 
and severity of collagen antibody induced arthritis, an animal model of rheumatoid 
arthritis (McCoy et al. 2002). In addition, both colon cancer and rheumatoid arthritis 
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prostaglandin levels are elevated and both conditions benefit to some extent by treatment 
with NSAIDs (Fujino et al. 2003). In colon cancer, it has been reported that the 
expression of cyclin Dl, an important regulator of cell cycle progression, is regulated by 
Tcf signalling (Fujino et al. 2002). However it has also been reported that the expression 
of cyclin Dl is regulated by EGR-l through a PI3K- and ERK-dependent pathway 
(Guillemot et al. 2001). Furthermore data shows that PGE2 synthase is upregulated by the 
binding of EGR-l to the promoter region of the mouse gene encoding PGE2 synthase 
(Naraba et al. 2002). Signalling through an EP4 receptor would have the potential, 
therefore, to increase the expression of cyclin D 1 and PGE2 synthase through a PGE2-
mediated induction of EGR-l expression. Since the product of PGE2 synthase is PGE2 
itself, this would have the potential to set up a positive feedback loop in which increased 
PGE2 synthesis would further drive EP4 receptor activation. 
In sexually active women, growth and invasiveness of neoplastic epithelial cells may be 
also under the direct influence of endogenously synthesised PGE2 and PGE present in 
seminal plasma. Prostaglandins are present in seminal plasma at 10 OOO-foid greater 
concentrations than those detected at a site of inflammation, and PGE2 is one of the 
predominant types detected (Templeton et al. 1978). Little is known of the effect of 
seminal plasma and seminal plasma prostaglandins, including PGE2, on neoplastic 
cervical epithelium of sexually active women. Hence the studies reported in this chapter 
were designed to investigate signalling pathways that may be activated by interaction of 




The initial aim of this section was to determine the optimal dilution of seminal plasma 
needed to produce a cAMP response in the cells. Once this had been determined, we 
could proceed to investigate the interaction between seminal plasma or PGE2 and cervical 
neoplastic epithelial cells overexpressing the EP4 receptor. This interaction may result in 
activation of various signalling pathways, such as cAMP, downstream MAPK signalling 
pathways (ERK1I2, p38 and cJun N-terminal kinase; JNK), or activation of the 
PI3kinaselAKT signalling pathway, all of which were investigated. 
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5.3. Materials and Methods 
5.3.1. Seminal plasma collection. 
Semen was collected from healthy male volunteers. The collected ejaculates were pooled. 
Seminal plasma was isolated from the pooled ejaculate by percoll density gradient 
centrifugation at 500 g for 20 minutes (Section 2.3). The seminal plasma was stored at -
70°C. Seminal plasma was used on the cells at various concentrations of 1: 50 up to 
1:5000. At these dilutions, seminal fluid has been reported to exert no effect on HeLa cell 
viability (Jeremias et al. 1999). 
5.3.2. PGE2 Assay analysis 
PG~ assays were performed on pooled seminal plasma samples as described in Section 
2.11. The ELISA was performed using 96 well plates (Amine-binding plates) coated with 
donkey anti-rabbit antibody. The link was prepared by ether extraction and reverse phase 
chromatography using 20 mg of synthetic PGE2, 320 fll dry dimethylformamide, 3 fll 
butylchloroformate and 0.05 mM biocytin. Samples and synthetic standards were diluted in 
ELISA buffer, and 100 fll of each added in duplicate to the plate. The link was diluted 
1:1.5x106 in ELISA buffer and 50 fll added to each well. Antisera, diluted 1:50 000 in 
ELISA buffer, was added to a final volume of 50 fll to all wells except those used for 
measuring non-specific binding. Plates were incubated at 4°C for 16 hours, washed and 100 
flllwell of 0.2 unitJm1 streptavidin-peroxidase was added. Plates were then incubated for 20 
minutes at 23°C on an orbital shaker, washed and substrate added to a final volume of 200 
flllwell for 10 minutes before quenching with 50 flllwelllM sulphuric acid. Colour reaction 
was measured at 450 nm by spectrophotometry. 
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5.3.3. EP4 receptor antagonist 
The specificity of EP4 receptor activation was ensured by the use of an EP4-specific 
antagonist (ONO-AE2-227) (Appendix II). It was deemed that EP4S treated with specific 
EP4 antagonist is a better control than EP4AS. This negated the need for the antisense 
clone, which was no longer used in further experiments. For this, EP4S cells were pre-
treated with 1 J.1M ONO-AE2-227 for 1 hour prior to stimulations with seminal plasma 
(1 :500) or 300 nM PGE2. Thereafter WT, EP4S and pre-treated EP4S cells were 
stimulated with dilutions of seminal plasma or 300 nM PG~ for time periods indicated in 
figure legends. 
5.3.4. cAMP assay analysis 
In order to determine cAMP accumulation following seminal plasma- or PGE2-EP4 receptor 
interaction, cAMP assays were performed on PGE2 or seminal plasma stimulated cells as 
described in Section 2.6. Cells (2xl0s) were seeded in 6 well dishes and allowed to attach 
overnight. The next day, cells were washed twice with PBS followed by incubation with 
serum-free DMEM for a minimum of 16 hours to allow synchronization. Cells were then 
stimulated with either seminal plasma (1 :250 up to 1 :5000) or 300 nM PGE2 for the time 
periods of 0, 5 and 10 minutes. In addition, EP4S cells were pre-treated with 1 J.lM of EP4 
antagonist for 1 hour followed by stimulation with seminal plasma (1 :250 up to 1 :5000) or 
300 nM PGE2 for the time periods of 0, 5, and 10 minutes. Following stimulations, the 
medium was removed and the cells washed in ice-cold PBS before being lysed in 0.1 M 
HCl. cAMP concentration was quantified by ELISA using a cAMP kit and normalized to the 
protein concentration of the lysate. Protein concentrations were determined using protein 
assay kits (Bio-Rad) as described in Section 2.8.2. Results are presented as Mean ± SEM 
from 3 independent experiments. 
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5.3.5. Western blot analysis 
HeLa WT or EP4S cells were grown until the desired confluency was reached in 5 cm 
dishes. Thereafter, cells were synchronised and stimulated with either seminal plasma 
(1:500) or 300 nM PGE2 for time periods of 0, 1,5 or 10 minutes. In addition, EP4S cells 
were pre-treated with 1 J.l.M of EP4 antagonist followed by stimulation with seminal 
plasma (1:500) or 300 nM PGE2 for 0, 1,5 or 10 minutes. Cells were lysed by addition of 
250 fJ.I protein lysis buffer. Proteins were extracted by allowing the dishes to sit on ice for 
10 minutes and the cells were then scraped off using a plate scraper. Thereafter, insoluble 
material was pelleted by centrifugation at 14000 g for 15 minutes at 4°C. The clarified 
lysate was then transferred to a new eppendorf tube for protein quantification and SDS-
PAGE. 
Proteins were quantified according to the BIO-RAD DC Protein microassay as described 
in Section 2.8.2. SDS-PAGE was perfonned using pre-cast 4 % - 20 % Tris-Glycine gels. 
A total of 40 fJ.g protein was resuspended in a total volwne of 25 fJ.I sample loading 
buffer, boiled for 5 minutes at 95°C and loaded into separate wells of the gel. 10 J.l.1 of 
pre-stained molecular weight markers were loaded into a separate well. Gels were run at 
4 rnA for about 90 minutes prior to inununoblotting. Following electrophoresis, protein 
was transferred to the PVOF membrane for 1 hour 45 minutes at 14 V using a BIO-RAD 
semi-dry blotter. Following transfer, membranes were blocked for 1 hour at 25°C using 4 
% BSA made up in TBS-Tween. Thereafter, membranes were incubated with the specific 
primary antibodies at 4°C for 18 hours. Specific primary antibodies used are listed in 
Section 2.1. After washing 3 times with TBS-Tween, membranes were subsequently 
incubated for 1 hour respectively with the relevant secondary antibody. Proteins were 
revealed and quantified by the ECF chemiluminescence system following the 
manufacturers instructions. Proteins developed by the ECF system were revealed and 
quantified by PhosphorImager analysis using the STORM 860 system. The molecular 
weights of the proteins were determined relative to the mobility of the pre-stained 
markers on SDS-P AGE. 
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~.4. Resulu 
POE: assay analysis ofllie p::lOled seminal plasma aljqooLS used in Ibis Sludy ih!.>Wed Ihal 
Ihe eoncentration of POEI in Ibesc aliquots was 43.6 J.lglmI. 
We optimised lbe EN-smunaJ plasma mcdJaled cAMP response by pcrfonning I 
dilution curve of seminal plasma. OiluuOfIS of seminal plasm. ranging from 1:25010 
1:5000 wen: lnvCSlig;lled. EP4-0vert.xpre:ssing sense (EN S) ceUr wen: pn:-Jrf:lled for I 
hour wllh I 11M ONO-AE2-227 prior 10 seminal plasma slJ muialioos. These pre-trealed 
cells an; designaled EN S+Ant. SliJll.llations were Ihen carried 011 on HeLl wild-type: 
(WT). ENS. and EP4S+AnI cells for time periods of 0, 5, and 10 minulCI wilb seminal 
plasm.:l dilutions ranging from 1:250 up 10 ]:5000 (Figure 5 I) . 
• 
• 
",<- ,?><- ~$" i'" i? ,?><- >oS" ~<- i? J><- Jo<- / ,s '" ~ .. ...'" '" .. ...'" '" ~ .. 'Ii>.....'Ii>.. .. <f"' 
'---v-' '-v------' '-v-----' '-....-----' '----..,.---0' 
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~',u .... S.I . <AMI' O<<."\In..,I .. "", til ~_ '0 '~:>I", ... t ..... th .. ';.1 dilutIOn' of .. """,I plas",a 11:250. 
I ~. I: I 000. 1.2500, I :SOOO) rClt O. 5.nII 10 ", ... uteI ,n Hell ",ld. l)"p< (Wl). !;P4S and 1oP4S .,.,11. pr<!' 
ltUIed r", 1 bout ... uh EP4 an' iI&O"'. (ENS+A noJ. 
"The highest levels of cA..'1P accumulalion were observed in ENS ceU. slilllUlaled with 
I.SOO dilution of seminal plasma (Figure 5.1). It was iherefortl decided 10 proceed with 
an further Cltperimcnts using the p::lOled seminal plasma lliquot, II I dilu llon of 1:500. AI 
a dilutIOn of I :500 the seminal plasma conuuns 247 oM POEl. AI thll dilution, seminal 
plasma has been reponed 10 exen no e««t on HeLl cell viahihly (Jercmiu (/ (l/ 1999). 
5.4 I cA:'1P accumulal,on m response 10 sClmnal plDsma or !'GEl 
cAMP s'g!lallinl; In HeLa cells "'3.> dClcnruncJ foilo"';nll 51imulQlion of cells ",nil 
smunal pl35m3 (I :500) {Fil;ure 5.2. A) or cXO!;eOOllS PO E) (300 oM) (Figure 5.2. IJ) m 
the absence or pu:scocc of I).IM spec:ilic EN rcccpl0r 3fl1Dllonisi (ONO-AE2-227), 
A rapid accllmulation of cA/I.'lp ",as obsCTI ed after 5 and 10 mmUles of SlllllUIDlioo ",ilh 
seminal plasm3 (1:500) III EN S cells(18.65 ± 1.04 pmol cAM Plml> prolell1 and 13A2 ± 
1.72 pmol cAMP mg protein, respa:I1\'ely), which was grt31er th3n lil31 ob~r'led in 
Hcu. wild-type cells (Vrn (13.27 I 1.38 pmol cAMp,mg prole,n and 9,63 ± 0.06 pmol 
cAMP I1lll pmtem, n:spccthely) (p < 0.05) (Figure 5.2. A). PrNreatmem of ENS cells 
for 1 hour with ONO-AE2-227 (ENS+Ant) rcsullcd in ~ !iignific~nl decrease in cA:' IP 
accumulallon al both 5 and 10 minulf.'S (10.84 ± 0.27 pmol cAMP mg prolein and 9.25 ± 
0.55 pmol cMIP, mll protelll, n:specll\cly) when compared \0 EN S cells trCatN wnh 
seminal plasma alone al tile same IlIlle points (p < 0.05) (Figure 3,2. AJ. 
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Il~un 5.1. A. cA\IP Ktumubn".. 1n ""pan« '0 trut", ..... "',,II. I SOO d, luu".. Q(.mnnaJ pl:t<m. for O. 
Sand 10 mmultl ,n neLl ""\d-t},,e{WT). ENS..,d ENS .. n, p .. ·trea\O<! for I II"", wr'~ EN 'nlaaonr" 
{ONO-"El·!27) (ENS-.-A",) On> <how .... \Ie .... SEM from J 'rnkpondcn' .'p"nrnc-nu ( .. II 
..... 'flc ... dldilT .... nt from ' (p'" O.OS), • • • II .,"',f"'>r,~y d,IT~, from · .nd · ' Ip" 0,051 
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A rapid accumulation of cAMP was also obscncd liner 5 and 10 OllOUtH of slullulllUon 
wilh 300 nM PGE, In EP~S cells (1701 ± I 15 and 18.33 % 2.37 pmol cAMP m& protcm.. 
respcct"·cly). \\hlch was signilicanlly grealer IIhen cOl1'\fl:lrcd to Hcu WT cells althc 
same time pomts (12A9 % 1.20 and 11 52 % 0.53 pmol tAMP m& proleln, r~~li\ ely) (p 
< 0.05) (Figure 5.2. 8 ). Pre-trealll1ent of EP-IS cells With I].IM O:-'O-AE2-227 
(EP-lS+Ant) resulted in D slgnifit:H1l dt(:rt3$e in cAMP accumulaliOll al.5 Dod 10 nunUle$ 
(]1.25 ± 0.68 and 1355", 0,79 pOlO] cAMP mg pJl)lcin. respa:li\"Cly) IIhen compared lO 
ENS cells trealed IIlllt 300 lL\1 PGE: alone at Ihe same lime pomts lIlone ip < 0.05} 




WT EP4S EP4S+Ant 
1"1~lIrt S.l. It. cAMP ""CU,,,"t~I' '''' 'n t=pon .. to lTeaI"""" ... uh ]00 n" P(it:, r", "me....,..,.w oro. 5 ond 
10 m,n .. "" on UcL. w,ld.,)p< (\\'f). FP4S .I\d EN S «U. "'~'rnl<J for I hour .. "h H4 .. ~nlS! 
(ONO.AE2·n7) (ENS-+"'nl). na .. ,1\Q .. n .. Me.n I SEI.1 frnm J ,ndc"...<lenl e~pcn".n". C" 's 
$t¥",'itanlly d'fferent from ' (p < O.OS): ... i. "gn,r,<;anll)' d,ffm"' from ' ",d •• (r < 0 OS) 
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5.4.2. ]nestigal;ons into Ihe activation of MAPK IX PI3kinnseJAKT signalling path\\a}s 
following treatmem with seminal plasma or I'GE~. 
5.4.2.1. PhospllOl)'lation ofERK 1/2 
HcLa WT and ENS cells were stimulated \\;th seminal plasma (I ;500) or 300 nM PGE1 
lor 0, I, 5 and 10 minutes. Ligand receptor activation r.:sulted in a rapid phosphorylation 
ofERK ll2 in EP4S and WT cells after I minute or stimulation with a 1:500 dihnion of 
seminal plasma (7.78 ± 1.11 and 2.87 ± 0.81 2 fold rcspl'<!tivdyl. This rapid activation of 
ERK 112 was elevated and sustained in ENS cells 3t.5 and 10 minutes (5.83 % 0.62 and 
4.52 ± 1. 11 fold rL'Spcctively) compared \lith the activation of ERK observed in WT cells 
at) and 10 minutes (1.81'" 0.94 and 1.41 ± 0.16 fold respectively). Pre-incubation of 
HeLa EP4S cdls with thl"" specific EN n:c.:plOr antagonist ONO-AE2-227 (EP4S+Am) 
abolished the activation of ERKI /2 in ENS cell!; at all lime points inv.:stig~lcd (1.55 ± 
0.16; 1.23 ± 0.06 and 1.89 ± 0.70 fold r~"Specli\"ely for I, 5 and 10 minutes) (p <:; 0.05) 
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fie"ro 3.J. A. R.p.-.:Knlativ. immunoblOl """,,"ing pnospboo}'lalion of ERI( 112 folk>win~ , .. ,111\0111 wi,h 
. .. "i",,1 plasm" in H.La ,,;ld' l)[>C (WT). EP4S ond EN~ c.11i .... · ..... O!od with I ~l>1 O",:o-"E~-2~7 
(ENS+Anlj. Cells wore stimuialod w;,h <eminol pl .. "",(1 ,5(0) (Of lime periods oro. I. S IU!d 10 min ..... 
ERK phosphoryt.,i""" .OO"".S fold .""" .• b .. aI {M •• n ± S~Ml f .... m J indopond.n< .xp.,.im""" {" ar. 
st"i"ically 'ignific""t from - (p < 0.05); • •• ore "at,,'ically .ign if,cant (rom ' ond •• (p < 0.05). 
Similarly. 300 oM I'GE, stimulalion re!lUl\ed in sillnificantly elevated ERIO/2 
phosphorylJlion after I minule in ENS (3.79 ± 1.31 fold) ce ll5 I'hen compan-d Ilith 
HeLa WT (2.60 ± 0.47 fold) (p < 0.05). \lith a suSlai~d increase: 81 5 mmu\es in [NS 
cells (3.59 ± 0.57 fold) __ hen compared 10 WT ce ll s al the same lime poinl (2.Jl ± O.II~ 
fold) (p < 0.05). ERK II2 pllosphorylalion v.as decreawd in both EP~S and WT cell§ 
f(l ilmlintl 10 minutes PGEI stimulation (1.36" 0.79 and 1.23 ± 0.32 fold respediveiy). 
Pre-treatmenl of ENS ccll§ II ilh EN ont:lgonist (ENS+"n!) signili.antly redul"Cd k~cJs 
of ERK I f2 phosphorylalion I, hen at all time points in' estigatoo I 1.77 :to 0 I I: 1.51 ± 0.1 ~ 
and 1.1 !; 0.17 fold re~ptct ively for I, S and 10 minutl"SJ (p < 0.05). 
" WT EP-tS EP-tS+Anl 
pERK - '::;; :. 
'" 
1-' i) : , .. 
II: •• ,-,,! 1 
ffi-, 
r_ 0 , • " 0 , • " 0 t S '0 (mlns) 
F"..:_.o 5.J. B. ~JtIIIM".~ I"""""""" """""II phoophoo}·l .. ion of !iRK 112 foll",,·,nll ,~~unm, ",j,h 
I'GE, In Hot.. "ild-typo (""'1l. ENS ond EP4S cell. prc-~ .. cd "i,b I .. \ 1 EP 4 ."....,..'51 (ONO-Al2· 
227) (EP-IS-An,). ecH. "= ,limlll.lllod ,,·illl JOG .... ' 1 POE, for htnl/ ponoc!. ofO. I.! Ind to m,"Ule' 
I:RK phosphor}la""" il ~>enotd .. !Old oboooe t.aI 1M."" .. SEM) fr¢m 3 ,,'dq>end~nl .,po"",..,," 
( .. I. oi""li<"moJy diff.reno from ' (P < 0.05): • • • II "lII'ificanlly d,ff"",", from •• and' \p -< 0 O~) 
Thc-se data continn phosp/lo0lation and activation of ERKII2 in response tl) seminal 
plasma I)r PGE~ stimulation of HeLa EP~ overexprcssing cells. In order to dctennine if 
I~ Illt.'(hanism of this PGErEN n:ceptor mediated ERKI I2 signalling OCCll rs via the 
EGF l"CCeplor, specific chemical inhibi tors were used. These included f'D9S 0S9 (cell 
~eable inhibitor thaI selooi\"ei> block!; the acti'3tion of MEK. there by inhibiting the 
phosphorylalil)l1 and the acti'alion of MAl' kinase) (Alessi el til 1995) and AGJ41K 
(selecti'·e inhibitor of EGFR tyrosine kinase) (Goluoovskaya el til 2002) (Append i.~ JI). 
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IIeLa EP-IS cells wer~ prc-Iremed for I hour w;lh I r-M ONO-AE2-227 (Ant). 50!-,M 
PD98059 (PD) or loon:\1 AG1478 (AG) prior to stimulation with a 1:500 dilution of 
seminJI plasma (HpJ (FIgure 5.4. A) Or 300 nM PeE, (+pge) (Figure 5.-1.. B) for a lime 
period of 3 ,"il1u[es. Control ENS cells were incubated with v~hicle and left 
unstimulated (-sp or - pge). 
Scminal plasma (I :500) stimulations of EP4S cells resulted in ~ 9.60 % 1.49 fold increase 
in ERKJl2 phosphorylation above vehicle-lreatcd cells. ERK l12 phosphorylation was 
s'J;!l1i f ,call\ly inhibited when cells werc prc treilled with PD98059 ( 1.81 % 0.91 fold). 
AGI478 ( 1.-17:1: 0.23 fold) or EN antagonist (1.41 :!: 0.19 fold) (p < 0.0 1) (Figure 5.4. 
A ). 
A -sp +sp +PO +AG +Ant 
pERK 






" ii , • 
• 'ig~ ... 5.4. A. Rcp'~"'""'{h. Imm""""I,>! .huwi"g F.JlK tl2 ph"<pI><,..,.lm'''" foll<>w,ng ",,,,i,,,,1 pla,ma 
(1:500) "irnula{~,n of 8'4:-' crll< (" 'p) aM Ef'~S coliS p'e--If"{,,d "ilh PD9lIOW ( .. 11)). A(] 147~ ( .. A(]) 
or EI'~ anl:t~,,"i'" , .. Ant). U .. !irnula,C(j COn{1'QI ",II, U'" .hm> n.' " p. R",u lt< Or< <11<,,, n , .. f" ld £ RK 112 
ph<><p,"",'1 lal;on abo> r ba",1 (M",n :t ~EM) from J ,oJ"!",",i,,nl ",~im.nt< I" i •• lali<lic.ll) "i~nifj~'"l 
flu",', p<O.(JI). 
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Similarly. PGE~ (300 nMllrcatml~lI ofEPJ$ cells resulted In a 6.22 oJ: 1.27 fold i~l't'ase 
in ERKln phosphoryl3lion abCl\e \Chicle-treated cells. ~ItK ll2 phosphorylation was 
signiflcamly inh ibited I\hen (ells were pre-lll:med wilh 1' 1)98059 (1.11 ± 0.1 I fold). 
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~1,u ... 5.~ . 8 IIq,,,eoe,""i'c imrrnmoblOl """"inll ERK I '2 ~Ia'i<>n ..... 10""'11 1 mi" ... Oi or 100 
n,'! I'GI'.: wlTOlllo,ioafI of ENS ",011< (-"ge) ... J I'.P4S edt, preoltnlal ",II. "OOIO~9 (, "01. ",01411 
(~"'G)u 1:./'4 .. I"""'" ('AnI~ U ... um .... al........x cdb..., ''''''''0'' -I'll< Raouh. ~ >11<>"" III IQId 
ERKt 2 p/IoIIphof)l.,IOIlIb<»'c "",,>I ("an." SEM) fium 1 irdcpcndcll c:cp:r;mtrllS {" 1I111Il11I",.lIy 
lianili .. , from ' . II "0 05~ 
To fUl1her explore a role- for the EGF receptor and small GTPase Ras in IKtivution of 
EItK In. we co-t/1ll1sfC(:ted HeLa EP4S cells with eDNA for cMyc-tagged Eft K with 
either the dominllllt ncgali~e (ON) form of MAPK kinase (MEK). EGF receptor. Ruf or 
With an emply vector (pcONA3.0) as described in Seclion 15. ENS cells (C)·tran-feeted 
I,nh emplY , ector (pc[)NA3.0) Were then either pre-treated for 1 hoor prior to 
§1imulation~ ..... ith J ~M ONO-AE2-227 (£1'4 Ant) or pre-treated \lith H-hielt and kft 
unstimulated (-sp or -pge) liS n control. C()-transfCclcd EN S cell5 "ere then stimulated 
by seminal pillsmo ( I :500) (Figu~ 5.S. A) or 300 nM ?GEl (Figure 5.5 11) for 3 minule$. 
followi ng 5timullltions. cells wert lysed and transreaw ell.t~·(-F.RK \I!IS 
immunoprecipi tated from cel l lysulCS and sobjeelw 10 Western bloc anal)·sis. 
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Stminal plasma (1:500) rnpidly p/losphor) lated cMyc-ERK I12 in EP-IS cells co-
lransfcaed with empty 'CClor (peONA) (-I.C'6 ± 0.55 fold above ,-chicle-treated cells). 
This d~ation in ERK phosphof)lation was abQlished by co-transfection \lith the 
O"lEGFR (1.58.% 0.06 fol d). DNRaf(1.79 ± 0.23 fold). or the DNMEK tU-I ± 0.10 
fold) (p < 0.05) (Figure 5.5. A). Pre-treatment ofEP-IS cells for I hour \~ith I ~~1 ONO-
AE2-227 (¥-'-EN Ant) decreased ERK 112 phosphorylation 10 1.59 .% 0.32 fold aboH-' 
vehicle-treated cdls (Figure 5.5. A). 
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R~a", s..s . A. ImmunohlOl showing cM~ERKI~ pImphOt)t"'''''' in EP45 c<lllo e<>-IRnSf«:lnl ,ulh 
empl) J><DNI\3D '-.<-'lor. OSEGFR, ONRofor ON'!EK in response IOlWl1il\lJ pI~ (I :~OO) U,mulilion 
for) m""'~ E.N5 c.lls e<>-\r-an,f"<'led ..-ilh empl) \·erto.- "" ... 1.., pre." ... ed ,,"h I I'M 01'00-1\1::2·227 
(EN AnI) prior 10 <Umuillions or Irfl un>umuilled ( •• p). Dol. ~ shown •• fold ERK lr.l ~ho<)l.uon 
(M • .,;,5£'1.I ) abm'C ,'ehick-tlt:awI cell. !Ton,) indtpcndoN "'penmen" I" i •• 1I"ltcally "gIIilkant 
rrom ' .p<o.OI). 
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Similarly, phosphorylation of cM)'c-ERK 112 \\'35 rapidl y elevate'" follo\\ ing 3 minutcs of 
300 nM PGE: stimulation of ENS c~lIs (2.46 " 0.30 fold). This elevation in ERK 
phosphor)lation \\'as abolished by co-trnnsf«tion with the DNEGFR (1.42 '" 1.91 fold), 
DNRaf (1.34 ± 0.14 fold), or thc DNMEK 11.29 '" 0.24 fold) (p < 0.05) (figure 5.5. Il). 
In addition, prc-ttc<limcnl of ENS ~"Clis for I hour wilh I IlM ONO-AE2·227 (sp+EN 
Ant) signi ficantl y decreased ERK 112 phospbor~lmion 10 1.34 '" 0.11 fold abovc vehicle-
trealed oontrol cells (p" 0.05) (Figure 55. B), 
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A"' 
~ig~ .. 5.!\. 8 . ImmunOOl<ll 5b:>,.in¥ c).tyc-[RKIr:! pho<pbor) tll'OO in EP~S ce lt. <<Hlan,reeled .... nh 
~mp'Y pcIlNAJ.O ,~,oc. DNEGFR, D"IR.f. DN~IEK in ~poruc 10 300 n)..\ PGE, ,tlmw.b"" foc 3 
m,mlle!>. EP4S ull< c<>-lran,fected with empl) vee'", "'e .. al.., 1""·1 .. .,ed ..... ilh I ~M ONO·At:2·227 
(~N Ant) prior 10 .Iimulalions or left uMlimwolO<l (·pgel. [)aIn are pr<smled OJ fotd F.RJOi2 
phosphoryl.lion (M.,n t SE.\1) lIbove 'Ofllrol Ii'om 3 in<kptnd.nl .~pelimrnu ( " i. ~.h",ull)' 
sill"ifICanl from', p < 0 OS). 
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54.2.2 Activation of JNK signalling palhway 
In order to in~eSligal e whelher PGE.,· or seminal plasma·EP4 receplor inlemcI;on 
activated other MAPK signalling pathways. we treated HeLa. \VT and EP4S cells with 
5(!rninBI plasma (1:500) or PGE., (300 oM) for lime periods ufO. 1.3.5. 10. 15.20 or 30 
mInutes. In addilion. EN S cells were pre-treated for [ hour with I flM EP4 an tagonIst 
ONO·AE2-227 follo .... C{! by stimulation with seminal plasma (1:500) or 300 nM PGE., for 
the tIme periods indicated. No significant differences were obser.ed In JNK 
ph05phorylation for celiS treated with seminal plasma ( I :500) (Figure 5.6. A. B) or POE., 
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5.4 .2.3. Acti,<ation of p38l\'lAPK signnlling p.tlhway 
Data published by Fiebich el al .. 2001. suggest that PGE, induces IL-6 via an EN-like 
receptor by the ~cti~at ion of p381\1A PK (Fiebich er al. 2(01). Invesligalions were 
perfomled 10 inwstigate Ih~ possible activation of p38MAPK following PGE-EP4 
receptor interaction in our model system. EP4S cells were pre-treated for I hour .... ·Ith EP4 
antagonist ONO-AE2-227. HeLl! WT. ENS. and pre-treat~d EP4S ceUs wen: then 
stimulated with seminal plasma (1:500) or PG F.., (300 n;"1) for time period. of O. 1.3.5. 
10. 15. 20 or 30 minutes. Phosphorylation of pJ8.\1t\ PK is shown as fold above basal. No 
significant differences were observed for cells treated with seminal plasma (1:500) 
(Figure 5.7. A. B) or PGE, (300 nM) (Figure 5.7. C. D). 
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5.4.2.4. AC1>'3110n of PIJ Ki naselA KT signallI ng pathway 
Stud,es pcrformed by Fujino el cl .• 2003 show activIItion of the EN receptor leads to 
phosphorylatIon of ERKI 12 through a PUkinase-dependent mechanism (Fujino t!I al. 
2003). In,estiglltions were performed to investigate whether signall ing in our HeLa EN 
ovcr-C.1prcssin~ model system in'·olves the PI3kinaseJA KT silln.1 lli nll- pathway. EP4S 
cells were pre-treated for I hour with I ~M ONO-AE2-227. HeLa WI". ENS and pre-
treated EP4S ce ll s were Ihen stimulated witl! !>eminal plasma (1:5(0) or 300 nM PGE, for 
lime periods of 0, I. 3, 5, 10. 15, 20 or 30 minules. AKT phosphorylalion is shown as 
fold above basal. No SIgnificant differ<'nces were observed for cells treated wilh seminal 
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5.5. Discussion 
In the classical model of GPCR signalling. stimulation of seven transmembrane spanning 
GPCR leads to the activation of heterotrimeric G proteins, which dissociate into a- and 
py-subunits (Hur et al. 2002; Yang et al. 2003). On the basis of G protein-coupling 
preference, GPCRs can be broadly classified in to Gs-, Gilo- and Gqlll-coupled receptors 
(Yang et al. 2003). Dissociation of the heterotrimeric subunits activate a host of effector 
molecules, which include second messenger generating systems, adapter molecules and 
receptor tyrosine kinases (RTK), giving rise to various cellular, physiological, and 
biological responses. Many cells express multiple types of GPCRs that signal through 
various effector molecules resulting in cross regulation and activation of multiple 
signalling pathways to modulate the net physio or patho-physiological response (Hur et 
al.2002). 
The EP4 receptor is a GPCR which is known to couple to Gas, leading to an increase in 
adenylyl cyclase. Adenylyl cyclases integrate positive and negative signals triggered by 
GPCRs to regulate the levels of cAMP. Nine isoforms of adenylyl cyclase have been 
cloned to date, and all of them are regulated by Gas (Hur et al. 2002). However their 
expression patterns and regulatory properties vary widely. Studies have also revealed 
variable sensitivity of adenylyl cyclases to regulators such as protein kinases and Ca2+ 
(Hur et al. 2002). The effects of various kinds of regulators on adenylyl cyclase isozymes 
suggests that crosstalk can occur between adenylyl cyclase-coupled receptors and other 
signals that regulate Ca2+, or protein kinases, such as growth factor receptors or even 
other GPCRs (Hur et al. 2002). The vast majority of the cellular effects of cAMP are 
mediated by cAMP-dependent protein kinase A (PKA), which is involved in activating 
numerous signalling cascades, including the MAPK pathway. 
As discussed previously, both EP2 and EP4 receptors have been identified on HeLa cells, 
and both have been shown to activate Gas. Data presented by Fujino et al., 2002, 
demonstrate an interesting observation that despite nearly identical receptor expression, 
maximal levels of PGE2-stimulated cAMP formation in EP4-expressing HEK293 cells 
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was only 20 % of the level obtained in EP2-expressing HEK293 cells. However under the 
same conditions, the ability ofPGE2 to stimulate Tcfsignalling was about 50 % greater in 
EP4-expressing cells as compared with EP2-expressing cells (Fujino et al. 2002). This 
suggest that the lower amounts of PGE2-stimulated cAMP formation in EP4-expressing 
HEK293 cells is because of less efficient coupling to this pathway and not because of an 
overall impairment in the signalling potential of these receptors (Fujino et al. 2002). 
These data are interesting in view of results depicted in Figure 5.2, which demonstrate 
intracellular accumulation of cAMP in the EP4-overexpressing HeLa cells following 
PGE-EP4 receptor interaction. This may be indicative of EP4 cell-type specific 
signalling, where EP4 may playa different physiological role in the cervix and couple to 
alternate signalling pathways. 
The more efficient coupling of the EP2 receptor to intracellular cAMP formation 
however, may be significant with respect to fmdings made by Dhillon AS et al., 2002 and 
Sidovar MF et al., 2000. These data reported that the phosphorylation of Raf kinase by 
PKA inhibits the activity of Rafkinase, and subsequently decreases Raf-mediated MAPK 
signalling in their cell model system. In EP2-overexpressing COS cells, therefore, a 
robust activation of PKA may inhibit RAF kinase and block the phosphorylation and 
activation of ERKs (Sidovar et al. 2000; Dhillon et al. 2002). In our HeLa model system, 
we have demonstrated that PGE-EP4 receptor activation leads to an accumulation of 
cAMP, however inefficient coupling to the PKA pathway by EP4 may allow for the 
activation of Raf kinase, and subsequent phosphorylation and activation of ERKs. It is 
clear from these findings that the EP4 receptor could work in concert with the EP2 
receptor to initiate physiological cell responses. In addition, the involvement of other 
GPCRs may also be crucial to various cell signalling responses. 
Cross-talk between cell surface receptors is recognised as a mechanism capable of 
expanding the cellular communication signalling network. Receptor cross-talk can, in 
fact, also occur among distinct families of receptors, such as tyrosine kinase receptor and 
GPCR (Gschwind et al. 2002; Schafer et al. 2004). In this context, studies performed by 
Spinella et al. (2004) demonstrated a role for another GPCR, termed endothelin receptor 
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(ET AR) in the progression of ovarian carcinoma. In this study, they show that in ovarian 
carcinoma cells, endothelin-l (ET -1), through the binding with ET AR, induces PGE2 
production, and increases the expression of PGE2 receptor EP2 and EP4 (Spinella et al. 
2004). The use of pharmacological EP agonists and antagonists indicated that ET -1 and 
PGE2 stimulate VEGF production principally through these EP receptors. They also 
demonstrated that this induction of PGE2 and VEGF by ET -1 involves Src-mediated 
EGFR transactivation. These results implicate EP2 and EP4 receptors in the induction of 
VEGF expression and cell invasiveness by ET-l and provide a mechanism by which 
ETARlET-l can promote and interact with PGE2-dependent machinery to amplify its 
pro-angiogenic and invasive phenotype in ovarian carcinoma cells (Spinella et al. 2004). 
Recent studies have also revealed that several distinct signalling mechanisms contribute 
to the activation of the MAPK pathway by GPCRs, as suggested in the case of the EGFR 
(Maudsley et al. 2000; Pai et al. 2002; Yang et al. 2003). EGFR belongs to a family of 
receptor tyrosine kinases (RTK), which undergo auto-phosphorylation upon agonist 
stimulation and activates the RasIMAPK pathway (Vlahovic et al. 2003). It has recently 
been reported that ERK1I2 activation in endometrial carcinoma is dependent on 
transactivation of the EGFR by prostaglandins, including PGE2 (Sales et al. 2004). This 
study confirms the potential mode of ERK1I2 activation in EP4S cells by seminal plasma 
and PGE2 occurs via the EGFR Although the mechanism of transactivation of the EGFR 
has not been investigated in this study, other studies have proposed possible mechanisms 
for transactivation of EGF receptor by GPCR's (Maudsley et al. 2000; Pierce et al. 2001; 
Pai et al. 2002). These mechanisms involve the activation of transmembrane matrix 
meta1loproteinases (MMP) and extracellular release of heparin-binding EGF (HB-EGF) 
from its latent membrane-spanning precursor in the plasma membrane. Once cleaved the 
HB-EGF ligand can associate with and activate the EGF receptor and induce ERK1I2 
MAPK signalling (pai et al. 2002). Alternatively, studies have shown that activation of 
the c-Src family of non-receptor tyrosine kinases is involved in GPCR-mediated 
transactivation of the EGFR. It is feasible to consider that in the HeLa EP4 
overexpressing cell model system, either method may be responsible for transducing 
signalling following EP4 receptor activation. 
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Data from this study have demonstrated that seminal plasma (1:500) or PGE2 (300 nM) 
stimulation of EP4-overexpressing cervical adenocarcinoma cells activates signal 
transduction cascades, which culminate in the phosphorylation of ERKll2 MAPK 
(Figure 5.9). This phosphorylatyion of ERK1I2 does not appear to be related to cAMP 
levels, as cAMP accumulation in the EP4 overexpressing cell line was increased to a 
similar extent in both seminal plasma-treated and PGE2-treated cells. Studies performed 
by Faour et al., 2001, implicate the EP4 receptor and downstream kinases p38 MAPK 
and, perhaps cAMP-dependent protein kinase in release of PGE2 by rhIL-1 beta in human 
synovial fibroblasts. In addition, studies by Martineau et al., 2004, indicate that key 
components of the eicosanoid pathway are upregulated by mechanically stimulated p38 
MAPK via the EP4 receptor in podocytes. These studies suggest the possible 
involvement of alternate signalling pathways that may be activated via the EP4 receptor, 
however in our study, at the time points investigated, no other MAPK or PI3 kinase 
pathways were activated at the time points investigated Investigations into the mode of 
ERK1I2 activation demonstrated that the EGFR was essential for activation of 
downstream ERK1I2, since co-treatment of the cells with AG1478 (specific EGF receptor 
kinase inhibitor) (Figure 5.4), and co-transfection of cells with DNEGFR (Figure 5.5) 
significantly reduced the phosphorylation of ERK1I2. This suggests that PGE-EP4 
signalling to ERK1I2 may involve the EGF receptor (Figure 5.9). These findings are thus 
consistent with a growing body of evidence suggesting that trans activation of the EGFR 
by GPeRs is a recurrent theme in cell signalling to promote target gene transcription 
(Gschwind et al. 2002; Schafer et al. 2004; Spinella et al. 2004). 
To our knowledge, there have been no studies performed on the effects of seminal plasma 
on the cervix in humans, and very little is known regarding any possible consequences 
that contact between seminal plasma and pre-neoplastic epithelial cells might yield 
Prostaglandin levels in seminal plasma are very high, up to 10 000 times those found at a 
site of inflammation. It is also noteworthy to consider that seminal plasma is a 
heterogeneous fluid, and that any differences in kinetics between seminal plasma and 
PGE2 in regulating EP4 receptor signalling observed in this study could suggest that other 
factors and effectors of signal transduction pathways may be fimctioning in synergy with 
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PGE2 to modulate neoplastic cervical epithelial cell function. These factors may include 
other prostanoid derivatives of the E series (pGE and 19-hydroxy-PGE), which may be 
acting in combination to shift the kinetics of signal transduction in cervical carcinoma 
cells. 
Taken together, these data indicate that endogenous PGE2 (which may synthesised de 
novo by COX enzymes), as well as prostaglandins available in seminal plasma can 
activate EP receptor signalling in cervical adenocarcinoma cells. Figure 5.9 is a cartoon, 
which depicts schematically the activation ofEP4 receptor in the HeLa cell model system 
to potentially modulate the transcription of target genes. In this figure, PGE, either 
produced intracellularly via the COX-enzyme biosynthetic pathway or present in seminal 
plasma, activates EP4 receptor initiating production of the second messenger cAMP 
(Figure 5.9). Activation of these second messenger systems may then initiate kinase 
signalling by the ERK1I2 MAPK pathway and target gene transcription (Figure 5.9.). 
Data suggests that target gene transcription can occur via EP4-receptor-mediated 
transactivation ofEGFR, either via the release of a heparin-bound EGF-like molecule to 
activate RTK directly or by intracellular mechanisms involving c-Src. In turn, the 
activation of target genes by EP4 receptor signalling may promote tumourigenesis or 
angiogenesis (by modulating vascular function and vascular tone). 
Although this study has provided a model system in which to investigate EP4 receptor 
signal transduction following PGE2 or seminal plasma stimulation, further studies are 
needed to map out the integrative network of signalling pathways activated in HeLa EP4s 
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After tbese Invesugations into tbe role tbat MAPK signalling proteins may play in 
cervical tumourigcncsis following PG E-EP rece ptor 3ctiv31ion. Ihe next chapter wi ll go 
on to investigate how Ihese signal s are integraled 10 give a gene-specific transcripllonal 
response. As me ntioned previously. Ihis is an imponalll consideration in s.:xuaJly active 
women with pre-neoplastic lesions. as e~posure !O high le>"els of proStaglandins may 
upregulale transcription of various genes invohed In tumnurigeneSls. such as COX-2. or 
angioge nesis.. such as VEGF. We Iht'refnre decided 10 investigate possible targe! genes. 
which t\ll ght be upregulau:d in response 10 seminal plasma or PGE, stimulation of EP-" 
overe.' pressing adenocarrilloma cells 
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C/I",PTEK 6 - GENE TRANSCKwno:-,' IN K£SPONSE 'I 0 [1'4 IU.O. I'TOI{ 
ACT[V ATION BY SL\UNAI" !'LAS,\ 1'" OK PGE l 
6. 1. r"l"NU~liu" 
As diseussed in the previous section, semin~1 plasma or PGE1-EP4 intcl1lction lelds to 
activat ion of various signalling pathways. and invoh'es the phosphorylation of ERKII2 
and tl1l11sactivation of th~ EGF receptor. Activation of tllcse pathways may ul!i!Tl.'ltely 
result in transcription of IJlrget genes to promote innammalion, growth ami angiogenesis . 
Some of the target genes that hD"C been shown to be regulated by the prostanoid 
signalling pathways include COX~2 , !'GEl s}TIthase an(1 vascular eodmhclial growth 
factor (VEGF), Studies by Fujino and ReSJn (2O(3) have proposed a mechanism thai 
could explain how Ihe EP4 receptor could induce the Cltprcssion of COX-l and !'GEl 
5}T1lhase. which are bolh \mol"n to be upregulated in cancer and [nflamm.lllOn PGEl 
stimulation of Ihe EP4 receptor can activate a PI3KJERK sign!lliing pathway ~sul!ing in 
the mduction of functional EGR-l expression (Fujino el al. 2003). Likewise. EN 
re<:eptor stimulation can activllIe a PI3K dcpendcnt palhwJy resulting in Tcf 
transcriptional activation (Fujioo 1'1 01. 2(02) and COX-2 expression has been shown 10 
be uprcgulalcd by nuclear J}-catcnin accumulation and Tcf-mediated tl1lnscripUonal 
activation (Araki 1'1 al. 2(03). ·!bus. stimulation of the EN reccplor has Ihe potential 10 
induce expression of both PGES and COX-2, therci'»' selling up a posith'c feedback loop 
in which the increascd synthesis of !'GEl may increase tumourigenic polential of cells 
(Regan 2003). 
As mentioned in the previous ehaptcr. studies by Spinella 1'1 af. (2()()4) implicate EP2 and 
EP4 receptors in lhe induction of VEGF expression and cell invasivtness by endothelin·1 
(E1"-1). They demonstrated that ET-l Ihrough the cndothclin·A receplor (ET ",R) induces 
COX-enzyme expression and that both. CllZ)1l1CS conuibutc to ?GEl and VEGF 
production in o~arian C3rcin01l13. celIs waugh EGFR lransa(1iv3tion (Spinella el al 
20(4). The n.'liuction of ET-1-jnduccd VEGF production and cell invasion by using a 
specific EP4 antagonist (AH23848) suggests tllal tile production of PGEl by ET ",R-
medialed EGFR transacti\"3tion could activ~le EN receplor-mediated signalling, aOO in 
tum stimulate aJ1giogc:nic and migr:llOry oc tion of ovarian cardnoma ccl ls. 
112 
Scv<:r.)l studies have shoWTI 8 corrclatioo be1v. ccn PGE1-EP4 receptor interaction alld 
tumour phcnot)pe in ,·anou.s tumour types and in other model systems (Sheng 1'1 III 
200 1; Dohad ..... ala 1'1 al. 2002; Sales 1'1 al. 2002; Scno ci al. 2002; Fujino <:1 (Jf. 2003; 
Sales rl af. 2()()4) In ..... hich EN recepl~ promote lumour progressIOn, irlCreBliIllt: pro-
angtogt'llie factors, and Ilunour eel! invasioo. Moreover. previous rt'pOrts demonstrate 
thai EP2 and EN rttcp101" In\nS("ripts arc inducible by cytoklne (Narko 1"1 al 2001) and 
Uul PGEl may regulale EP.;I receplor expr('$$ion III non·small cell lung carcinoma ccUs 
(Dohadll'ala I'r al. 2002) and EP2I4 receptors in COX· ] lransfa;:lCd cervical carcinoma 
cells (Sales <!I al. 2(02). [n rndomclriaJ CarKCf cdls, elevaled EP2 ra;:eptor e~prcs.slon 
may faelhtotc PGE)-induced release of pro-ilIIgiogcnic factors (Sa[es 1'1 al 10Q(1). TIlus. 
an increase in !'GE-EP rccqJ\OI" mlCf3C!ion may promoIc a po$l\t"e fccdblKk mechanism 
\II f;a[1;lIloma cells by aCliva!ing specific Signalling paihll'oys 10 modulo!c Ihe c~pn:sslon 
of EP receplors and s)lIlhesis ofPGEl 10 enhmce and SUSlalll!1.UOOungencsis. 
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6.2. Aim 
The aim of this section is to investigate pos.sible target genes regulnted by seminal plasma 
or PGE1-EP4 in teraction. The genes 10 be investigated include EP1. EP2, EP3, EN 
receptor and genes involved in lumourigencSls, soch as COX-2, or angiogenc:sis such as 
bFGF and V£GF. 
6.3. Mnterials and Methods 
In this study we mveSl igated the enCeI of seminal plasma (1:500) or 300 nM PGEl on thc 
expression of various genes. HeLa wild·type (WT) and EP4S cells were pre-treated lor 1 
hour prior to stimulations "'1th I ..,M EP4 anlagoniSI (ONo..AE2~227), or in some 
experiments with specific inhibitors 50 ..,M PD980S9 (Inhibitor of t-.lliK) or 100 nM 
AG1478 (Inhibitor of EGFR kinase) lor I hour prior 10 stinmlations. Thcrcatlcr, HeLl 
WT, EP4S. pre-treated \\IT and pre-treated EP4S cells were stimulated for various time 
periods (as indicated in fib'llre legends) with eitheT S\."Jl1inal plasma (1;500) or 300 nM 
PGE!. Thereafter. RNA was iSOlated and samples were suhjected to quantitative real-time 
RT·PCR using primers spet:ific for various genes. Data nre presented as Mean ± SEM 
from 3 independent experiments. 
6.3. 1. RNA Isolation and Quantitative real -time PCR analysis 
RNA isolation was perfomled on cells as described in Section 2.7.1. Following 
spectophotomelry to determine RNA conccllIration and quality (Section 2.7.2). realtime 
quantitative RT·PCR was perfonncd for genes encoding EP TC<:CplOrS, COX·2. VEGF 
lIIld bFGF usiog specific primers:md probes (TJble 5) (Section 2.7.3 and Se<;tion 2.7.4). 
Fold induction was calculated by dividing Ihe relative mRNA expression of cells treated 
with PGE1 (JOOnm) or seminal plasma (1:500) by lhe relative mRNA expression in 
\'Chie!e-lreated cells 3tlhe same time point. 
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6.3.2. Wcstern blot analysis of prole in 
In order to investigate protein expression following EI'4 receplOr activation. cells were 
pre-treated and/or stimulated "'ith seminal plasm.:! (I :500) or 300 nM I'GE1 as described 
in Seetion 6.3. Protein was eXlracled from stimulated cells and subjocted 10 Weslern bIOI 
analysis using I}-oclin and COX-2 specific antibodies as des<:ribed in Section 2.8. Protein 
expression was nonnalised to I}-aclin 10 correct for any di fTcrences in protein loading. 
6.3.3. VEGF ELlSA analysis 
$ccrction of VEGI' protein into (;ulture medium was in'·csligated using VEGF ELISA 
assays as described in $cetion 2.10. Quantification is IIChieved by the construction of a 
standard curve using kno"'ll conc::entrations serial dilutioru; of hWl1Bn VEGF standards 
(15.6 pwml up to lOoo pglml). By comparing the absorbance obtained from a sample 
containing an unkno"'ll amount of human VEGF prOlein with that obtained from the 
standards. the concentration of human VEGF prolein in the test samples were detenninoo. 
Results arc presented as secreted VEGF protein (pglntJ) (Mean ± SEM) prcsent in the 
sample cultW"l' medium from 3 in<kpcndcnt experiments. 
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6.4. Results 
6.4.1, QPCR analysis of EP-receptor mRNA crpression 
HcLa I:P4S (I:.P4S+Anl) and WT (\VT+Ant) cells were pre-treated witll ] pM spocifie 
EN Te(:cptor antn~ol) ist (ONO-AEl-2:27) lor I hour pno.. to stimulation witll 300 nM 
PGE j . Thereafter HeLa ENS, WT, pre-treated EN S (ENS+Ant) and pre-treated WT 
(WT+Anl) cells were stmJUlaloo for lime periods ofO. 2, 4, 8, 16 and 24 llouT"!i (II) "1111 
300 nM PGEI. 
Real'lIme qunntitath'c RT-PCR analysis showed 110 significant changes m the Ie-.·els of 
EP] receptor (Figure 6. ] . A), EP2 ra:eptor (Figure 6. ]. B) or EP3 recepcor (Figure 6 I 
C) mRNA expression at C<lC1i of the linr points investigated. This iTidicates that 
signal1tn~ via PGE-EN interaction does IlOl result 111 an upregulatloo of EPI . EP2 or EP3 
rtteptor mR..'1A at the time POUlts IIlvestigatoo.. 
11000'eo.:CT, EP4 ra:cptor mR..'1A (Figure 6.1. D) In EP4S cells was significam!y increased 
at the 2 h (1 .66 % 0.]5 fold). 4 h (1 .8) ,j; 0. 19 fold), and 8 h (3.47,j; 0.65 fold) time points 
"lien compared to ENS cells treated with EN anta"'omst and 300 nM POEl (ENS+Anlj 
(0.7 1 :i 0.20: 0.60 % 0.24: 1.44 ,.. 0.28: respeo;ll"ely) (p -< 0.01) (Figure 6.1. D). In 
addition, WT cells trcated With !'GEl also respood in a rttcptor·spetific manncr with an 
lI1erease in EP4 mRNA obser.,.ed follO"'lng 8 hours of 300 nM PGEI stlmul~lIOn (Figure 
6.1 D). 1l1cse data II1d ieate the possibil it y of a positive fcedbac:k toop In which increased 
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6A.2.1 . QPCR analysis of COX·2 mR:-.rA exprt'Sl;ion 
The effect of EN receplor aClivHlion on Ihe uprcgulalion of COX 2 mRNA In response 
10 seminal plasma (Figure 6.2. A) or PGE, (t-Igurt' 6.2. B) was inv'"stigaled. ~IeLa ENS 
and WT cells were stimulated with either seminal plasma ( I :5(0) (t-Igure 6.2. A) Of 300 
nM PGE, (Figure 6.2. B) for O. 2. 4. 8. 16 and 24 hours (h) either ~lol1e or followin:: pre-
treatment for I hour wilh I I,M specific EN receplor antagonist (ONO-AE2 227). 
Treatment of WT cells with seminal plasma had no significant effect on COX-2 mR:-IA 
levels. How,",·e r. treatment of EP-I·S cclls wjlh seminal plasma ( 1:500) resultcd in II 
sil;nifi~ant increase in COX-2 mRl\"A at 8 h (5.03 % 0.59 fold ). when oomp.ared u) HeLa 
WT (2 27:1: 0.18) (p < 0.0 1) cells. Pre-treatment of ENS ex-lis "ilh IfI.,\·1 ONO-AE2-:l:27 
(I:.NS+Ant) abolished the seminal pl&srna induced up·rc,!!ulation of COX-2 eApression 
(1.40 % 0.25 fold) (p < 0.01) (Figu re 6.2. A). 
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~~ogU" 6.l . /I. t"OX·~ mll!li/l. I<.'P"'''''''' foll<...,o, ""I1M1\Ial pIao.ma 1I.50tH Slimulih.,. ollld.a .... 1Ii. 
U'-l~ (U·~~.A n') aJld "''1 /WT.AntJ all> "r", I"" Ik:lt<'d "lilI I ,.\1 MO-AI:l-n~. Sut.....q..,n~). 
IJ'~~. WT. ~tn:a"'d U'~~ U;/'~~./l.nt ) IJId I'"' tn:al<"<l WT 1"''''./1."1) ",II, ,,~'" .~muLa'«I ""t. 
... ""1""'1'1,,,," ... (1.».1) ( .. , z.~. II. 16 .. ",!~ 1.",,,,- D ...... ,~ 1"<>'"'''''' a. f,;ol..! ..... ,.- ' M<an '" SU.-1) of 
(UX 2 ",1!'lA aoo. .. mmrol (,"'" J 1ndcpcndonl ~'p<n .... "" , .. ;. .",lIo'icol'l sI~nirocanl (rom' (P < 
11 O.s ), ••• I. ~~ .. blll ~.nl(lcan' (tom •• and • (p < II O.s ~ 
"' 
Sllmulauon of EP.tS ~1t5 wilh JOO n\1 PGE, rtSulled in I Signifkanc illfrC'ast in COX-2 
mRNA al lhe 8 and 16 hour lime points ( 1.6 1 % 0.13 and 1.25 % 0.01 fold rtsp«li~ely ). 
when t(lll1partd 10 ENS ~II~ pre-Irt:lled wull O};"O-AE2 221 (EP-JS+Anl) (0.617 % 0.07 
JlKI 0.8S %0.09 fold rtspecli~e l y at 8 ar>d 16 hours) (p <0.01) (Figur~ 6.2. B). Similarly. 
stimulation of WT ctlls willi JOO nM !'GE, resulied in a signifi calll Intrease in COX-2 
mRI\A al 8 hoors ( 1.19 % 0.06 fold) when tompared to pre·treated \vr cell~ (\vr ... Am) 
at the same time point (O.M % UOS fold) (p < o.OS). 
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c WT' Anl 
~-"Ul"f 6.2. 8. ('OX ~ mlto'lA nprcsWoi ("'Iu..ln, 100 nM I,(;~_ OIimullliolll ..... H~u. <~1I .. H~la 1:14~ 
aDd WT edt ... ...., .Om~111OJ for 2. .... g. 16 and N Ioou .. Ib) "'Ih lOU nM PI.J 1-_ elmer alone Qf folm.. inJ 
pr~ v.oaR"Cll' "ilb t ~M O'l{)·A,i:l-ln 1+.1.", ). I ....... PfI::lo<dl<'d .. fok!"'<f(a:!< IM<3Il " SI-~\1) ~ 
rox 1 mRNA all<1>" ronlmt f ...... .I ",JI'~nIkm ~'ptrimcnll. I" i> "",1!)licall) "&nir",anl from • IP < 
0.05) .... .. ""~,,icall~ .. ""r"",nl tr<lln" Ind' Ip < (I.W). 
In order to in ' esugale Ihe signal IrlInsduClion pailiways by which COX-2 gene 
uanscriplion may be up~gulaled. HeLa \VT and EP~ cells were )\Inlilialed with either 
seminal plasma (1:500) (Figure 6.3. A) or 300 n"l PGE, (Figure 6 .. 1. B) alon ... or 
foll",,"ng prt-treatment for I hour wiTh specific chemical Inhlbiton. Thest inhibITOrs 
included 1'098059 (MAPK kinaS(' inhibitor) (SO I'M), ,\G 1478 (EGFR kiuase inhibiTor) 
( 100 11M) or ONO-AE2·227 (EP4 antagonisT) (I I,M). Conlrol cdls .... ere pre·TreaTed wiTh 
_ehicle ~r>d left unstimulated. 
'19 
Seminal plasma (1.500) (sp) Stimulation of ENS cells resuh¢d in ~ 5 ,17:1: 0 ,85 fo ld 
incr~a,~ in COX-2 mRNA. which W:l' abolished by pre-incubation with PD98059 
(sp+PD) (1.40 ±O 14 fold) (p < 0.01). AG 1478 (sp+AG) (0.73 :1:0.16 fold ) (p < 0.01) or 
O,'\;O-AE2-227 (sp+Am) (1.05 :I: 0.11 fold) (p < 0.01) (1-igure 6.3. A). PGE, (300 n:-'1 ) 
(Pl!.t) slimulaJion of ENS (S) cell, r~suhed in a 1.57:1: 0.03 fold increase in COX-2 
mRNA. which was abolished by pre-Ireatment "ith PD98059 (pge+PD) <0,74 :I: 0,05 
fold) (p < 0.01), AGI478 (pge+AG) ( 1.2 1:1: 0.03 fold) (p < 0.01) and ONO-AE2-227 
(pgt+t\m) (1,11 :I: 007 fold) (p <0,01) (Figure 6.3.8). 
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r igure 'J. ~(lId ioou<'tion of COX-2 nlRNA <'p",,,loo. EI'.f~ or I','T ""11, ,..ore p"' -Irt3tc<j "i,h P1)98059 
(+1'0). A(i 1.178 (+AG ) .)1 ONO-A I:.! 227 (+A nl) ror 1 "',u, priM '" .timulallo,..., ~"h""<l"c"tI). F-".JS IS). 
WT .. II; (Wf). pre.\reol<d ioNS ~oo p"'-'rcalCd WI' "" li s II,,,,, "'",uIOl.:<I fnr 8 hnUTJ; \\IIIl semi .. ] 
pi.""", (splll:500, (~Igu", 6.3, Al nr 3OO"M ffiE, (p~<l (I'igUT< 6 . .1. II). Data.,. p",,,,,nlrtl a. rok! 
inc"'"", IM"4n .. Sf\1) (I( COX·2 mR1'>A "1><:»'< contrOl rrunt J iruloporkk nl "'I,,·,imrnl> I" " 
,I~ntficanll) diff.","l rrnm' Ip < O,Oj), ••• is ., ignir,rnnu) diff,,,,nl front ".00 • (p <(J.OSI, 
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6.4.2.2. COX-2 protein e~pression in HeLa \VT and ENS cells 
In order to investigate whether up-regulation of COX-2 mRNA initiates gene 
trnnscnption and resultant translation of COX-2 protein. Western blot analysIs (as 
outlined in Section 2.8) was used to detC11nine COX-2 protein expression in seminal 
plasma or PGE! stimulated Hela cens in the absence Or presence of various chemical 
inhibitors. These chemical inhibitors induded PD98059. AGI-I78 or ONO-AE2-227. 
HeLa \'/T and EI'4S cells Were stimulated with either seminal plasma 0:500) (figure 
6.4. A) or 300 nM PGEl (figure 6.4. B) for 8 hours either alone or following pre-
treatment for I hour with PD9S059 (5 11M), AGJ-I78 (100 n~1). Or ONO-AE2-227 (I 
11M). Control HeLa EP-IS 3lld WT cells were pre-treated for 1 hour witb vehicle and left 
unstimulated. 
I2l 
Stimul~tioo of HeLa EN S cells with seminal plasma (I.SOO) for 8 hours I"tSill ted in a 
4.40 % 0.56 fold increase in COX-2 protein (p < OOS) (Figllrt' 6.4. A). which corresponds 
witll tbe inCftMe in COX-2 mRJ'/A obsel"\'ed at tile sanle time poinl (FigLire 6.3. A). This 
increase in COX-2 protelll e.\pression was abol ished by pre l/1CubaliOll lI< ;th AGI478 
(ENS+sp+AG) ( I (17 :t 0.38 fold, p < 0.0 1), P098Q59 (ENS+sp+PD) (0 .97 % 0.24 fold) 
(p < 0.0 1) or O" O·AE2-227 (EP4S+sp+Am) (1.02 % 0 OS fold) (p < 0 .01 ) (Figure 6.4 . 
A) Similarly. st imulation of 11d..a WT cells ( \\1) with seminal plasma (1 :500) for 8 
hours reSillted in I 2.14 %0.35 fold in<:rease in COX-2 protem (p < O,(5)(Figure 6.4. A), 
wh ich corresponlh .. ilh Ihe increase obser\'ed in COX 2 mR"A at the same lime point 
(h gure 6.3. A) This increase in COX·2 proIe;n upression was abolished by pre-
incubaLioo wilh AG 14711 (WT +sp+AG) (I 07 % 0.3 I fold) (p < 0,01), PD911059 
(WT +sp+PD) ( 1.13 :t 0 .91 fold) (p < 0.01) or OSO-AE2-227 {WT +sp+Anl) (I.OJ % 0 15 
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~igH" 6.-1. A. Immur,obh. .. ,Ix'" In, COX.l p«Hein. lI el. .. wr 0< f.j'4<; edl. were $I;"",lalcd ... ·it/l ... mi ... t 
pl31ma 1J:SOOl (. '1'1 tOr 8 1\Qo~ either alone 0< foll"";"1 pre-.",OImcnt "j.b A(i1 47l1 (.A(Ol. r'Dlll\O~9 
(.1'1I) 0' O:-'O_AF.2.227 t+A "'1. rOflttO! «110 "rr< I"~.inc"":""d ... itll Hhj~l .... d I .... , ""<lim"IOIed ( .• I'~ 
11;"","1" .. erc n(ormallSC\! t<I ~-""t1n to ron'ect for an) diff ... ncei In proI,;n Ioodin~ DaL11lJ'e pl'esontcd .. 
fold Inc."" ... C \1 1.':1" :t SfMI In O)X 2 prOI~in "I"'<"';i"" ;oro.. < COOltOi flum j ;nokpeft«nl ~'r><rim~l' 
C" i. 'l>li'licall) significanl frum' (I'<O.US1 .••• IJ s ... ,iWrnllj ,1~nln""'1l (rom·' and ' IP <O.O~I_ 
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Sti(1lulalioo of Hew ENS cells wnh 300 nM PG~ for 8 hours resulted in D 4.28 :t 0.74 
fold increase in COX-2 protein (I' < 0.05) (Figure 6.4. B). which corresponds wilh Ihe 
increase in COX-2 mRNA obsen-'cd II! thc same lime point (Figure 6.3. B). This I/lCrease 
in COX-2 prolein ~xprcS5ion was abolished by prc-incubalioo wilh AGI·-l78 
(EP.!.S+pge+AG) (I 13 :t 0 2 fold) (I' < 001). PI)98059 (ENS+pgc+PD) (1.10 :!: 008 
fold) ( I' < 0.01) or ONO-AE2-227 (EP4S+pge+Ant l (I 25 :!: O.OS fold ) (I' < 0.0 1) (Figure 
6 .... B). Similarly. sumulalion of Hel..a WT cells ( \VT ) YHIh 300 oM PGE, for 8 hours 
resulted in a 2.25:t 0.05 fold incrcase In COX-2 protem (I' < 0.05) {I'igure 64, B). which 
corr~ponds w,11l lhe increase obsen-'ed in COX 2 mRNA al the: same lime poin! (Figure 
6.3. B). This Incr .. ~ in COX·2 protein ellpressioo was aboli~hed by prc-incuMIIOli With 
AG 1478 (Wl"+pge+AG I (0.89 :!: 0.03 fold) (p < 0.0 II. PD98059 (WT+pge+PD) (US3 ± 
0.10 fold) (p < 0.01) or ONO-AE2-227 (WT+pge+Anl) (0.86:t 0.09 fold) (p < 0.01) 
(Figure 6.4. B) 
" 
COX-2 ':::~~:::~:..::~ - -
~'Igu"" ' ..I. R. ImmunolllOl. """"ing COX·! pfI.lI<in . u ..... wr or EJ'",S ~. Il " w.r. otimul. lcd for 11 boll'" 
"ilh ~\lhtr I'G ~~ I lOO "M) (+pg<) alon. or foil"" In, pre.I,..HII,,"1 "jlh ... t; 1",7R (+"'GI. ''D'I805'1 ( ... '>1)) 
00 OSO-... O 227 ( ...... nll. Conlr<> <el15 '"'''' I"e·,""uho'cd "uh 'chi<:1~ ~",J "'fl un,timul.,cd (-PIC). 
!l.elul" I"" .100<," as (oW ;""reo ... ( Mea n '" Sl;.\,I ) in COX 2 fY<l1r1~ ~'fI'es.i<'a ."'". ,"""",,( ("; • 
.. ~nln~.nl') ,Jirr.,.n' from • (II ., 0.0.5) .••• 1< .i8rur.""oil) ,Jiff.renl (rom •• IUkI • Ip ., 0.0.'l1. 
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6.4,}. J _ QPCR anal}SlS of VEGF mRNA upress.ion 
Tile effect 0( EP4 receplor ac1i~al lon on the uprepilal.on of VEGF mRl\A In response 10 
~minal plasma (Fi~ure 6.5. A) or PGE, (Fi,gure 6.5. 0 ) was In'esligaled. HeLl ENS and 
WT cells were slimu l~tcd wilh eilher seminal plBSIfIlI (1:500) (Figure 6.5. A) or}OO 11\1 
PeE., CI-igure 6.5. 0 ) for lime periods of O. 2. 4. 8. [6 and 24 hoors (h) alone or follow'n! 
pre-trealment for I hour with I}lM Oi\O-AE!:-2Z7. 
SlImll lalion of ENS ce ll s Wllh semiTlilI plasma resultoed in a signifirnnt ,"crease of VEGF 
mR.J~A al 8 hours (3.73 :t 0.59 fold). which was abolished in ENS cells pre· trealmenl 
with ONO-AE!:-227 (ENS.Am) (0.80 :t 0.()6 fold) (p < 0.01) at the same lime poon. 
(Figure 6.5. A). Sinularly. stimulation of HeLa wr cells resulled in ~ S;I!RlfiCant ,RCrease 
in VEGF mRNA al 8 hours (3.IJ:t O,jol fold). which was aboli shed in wr cells pre 
m~at ed wl lh O:\'O·AE!:-227 (\Vf .Am) (I 3 [ :t 0. 11 fold) (p < O.OS) (Fi,ure 6.5. A). No 
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p«-tn:!IImcn' "'Ih I 1, \10»0 Ahl21' I .Anl~ D.", ... p,..,..n,"<i a< f,,1d iMuOIion (Mean., ShM) nr 
\I~JJ~ mltNA Ih<n~ """Irol frnm J illikpc''''''fII e'I'<.lmtnll ( •• 10 >tJ~S!k.lly olgnlf,cam flO/ll". (p < 
0.0$). 
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Stimulmiol1 of ENS cells with 300 11M PGE1 resulted ill :I ,ignifiC.:lnt increasc of VEGF 
mRNA at 8 hours (2.64 ± 0.32 fold), which was abolished in ENS cells pre-treated with 
ONo..AE2-227 (ENS+AntJ (0.78:!: 0. 12 fold) (p -< 0.01) at the same time point (Figure 
6.5. B), Similarly, stimulation of HeLa WT cells resulted in a signilicant increase in 
VEGF mRNA at 8 hours (1.50 :!: 0.37 fo ld), which '\illS abolished in wr cdls pre-treated 
with ONO-AE2-227 (WHAm) (0.95 ± 0.16 fold) (p < 0.05) (l'igure 6.5. B). No 
significant differences were observed m the other time points of211, 4h, 16h or 2411. 
B 





~12""" 6.S, B. VEGF mR;o.IA induction follo"ing POE , .. imul.,i"" of HcLa <c1I .. ENS and WT «II, 
,.,,, •• !imula,td with 300 n.\1 PGE, for ,ime pcrinds uf 1,~, &, t6 and 14 h"" .. either 01<>0< '" roJlo"'ing 
pre-m.,ment .... ill! 1 ,,)'1 ONO-AEl_127 (tAn!). nOta an: prescnted ... fold induction ( Mean '" SE\I) of 
VEOf mR."lA .bo, ... conunl ftom J indtpendc:m cxpc'It ... nl< (00 I, .. ati .. ical ly .ignifi."", from • (p < 
O.Oj), ... i, ".'i"kall~ -ilgnif,canl flOl1I •• and' (p "" O.OS). 
In order 10 investigate the signal tmnsduction pmhwa}'s by which VEGF gene 
transcription may be uprel,'Ulaled, HcLa WT and ENS ce lls wen: stimulated for 8 hours 
"ith either seminal plasma (I :500) (Figure 6.6. A) or 300 nM PGE~ (Figure 6.6. B) alone 
or fol1o\\ing pn:-treatmcm for I hour with speciftc chemical inhibi tors. These inhibitors 
irodudcd PD98059 (MAI>K kinase in hibitor) (50 ).1M). AGI478 (EGFR kinase inhibitor) 
(100 nM), or ONO-AE2-227 (I ).1M). Control cells "'ell: treated with vehicle for I hour 
and then left unstimula1ed. 
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Semmal plasma ( l;500) (sp) stimulation of EP4S C~U S resuiled In a 3.22 :1: 0 .10 fold 
increase in VEGF mR:-.IA. " 'h ich was Hbolished by co·treaunem with PD980S9 (sp+PD) 
11.29:1: 0.128 fold) (p < O.QJ). AG 1478 (sp+AG) (0.79:t 0.03 fold ) (p < 0.01 ) or ONO-
AE2-227 ($p+Anl) (O.~:I: 0.08 fold) (p < 0.0 l) (Figure 6.6. AJ. 300 nM PG£, (pge) 
s-umulation of ENS ceU~ resuiled In a 2. 15 :I: 0. 16 fold increase in V EGF mRNA. which 
was abolished by co·treatmem wi lh i'l>980S9 (pge+I'D) (0.89 :I: 0.74 fold) Ip < 0.01). 
AGI478 (pge+AG) (1.08 1: 0.09 fold) (p < 0.01) or ONO-AE2-227 (pge+Anl) ( 1.02:1: 
0. 12 fold) (p < 0.01) (Figure 6.6 B). 
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~1!u"" 6.'. f·old ,nducti,," ,,f V"OJ- mR1'o'A npn:S.lOo. Hd." lol'4!> or wr (~IJ, ''''n: ,limul'lod "i,h 
"'minal pla>tf1a ('P) (':~()()) (Nl ure 6.6. A) or 300 nM PCe, (pg<cl (FiKU'" 6.6. Ii) fot 8 hooJrs ohtw:-. alone: 
u' foUu,,,ng pt<.treatm<:nI ",til AGt"78 (+AG). 1'1)98059 1+1'1» or O:-;().AE2·!27 (oAnI). Dow arc 
p"""m<:d a. feld ioouct Kl<t (Meat! :I: SEM) ... f VEGF mRNA aW,. control from 3 independent .'perim<:nlj 
t U is .taliOlicali} .1~nlr!Cant from· Ip <0.05).··· I. ,,,!lliIicall) sI~mfic~nI from" and· {p < 0.05). 
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6 ... .3.2. VEGF protein upression in HeLa \\IT and (P-IS eelb 
Secre:tion of VEGF protein into the cuhure: medium follo\\in& tre:allnent of cells with 
seminal plasma (1 ;~) (Figure 6.7. A.) or 300 RM PGE~ (Figure 6.7 B) .... lIS in\('stig:ued 
using a VEGF ELISA lit. HeLa WT aRd HeLa ENS ccll~ ..... ere stimulated with either 
seminal plasma (I ;500) or 300 RM I'GE: for 8 IIoors alone or follo\\in& pre-treatment for 
I hour ..... ith sp«ilk chemical inhibitors. These inhihitOfli included 1'1)98059 " ~M). 
AG 1478 (100 nM) or ONO-AE2-227 (I~M). CORtrol cells .... ere: treated '\ith whkle and 
len uostimulatl-d. 
TrC3tment of lleLa EP-IS cells (black bars) with semiRal plasma (sp) resulted in VEGr 
acculTlulation of 8540.17 * 6 15.)6 PlVml. when compared to control (-sp) (299.03 :!: 
56.56 PlVml) (p < 0.05) (Figure 6,7. A). VEGI' accumulatioR .... -as significantl} n:duced in 
EI'-IS cells followi ng pre·treatment with 1'098059 (-I'D) (5085.23:!: 568.75 pglml) (p < 
0.05), AG1478 (fAG) (4579.87 ., 390.06 pglml) (I' < 0.01) or ONO-AE2·227 (+Ant) 
(5109.331: 550.52 pglml) (p < 0.0 1) (Figurt' 6.7. A). Similarl}. treatment of 1 lela \\IT 
cells (open bars) ',ith seminal plasma (sp) n:suhed in VEGF accumulalioR of 6621.27 ". 
818.79 plVml. I,hen campa"'..:! to ~hidc-trc:ated cells (-sp) (4 17.77:!: -16.79 pg/ml) (p < 
0.05, (Figun: 6.7. A). VEGr accumulation was significantl} reduced in \\IT cells 
foll",.\;ng pre:-U'C3unenl \\-ith 1'098059 (sp- I'D) (3952.97 ± 0151.34 pglml) (p < 0.01). 
AGI478 (sp+AG) (5060..13 ± 682 ().I pg/ml) (p < 0.01) or ONO-AE2_227 (sp-.-Anl) 
(4825.2) .i 614.25 pglml) (p < 0.01) (Figure 6.7. A). IR additioR. a significant ;llCreaSC 
was observed in seminal p!aSlTl3-trc::ued ENS cells (8540.17 ± 615.36 pg/ml) when 
compared 10 seminal plasn13-Ire:ated WT .:ell s (6621.27 :!: 818.79 pglml) (p < 0.05) 
(Figure: 6.7. A). 
Treaunen! of l1eLa EP-IS ce lls (bIDc~ bars) with 300 nM J>(iE2 (pgc) resulted in VEGr 
mccumulation of906.97 ± 67.06 psfml, Ilhcn compared to control (-pge) (516.87 ± 48.33 
pglml) (p < 0,05) (Figure 6.7. B). VEGF accumulation \\-as significlInlly rc:duced in ENS 
cells following pre-trealment with 1'1)98059 (--- I'D) (535.93 + 125,19 pglml) (p < 0.05). 
AGI478 ("'AG) (428,43:!: 65.66 pg/ml) (p < 0.01) or ONO·AE2-227 ( IAnt) (449.90 '" 
127 
86,60 pglml) (p < 0.01) ( Figure 6.7. B). Similarly, treatment of Jle1..u WT tells (opc:n 
bars) wit h 300 nM PGE2 Wilt') resuhw in VEGF accumulatiorl of 552.83 t: 4g, 13 pg/ml, 
when compared to conLIol (-Pgt") (3]3.-10 '" 18.)6 pgfml) (p < 0.05) (Figure 6,7. I) , 
VEGF ~ccumulation was significantly reduced in WT cells followinG pre-LIeatment with 
P[)98050 (5P+P[) (339.80:1- 45.]9 pg/m1) (p < 0.05), AG 1478 (sp+AG) (363.90.i 21 .34 
pglml) (p < 0.05) or ONO-AE2-n7 (SP+AnI) (402.03 '" 36. 12 pglml) (p < 0.05) (Figure 
6.7. IJ). In uddilion, a sign ilit-ant increase was observed in PGE1-trealed ENS cells 
(906.97:1: 67.06 pglmlJ when compared to seminal plasma-lreated WT cells (552.83 :t 
4H. 13 pglml) (p <0.01) ( Figure 6,7. IJ). 
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0011> _.e ,ndl>lkd ... "","lfol. Data .... pr~~ OS Mtan ~ S£M (n:t<tt J itoJopmJtrnIoxp<n",<"'. ("' i. 
""" .. ,cally oilJl'r,coo' ""Ill . (p " o,on ••. (i i+ ..... k:aUy ..... ,Ii'*- lion, •• otoJ • (I>" 0,05) . .... i> 
... ,,,,c.llnian'fi<all' from '" . •• and • (p "0 OS), 
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6.4.4. Elt pression ofbFGF mRNA follo" inll PGI:.-EN receptor interoetion 
The dlCct of EP-I receptor aeth'alion on the upregulation of bFGF mRNA in response to 
seminal plasmu ( I :500) (Figure 6.8. A) or 300 nM I'GE2 (Figure 6.8. lJ) W:l!. investigated 
using Rcal -tim~ quantitative RT-PCR analysis. Hel a ENS and WT cells we ..... stimulaled 
", ith either seminal plasma (l:500) or 300 nM PGE~ for 0, 2. 4. 8. 16 and 24 hours (h) 
alone or following pre-tre.atment for I ho ur with 1 J.lM EP-I antagonist (ONO-AE2-221) . 
Treatment ofEN $ cells wilh seminal plasma ( I :500) resulted in a s ignificant increaSl: in 
bFGF mRNA at 2 h and g h (1.10 :1:. 0.06 and 2.S1 :I:. 0.09 fold . n:spectively), ..... hen 
compared 10 ENS cells treated 'lith ONO-AE2-227 and seminal plasma (EP-IS+Ant) lit 
thi: same time points ( 1.03:1:. 0.07 and 1.57 ± 0.11 fol d) (p < 0,05) (Figure 6.8. A) . 
Similarly. tre3Wtent of W I" cells wilh Sl: minal plasma resulted in P significant increase in 
bFGF mRNA 31 8 hours (251 ± 0.38 fold) (p < 0.05). "'hen compared to wr cells tremed 




.,g~ • EP4S 
~ ~ , EP4S+Ant 




Time 2h 4h 8h 16h 24h 
.1~ure 6.S. A bl:GP mR.'li\ ~'I' ... , .. lon follo"'i"K .. mlrW pi ... "", Aumul .. ,on of Hd .... «It •. II.La EP4S 
and WT «It< W<TO 'Um"l.kd tbr 1, I . 16. af'Ml 24 too.urs (h) "",,[0 oeml".! pI • • ma (I :500) .1""" o. folio" 'oS 
pr<_lt .. "n~'" " 'Ilh I J,~l ONo.AE2·227 t _A",j , n ......... pr"«n«d ... (old l""rca« of bFGr mRNA 
(\I<an . SE'.\I).bov.: ba ... 1 ", .. d. f",,,, J In<kpendem .~I"'rimonl' (" I •• ,&olfoca",l) dlff.rent from' (p "" 
0.05). ... .... gnif,c ..... l)' dlffercm Ii'om •• and • lP < 0 05), 
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SUnlldmHJn of IkLa EI'4S ('ells wlln 300 n\1 rGE, resulted in a signifkam innease in 
bFGr mRNA at the 2 hour and 8 hour ume point~ (1.19 :1: 0.03 ami 1.72:1: 0.27 fold. 
fC'SIK'ctilely), which was reduced in ENS ,ells pre- treated ..... iln ONO-AE2-227 
(EP4S+Am) (0.89 :!: 0.06 and 0.27 :!: 0.10 fold. respecti"ely) (p < 0.01) (fignre 6.8. B). 
Simdarly. stimulntlon of WT cells wiln 300 nM reEl resulted in a significanl in~rease in 
bFGF mRNt\ nt 8 h-onrs. EN ~ntagQniSI {wr +AntJ significamly decreased bFGF mRNA 
e~pres.lon ~I 8 hOllrs ( 174:t 0.28 fold), which ..... as reduced in WT cells pre- treated ..... ith 
O~O-AE2-227 (Wf+Ant) (1.04:!: 0.16 fold) (I' < 0.0 1) ( figure 6.8. R). No signific~1l1 
difference. were observed at the Olbu time points. 
II 
... 
'-" • EP4S -, h , EP4S+Ant 1 , 
0 WT - I '. , WT+Ant 1-
Time 2h 8h 16h 24h 
FiJu,.., 6.8. II bFGF mRNA O\prr~~HI (,~~»Oins f'Ot- "lmlli)lioo"( Hd .. «11<. lIel .. I-N~ .nd WT 
""II. ".,.., ,,;mul.,,:d r,,.. 2.~. 16 .• nd 2~ 110:'"", Ihi .. iln JOO qM l'Of. ~klnc ("of fl~""'ln, fJf~·Ir"I ..... nl 
" iln I I'M 0:-.0·1\ 1-2·221 (+Am). 1)11."1'" pl\'«'nIN ... (\lid )«,n'<' (( l>F<lf mR!I;A (Mtan :t SI-" l 
.t><,,·e ba",1 k' .1. f """ .I ilk.kpt",knl .'pt'im<"MI \ .. II ~ ... illic'lI) .1~n.ir!Call' frt)ftl • Ip < O.CIj), ••• I. 
'l3lIfoIkall) <ignir"""" (rom ••• 1Id • (p < O.O~). 
III order 10 ill\esligale tbe signnllrDlisductiOll patbways by .. bieh bFCiF mRl\"A mw)' be 
upregulDled. lieLa WT and EP-lS cells were sllrnulmed fO( 8 hours \\ li b either semlnnl 
plasma ( 1:500) (Figure 6.9. A) Ol" 300 nM 1'Gc, (Figure 6.9. 8 ) alone or followmg. pre 
treatment for ] hOllr wi tb specific chemical i nh i bitor~. The..e HlCluded 1'098059 (MAPK 
kmase InhIbitor) (SO ~\I). AG 1478 (EGFR kinase Illhlboto.-) (100 nM), or O~O-AE2·227 
{I lAM}. Control cells wen' pre treated with \ehicle and left un\ollnmluted 
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Treatmem of EP-lS cells "'lib seminal plasma (1:500) (sp) rtsulle(l III R 2.-l9 :1:0.19 fold 
illCn'3!IC in bFGF mRr-oA. which was siJl:nificandy decreased by CO-TreaInJem wnh 
PD98059 (sp+PD) ( 1.86:1: 0.18 fold) (p < 0.05). AG 1478 (sp+AG) (lo ll :I: 0.14 fold ) (p < 
0.0 1) 0' 0:"O-AE2-227 (sp+Ant) I I 30 :I: 0.24 fold) (p < 0.0 I) (Figll re 6,9. A). I'GE: 
(l00 n\1 ) (pge) stimulation of ENS celb resulted in a 1.43 :1:0.09 fold increase in bFGF 
mR,'A. whicb WIS significantly d~cr~Rstd by pre-IllCUbmlOn wllh 1'0980.59 (pge+PD) 
(O.8l :I: 0.04 fold) Ip < 0.0 1). AG 14711 (pgHAG) (0.93 ± 0.05 fold) (p < 0.0 I) or 0 ,'0 
AE2-227 (pge+Am) ( 1.0"72; O.OS fold) Ip < 0.0 1) (Figun' 6.9. B). 
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~'Isu"" 6.'. h,1.,I Induelinn (of bH]~ mkNA tkl.JI ENS """ WI" cdt. ""'C >I,_la:.d r", 8 boo .. ",th 
•• ther ""mlnol 1'1"'"'1 ('1') ( I :~OO I j ~llurr (>,'1 Al ,,, .lOO oM I'(OF" Iplr t m,u", {o 'I 61""-- or folkm in~ 
P"-'''''''''''''' ,,;,h t'lm059 ( ... I'D I. AG I41ll I+A,, ) "" O .... O·A~:l·n7 I.Aal~ !);au ;., .tIo .. a ;n fokl 
In(r.:.'k I Mr~n :t ~EM I 0( bt"GF m!lNA .00. c ba<aI from j Indq>croknl ~",,""'''''' I" is ~L>,l;lic:oU) 
,;,nin",,", fn)m • Ip < O,Oj I •• •• is ~L>li,tlo:al!1 \I~ni~l fn)m • and • Ip < O.OSI. 
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6.S. Discussion 
As discussed previously. the action of PGEI 15 mediated through a family of G-proteln 
coupled rcccpton; (GPCR's) lenncd EP receptors Recent ~ludie5 ha" e suggestal • role 
for the EP recepto~ In tumourigencsls. Sheng CI Ill. (ZOOI) Btlributed a dirl"<:t role for 
PGE, and EP receptors In eolorectal l:al'l:momas. In this model. enhanced prohferJh\e 
and lumourigcnic effects .... ere mediated by PGEl fol1o .... inll inteTllCtion with the EN 
receptor (ShCllg ,!I a/. 2001). Similarly. other data has demonstrated a role for PGEl and 
EPZ n:ccp!Of in accderating inteslinal polyp formation in APe'l .. knod.-out nuce 
models (Sonoshita rI 11/ 2001)_ In addition. OIher studies nave shown that COX-C'l\Zymc 
products TllIIy IlUlorcgulate the o;pression of their own r~eptoT5 (Spinelli el 01. 2(04)-
TIus lead 10 m\·e:sligations into whl'thcr up-regulated EN n:eeptor apression, and 
resullln& cnh~ed SynthesiS of PGEI may form a feedback: loop to further upregulate 
aprcssion of EP rectptOfJ. Out dalll indicates thaI PGE-EN inleT1lClion does not alter 
expression of Efl or EP) mRNA in ENS cd Is (Figure 6.1. A. C). Although preltnUIW)' 
d:lI:1 indicated lhat there nught be an increase in EPZ mR..'1A at the 2 and" hour time 
pomts., subseqUent stahstlcal analYSIS conlinued that 1::PZ mRNA exprc:$Slon Ie..-els ... ere 
001 significantly increased at these time pamts in PGEI stimulated EPoiS cells (Figure 6.1. 
B). Hoy,e,er. a sigmfic:mt increase in EN mRNA e~presslon was observed III the EPoiS 
cells following 2. 4. 3Ild S bour stimulutions with 300 nM PGE) (Figure 6. 1. B). Thll 
IIlCTeas¢ III EN mRNA might be Indiclllive of allloregulatiOil .... here increased levds of 
PGE1 may lC3d to upregulauon of its own reccpton. In this case, PGEJ 5umutallon of 
Bela EP4-overclIpressing cells may lead to an increase in ""';005 foctolS ..... h ic h nllght 
x l synergisllcally to auwrcgulate e~pression of EN receptor. TIlis will lead to elevated 
receptor Signalling in 1'leLa cells. and enhance IUmourigeruc gene IramcriPIiOn. 
InvestigatIons were theu performed mto the possible upregulation of target genes 
associated witll \I,ll1}ourigenesili. such as OOX-2. The COX·2 gene is an i nunediate early-
rc:sporue gene (Chandlllsckhal1ll1 elili. ZOO4), PosI-tl1lllSlallona\ processing of the COX-2 
tnu\SCripl results III the expressIon of protem Iiomodimers of 72 lcDa or hetcrodlmcrs of 
72 illa and 74 kDa. The COX \$Ofom1S exIStS as dlmcr5 both slrur.'tur~l\y IlI1d 
Il2 
functionally (Kniss 1999). COX-2 is present on the luminal surfaces of the endoplasmic 
reticulum and inner and outer membranes of the nuclear envelope. This nuclear 
localisation of COX-2 raises the possibility that it may be involved in gene transcription 
or regulation at the nuclear level (Fritsche et al. 2001; Hawk et al. 2002). COX-2 has 
been shown to be upregulated in numerous cancers, including colon, pancreas, 
oesophagus, lung, prostate, bladder and cervical (Tsujii et al. 1997; Jabbour et al. 2001; 
Sales et aI. 2001; Hawk et al. 2002; Kundu et al. 2002; van Rees et al. 2002; Zweifel et 
al. 2002; Mann et al. 2004; Wang et al. 2004; Zha et al. 2004). COX-2 is rapidly induced 
after stimulation of quiescent cells by growth factors, oncogenes, carcinogens, and 
twnour-promoting phorbol esters (Sales et al. 2001). COX-2 can also be upregulated by 
dibutyryl cAMP (Maldve et al. 2000). Although the exact role for COX enzymes and 
their respective products in cervical pathologies remain to be elucidated, studies using in 
vitro model systems have shown that enhanced synthesis of PGE2 resulting from 
upregulated COX-2 enzyme expression plays a role in promoting angiogenesis (Tsujii et 
aI. 1998), inhibiting apoptosis and enhancing proliferation (Tsujii et al. 1995) and 
metastatic potential of epithelial cells (Tsujii et al. 1997; Sales et al. 2003). 
Moreover, COX-2 and PG~ may promote cancer development and invasiveness by 
mediating the transcription of angiogenic factors, such as vascular endothelial growth 
factor (VEGF), that promote both the migration of endothelial cells and their arrangement 
into tubular structures. Several studies have shown a relation between angiogenesis and 
COX-2 (Tsujii et al. 1998; Leahyet al. 2002). By use of two in vitro models using co-
culture of endothelial cells, Tsujii et al., 1998, showed that COX-2 modulates the 
production of angiogenic factors by twnour cells, whereas COX-l regulates angiogenesis 
of endothelial cells and nonnal tissues. In endothelial cells in vitro, basic fibroblast 
growth factor (bFGF) and VEGF increased by three to five times the synthesis of another 
prostaglandin, thromboxane A2 and increased the migration activity of the cells as well 
(Daniel OT et al. 1999). Studies by Dormond 0 et al., 2001, showed that PGE2 and PGI2 
are involved in activation of the small GTPases CDC 42 and Rac (as described in Chapter 
5), as a result of engagement of integrin-av(33-dependent with its substrate (Dormond et 
al. 2001). Inhibition of COX-2 suppresses integrin-avf33-dependent activation of small 
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GTPases and as a result, inhibits endothelial cell spreading and migration in vitro, as well 
as FGF-induced angiogenesis in vivo (Dormond et al. 2001). 
Since COX-2 derived PG~ is the most abundant PG found in solid malignancies that 
express elevated enzyme levels, and studies have shown that COX enzyme products can 
autoregulate the expression of their own receptors (Spinella et al. 2004), we decide to 
investigate whether PGE-EP4 interaction would lead to enhanced signalling and possible 
upregulation of genes involved in tumourigenesis, such as COX-2 or angiogenesis, such 
as VEGF and bFGF. Studies performed in Section 6.4.2. investigated the upregulation of 
COX-2 mRNA expression in HeLa EP4S and WT cells following stimulations with both 
seminal plasma (l :500) (Figure 6.2. A) or PGE2 (300 nM) (Figure 6.2. B). Levels of 
COX-2 mRNA expression were found to be significantly increased in the EP4S cells 
following 8 hours of stimulation with either seminal plasma (1 :500) or PGE2 (300 nM) 
(Figure 6.2.). This indicated that prostaglandins (PGs) present in seminal plasma may be 
acting via the EP4 receptors to upregulate tumourigenesis via the upregulation of 
tumourigenic factors, such as COX-2. Although levels of COX-2 mRNA induction after 
PGE2 stimulation (Figure 6.2. B) do not reach those achieved following 8 hours of 
stimulation with seminal plasma (Figure 6.2. A). Seminal plasma contains 19-
hydroxyPGE2 and various other prostaglandins. These are present in seminal plasma at 
very high levels, and although the levels of PG~ we measured in seminal plasma are 
comparable with those used for the PG~ stimulations, levels of other prostaglandins at 
such high concentrations in seminal plasma may exert effects or cellular responses not 
observed when cells are stimulated with PGE2 alone. 
Studies performed by Therland et al. (2004) on the kidney, demonstrated co-localisation 
of COX-2 with EP4 receptors in the vasculature (Therland et al. 2004). This implies a 
role for the EP4 receptor in transducing PG signalling as a result COX-2 expression in 
the vasculature of the kidney and demonstrates a close association between the EP4 
receptor and COX-2. As mentioned previously, upregulation of COX-2 is an important 
factor in regulating angiogenesis and maintenance of neoplastic tissue. Therefore, 
elevated PG~ levels in seminal plasma may act in an aurocrine/paracrine manner via 
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cAMP-linked PG~ receptors to mediate an effect on target genes, such as COX-2. Thus, 
it would use the cAMP-dependent protein kinase pathway to activate adenylate cyclase 
and increase intracellular cAMP. This in tum may elevate expression of COX-2 via the 
cAMP responsive element (CRE) on the COX-2 promotor. This positive feedback loop 
between COX-2 and PGE2 may potentiate the progression of the disease, which may be 
further enhanced in sexually active women. 
As discussed previously, cellular responses, such as proliferation or differentiation 
involves the regulation of transcriptional events through intracellular signalling cascades, 
including pathways that activate kinases of the MAPK family. The ERK sub-family 
become activated in response to growth factors either through receptor tyrosine kinases 
(RTK)- or through GPCR-triggered signals. Recently. the epidermal growth factor 
receptor (EGFR) was identified as an essential link in the GPCR-mediated MAPK 
activation pathway in rat-1 fibroblasts. These studies suggest that transactivation of 
distinct receptor tyrosine kinases (RTKs) might contribute in a cell-type specific manner 
to GPCR-mediated mitogenic signalling (Daub et al. 1997). In addition, studies 
performed by Pai et al. (2002) demonstrate that PGE2 transactivated the EGFR, resulting 
in gastric and intestinal hypertrophy as well as growth of colonic polyps and cancers (pai 
et al. 2002). 
In order to investigate possible signalling pathways involved in this upregulation of 
COX-2 expression following stimulation by seminal plasma and PGE2, specific chemical 
inhibitors were used (Section 6.4.2.1). Treatment of EP4S cells with PD98059 (inhibits 
ERK activation), AG 1478 (inhibits EGFR kinase), and the EP4 antagonist (ONO-AE2-
227), results in a significant decrease in COX-2 mRNA expression. These data suggest 
that stimulation of HeLa EP4S cells by both seminal plasma and PGE2 results in the 
upregulation COX-2 mRNA via the EP4 receptor and may require phosphorylation of 
ERK1I2 and transactivation of the EGF receptor. These data correspond well with results 
published by other groups, which also implicate the involvement of EGFR and COX-2 in 
other cancers (Araki et al. 2003; Kim et al. 2004). Kim et al., 2004, demonstrated that 
synchronous expression of EGFR and COX-2 in carcinomas of the uterine cervix, were 
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an indication of poor survival rate in these patients. Data published by Araki K et al., 
2004, also implied an important role for EGFR signalling in regulating COX-2 
expression in hwnan bronchial adenocarcinomas (Araki et al. 2003). Detection ofEGFR 
mRNA in peripheral blood of cervical cancer patients was also suggested as a useful 
marker oftumourigenesis (Cho et al. 2003). It has been postulated by several authors that 
autocrine activation of the EGFR may provide a growth advantage to EGFR-expressing 
tumours (Laskin et al. 2004). In addition, activation of the EGFR may contribute to 
several other essential tumourigenic mechanisms, including tumour survival, invasion, 
metastatic spread, and angiogenesis (Eccles et al. 1994; Salomon et al. 1995; Woodburn 
1999; Wells 2000; Yarden 2001). It is therefore not surprising that our data indicates an 
important role for the EGFR in signalling via the EP4 receptor in our cervical 
adenocarcinoma model system. 
There is a distinct relationship between the prostaglandin-cyclooxygenase system and 
VEGF (Buchanan et al. 2004). Prostaglandins influence renal blood flow, are important 
in inflammation and are also pro-angiogenic (Wilkinson-Berka 2004). Recent evidence 
has suggested that COX-2 modulates angiogenesis by interacting with the VEGF system. 
Like prostaglandins, nitric oxide is a vasodilator and is implicated in VEGF-mediated 
vascular permeability and angiogenesis. Emerging evidence also suggests that COX-2 
interacts with nitric oxide, and that these two systems have reciprocal effects on each 
other (Wilkinson-Berka 2004). Studies performed by Miura S et al., 2004, suggest that 
COX-2 plays a key role in VEGF production in gastric fibroblasts, and that angiogenesis 
induced by the COX-2-VEGF pathway might be involved in gastric ulcer healing (Miura 
et al. 2004). COX-2 has also been shown to be a key enzyme for IL-l-induced 
angiogenesis via the upregulation ofVEGF (Kuwano et al. 2004). 
As described previously, the onset of angiogenesis is believed to be an early event in 
tumourigenesis, which facilitates tumour progression and metastasis (Folkman et al., 
1997). Both VEGF and bFGF are growth factors with angiogenic potential. VEGF 
expression has been demonstrated in a number of tumours, and it has been linked to 
promotion of tumour growth and metastasis (Folkman 1997; Jain 2003). Studies were 
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perfonned to investigate the possible upregulation of VEGF in our model system 
following stimulation of HeLa EP4S and WT cells with seminal plasma or PGE2. Data 
from Section 6.4.3. demonstrate stimulation of HeLa EP4S cells by both seminal plasma 
(1:500) (Figure 6.5. A) and 300 nM PGE2 (Figure 6.5. B) result in the upregulation 
VEGF mRNA via the EP4 receptor and requires the phosphorylation of ERK1I2 and 
transactivation of the EGF receptor (Figure 6.6. A and Figure 6.6. B). In our EP4-
overexpressing cervical adenocarcinoma cell model system, intracellular signalling 
upregulates VEGF in response to PGE2, which could act on endothelial cells and lead to 
recruitment of new blood vessels to enhance tumour mass. Recent studies by Spinella F 
et al., 2004, have also implicated the EP2IEP4 receptors in the induction of VEGF 
expression and invasiveness by endothelin-l (Spinella et al. 2004). These studies 
therefore suggest that phannacological blocking of the EP4 receptor may represent an 
additional strategy to control PGE2 signalling, which has been associated with cancer 
progression. 
The vast differences observed in the accumulation of VEGF between cells stimulated 
with seminal plasma (Figure 6.7. A) or PGE2 (Figure 6.7. B) may be attributed to the fact 
that seminal plasma contains very high levels of VEGF. This is supported by the 
observation that in PGE2-treated cells, co-treatment with EP4 antagonist reduced VEGF 
levels to those observed in vehicle-treated cells. Whereas VEGF levels in cells treated 
with seminal plasma and EP4 antagonist remain significantly higher than levels observed 
in vehicle-treated cells (Figure 6.7). The ability of PD 98059, AG1478 and ONO-AE2-
227 to reduce VEGF accumulation in culture medium (Figure 6.7.), demonstrate that this 
upregulation may occur via phosphorylation of ERK1I2 MAPK and transactivation of the 
EGF receptor. These data therefore confinn previous results obtained in Chapter 5, which 
demonstrated that PGE2 or seminal plasma rapidly augments the activation of the 
ERK1I2 signalling pathway in an EGFR mediated manner. Activation of these molecular 
signal transduction pathways resulted in an increase in VEGF mRNA expression (Figure 
6.6. A and Figure 6.6. B) and secretion of VEGF (Figure 6.7. A and Figure 6.7. B), 
indicating that the EGFR and ERK1I2 pathways are necessary for transducing signalling 
via the EP4 receptor. 
137 
Data obtained from Section 6.4.4 investigate the expression of bFGF mRNA following 
stimulation of cells with seminal plasma or PGE2. These data demonstrate that 
stimulation of HeLa EP4S cells by both seminal plasma and PGE2 results in the 
upregulation of bFGF mRNA via the EP4 receptor and may require phosphorylation of 
ERK1I2 and transactivation of the EGF receptor (Figure 6.9). Although, pre-treatment of 
cells with the MEK kinase inhibitor and EGFR kinase inhibitor did not reduce bFGF gene 
expression to basal levels, which indicates that stimulation of cells with seminal plasma 
may activate alternate signal transduction pathways, which are contributing to the 
upregulation of bFGF mRNA expression. Therefore, in this model system, activation of 
these molecular signal transduction pathways via the EP4 receptor resulted in an increase 
in bFGF mRNA expression (Figure 6.9. A, B), possibly involving EGFR and ERKl/2 
pathways, however other signalling pathways may also be playing a role. The resultant 
production of bFGF could act on endothelial cells and lead to recruitment of new blood 
vessels to enhance tumour mass. 
In summary, data from this Chapter demonstrate that PGE2-EP4 receptor interaction 
results in an increase in EP4 receptor mRNA expression, which may involve a positive 
feedback loop, in which exposure to PG~ may lead to upregulation of its EP4 receptor. 
In addition, both seminal plasma and PGE2 stimulation of EP4 overexpressing cervical 
adenocarcinoma cells resulted in a significant increase in both COX-2 and VEGF gene 
expression. This upregulation of COX-2 and VEGF seems to be transduced via the EP4 
receptor by ERK1I2 and EGFR. bFGF mRNA was also upregulated in this model system 
following EP4 receptor activation, however the mechanism via which this target gene is 
upregulated appears to be partially transduced via the EP4 receptor through ERK1I2 and 
EGFR This upregulation of angiogenic factors by seminal plasma has important 
implications for sexually active women with pre-neoplastic cervical epithelial cells. 
These cells may be in contact with seminal plasma containing very high levels of 
prostaglandins, which may contribute to their neoplastic transformation. In women with 
cervical neoplastic cells, the upregulation of angiogenic factors such as VEGF and bFGF 
would allow for the endothelial cells to migrate, divide and form new vessels which may 
further contribute to enhanced tumour mass and invasion into surrounding tissue. These 
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studies, therefore, raise the possibility of using receptor-specific antagonists together with 
NSAIDs in order to reduce the tumourigenic potential of pre-neoplastic cervical epithelial 
cells in sexually active women. The use of these two therapeutic agents in combination 
may provide a more effective treatment than simply using NSAIDs to block COX-
enzyme activation, as enhanced signalling and gene transcription resulting from EP4 
receptor activation would also be inhibited. 
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CHAPTER 7 - DISCUSSION AND CONCLUSIONS 
Discussion and Conclusions 
As mentioned in Section 1.1, a role for cyclooxygenase (COX) enzymes, prostanoids and 
prostanoid receptors has now been ascertained for promoting inflammation and growth of 
numerous tumours. Recent data have demonstrated elevated expression of COX enzymes 
and prostanoid EP2 and EP4 receptors and synthesis and signalling of prostaglandin E2 
(PG~) in cervical carcinomas. Gynaecological malignancies of this nature have an 
enormous impact on the socio-economic status of developing countries, including South 
Africa, and place a huge burden on the national health care system. An understanding of 
the molecular mechanisms whereby prostaglandins (PGs) may mediate their role in 
cervical epithelial cells which could exacerbate cervical tumourigenesis may lead to the 
development of improved therapies for women presenting with cervical carcinoma. An 
important consideration in the aetiology of cervical cancer is the potential role of seminal 
plasma PGs in mediating the activation of bio-molecular signalling pathways, which in 
sexually active women, may further influence the progression of cervical cancer. The aim 
of this research was to investigate the potential role of seminal plasma PGs in mediating 
cell signalling and targeting gene transcription to facilitate cervical tumourigenesis via 
the EP4 receptor. 
Chapter 3 reported on the localisation of EP4 receptor in cervical sections, the role of 
elevated EP4 receptor in cervical carcinomas and the interaction between seminal plasma 
and EP4 receptor in cervical neoplastic epithelial cells. 
Initially, studies were designed to localise the site of expression of the EP4 receptor in 
cervical sections. Previous data generated in this laboratory had confIrmed upregulated 
expression of EP4 receptor in all cervical adenocarcinoma and squamous cell carcinoma 
cases investigated. The site of expression of the EP4 receptor was localised by 
immunohistochemistry using paraffin wax-embedded cervical carcinoma and normal 
cervical tissue. EP4 receptor expression was localised to the neoplastic epithelial cells of 
the cervical carcinoma tissue. 
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In order to ascertain a role for EP4 receptor in cervical carcinomas. we constructed an 
EP4-overexpressing epithelial adenocarcinoma cell model system in HeLa (cervical 
carcinoma) cells (Chapter 4). EP4 receptor cDNA was introduced into the cells and made 
stable by antibiotic selection. Over-expression of EP4 receptor in this cell line was 
confirmed by Western blot analysis and real-time quantitative RT-PCR, which showed 
significantly elevated levels of EP4 receptor mRNA in HeLa EP4 overexpressing cells 
when compared to wild-type HeLa cells. Since EP4 receptor activation is coupled to 
cAMP accumulation. cAMP assays were performed to confirm increased accumulation of 
cAMP in the EP4-overexpressing HeLa cells (EP4S) following PGE2 stimulations. 
Next. to investigate the interaction between seminal plasma and EP4 receptor in 
neoplastic cervical epithelial cells, investigations were performed into possible signal 
transduction pathways and gene expression regulated by PGE2-EP4 receptor activation 
(Chapter 5 and 6). Treatment of EP4S cells with PGE2 or seminal plasma resulted in a 
rapid accumulation of cAMP and phosphorylation of ERK.1I2, which was significantly 
greater compared with WT cells. The phosphorylation of ERK.1I2 was inhibited by co-
treatment of cells with seminal plasma and MEK inhibitor (PD98059), EP4-selective 
receptor antagonist (ONO-AE2-227) or an inhibitor of epidermal growth factor (EGF) 
receptor tyrosine kinase (AG1478). Our data demonstrate that PGE2 or seminal plasma 
prostaglandins can activate signalling via EP4 receptors. which may involve 
transactivation of the EGF receptor and ERK.1I2 in the downstream signalling cascade 
(Figure 8.1). These data are supported by several studies providing evidence that 
prostanoid GPCRs activate receptor tyrosine kinases (RTKs) (Pai et al. 2002; Buchanan 
et al. 2003; Sales et al. 2004; Sales et al. 2004). This cross-communication results in 
increased auto-phosphorylation and dimerization of RTKs (such as the EGFR and 
platelet-derived growth factor receptor) culminating in the activation of MAPK or 
PI3kinase signalling (Pai et al. 2002; Buchanan et al. 2003; Sales et al. 2004; Sales et al. 
2004). The diversity of RTK activation by prostanoid receptors, the exact intracellular 
mechanisms of the activation. and the physiological or pathological significance of this 
cross-communication are not, however, fully elucidated. 
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Investigations were also performed to investigate possible signalling via the p38 MAPK, 
JNK or the PI3 kinase/AKT signalling pathways. These pathways do not appear to be 
activated by seminal plasma or PGEz stimulation of HeLa EP4S or wr cells over the 
time course investigated, which suggest that they may not be involved in signalling via 
the EP4 receptor in our model system, or alternatively that they may be involved at later 
time points. 
PGEz or seminal plasma stimulation of EP4S cells culminate in elevated expression of 
COX-2 mRNA and protein, which has been implicated in tumourigenesis, and elevated 
expression of two genes associated with angiogenesis, namely vascular endothelial 
growth factor (VEOF) and basic fibroblast growth factor (bFOF). Expression of COX-2 
and VEOF mRNA was inhibited by co-treatment of cells with seminal plasma and the 
MEK inhibitor, the EP4-selective receptor antagonist or the EOF receptor tyrosine kinase 
inhibitor. This implies that EP4 receptor signalling can activate expression of 
inflammatory and angiogenic genes via downstream signalling pathways involving 
productive cross-communication with the EOFR. Furthermore, co-treatment of seminal 
plasma-treated HeLa EP4S or wr cells with Indomethacin (COX-enzyme inhibitor) or 
the EP4-selective antagonist resulted in a significant decrease in proliferation of both 
EP4S and wr cells. 
The autocrineiparacrine regulation of EP4 prostanoid receptor signalling and the 
downstream effects on biological function are illustrated in Figure 8.1. POs, either 
produced intracellularly via the COX-enzyme biosynthetic pathway or present in seminal 
plasma, activate the EP4 receptor, initiating the production of the second messenger 
cAMP. Activation of cAMP can then initiate. kinase signalling by the MAPK pathway 
and target gene transcription. Data suggest that target gene transcription can occur via 
prostanoid-receptor-mediated transactivation of RTKs, such as the EOFR. In turn, the 
activation of target genes (COX-2, VEOF and bFOF) by prostanoid receptor signalling 
can promote angiogenesis (by modulating vascular function and vascular tone), cellular 
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Non-steroidal anti-inflammatory drugs (NSAIDs) and specific inhibitors of COX-2 are 
therapeutic groups widely used for the treatment of pain, inflammation and fever. 
However, there is growing experimental and clinical evidence indicating that NSAIDs 
and COX-2 inhibitors also have anti-cancer activity. Epidemiological studies have shown 
that regular use of aspirin and other NSAIDs reduces the risk of developing cancer. 
Studies have demonstrated that COX-2 overexpression promotes tumourigenesis, and that 
NSAIDs and COX-2 inhibitors suppress tumourigenesis and tumour progression. Recent 
advances in the understanding of the cellular and molecular mechanisms of the anti-
cancer effects of NSAIDs and COX-enzyme inhibitors have demonstrated that these 
drugs target both tumour cells and the tumour vasculature. New vessel formation permits 
tumour growth, survival and metastasis. We have identified an upregulation in both bFGF 
and VEGF, which are both able to promote formation of tumour-induced angiogenic 
blood vessels. In pre-clinical models, numerous approaches to inhibit VEGF activity lead 
to decreased tumour growth and angiogenesis. However, although inhibiting either COX-
2 or VEGF may be valid therapeutic strategies to treat cervical carcinoma, this will only 
lead to suppression of endogenous prostaglandins. In sexually active women, any 
increase in prostanoid receptor activation can be further enhanced by seminal plasma 
prostaglandins. In addition, seminal plasma contains high levels of VEGF, which could 
act enhance angiogenesis. From the observations reported in this thesis, it is envisaged 
that an understanding of the role of specific prostanoid receptors, their signalling 
pathways and their phenotypic effects in the female reproductive tract might result 
ultimately in the development and implementation of more efficacious interventions in 
the clinic. This focus has opened a new vista into the understanding of the complexity of 
signalling networks and cross-communication that exist between prostaglandin receptors, 
and between these receptors and RTKs. Umavelling these networks might lead to a better 
understanding of the role of the prostanoid receptors in cervical carcinoma and might 
outline further novel therapeutic directions in the clinic. 
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In conclusion, these data suggest a role for the EP4 receptor in regulating tumour cell 
growth and proliferation through target gene transcription. They also imply that cervical 
carcinoma in sexually active women may be exacerbated following exposure to seminal 
plasma and activation of EP4-receptor signal transduction pathways. Once again, this 
opens up the possibility for the use of selective receptor antagonists and modulators of 
signal transduction in combination with NSAIDs, to block signal transduction and 
resultant gene transcription, as well as COX-enzyme actions. This may be of particular 
therapeutic benefit to sexually active women receiving treatment for cervical carcinoma, 
as they may not only be exposed to endogenous prostaglandins, but also very high levels 
of exogenous prostaglandins available in seminal fluid. 
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APPENJ)lX I 




The eDNA ( 1.5 kb) for human pro$llln'od recepmr EP4 was ligated imo tbe EcoRV site of 
tbe mammalian u.pression vectort, pcDNA3. I ( Invitrogen). The size of the EP4 pcONAl 
conSlruct is 6.9 kb. The: eDNA can be CUt out using HindlJl and Xhol. 
Adapted from Invitrogen website <_w jllvilTQg¢n,coml. 
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APPENDIX II 
Chemical structure of compounds 
ONO-AE2-227 
(Chamwood Molecular Ltd, UK) 





2' -Amino-3 'methoxyflavone 
AG1478 
(Calbiochem®, UK) 
4-(3-Chloroanilio )6,7 -dimethoxyquinazoline 
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